PSJ3 Exhibit 150

Campbell Alliance Group, Ltd. REMS Management Support Project

1. Overview

	variance views of the REMS project. Additional schedules may be included in future submissions based on RPC member company feedback
2. Schedules	
	Summary by Vendor
	Billing by Member
	Cost by Member
	Budget
	PO Status
	Forecast Changes
	Member Allocations
	Deposit Activity
	CE Pre-Paid
	CE Grant Summary by Grant
	CE Grant Summary by Month

Case: 1:17-md-02804-DAP Doc #: 2313-100 Filed: 08/14/19 3 of 49. PageID #: 369832

	AR Aging
	AP Aging
3. Definitions	Forecast
	Budget

The Summary by Vendor page summarizes all costs by Vendor name and presents the full year forecast the budget.

The Summary by Vendor page summarizes all costs previously invoiced and estimated to be invoiced to each RPC Member company. The full year forecast is presented in this tab. Costs shown on a cash accounting basis.

The Summary by Vendor page summarizes all costs allocated to each RPC Member company. The full year forecast is presented in this tab. Costs shown on a cash accounting basis.

The Budget tab shows the budget by area of spend. The data presented is full year forecast for 2012 compared against the budget for 2012. Data is also presented by each project phase and for 2013 and 2014.

The PO Status tab details data on a PO issued by each RPC member company. PO issues are highlighted and presented in this tab.

The Forecast Changes tab shows the detail of the changes to the forecast and explanations for changes in billing for the current month on the Summary by Vendor tab from the prior month.

The Member Allocations tab presents the IMS market share data for each RPC member company. The market share data has een adjusted to sum to 100%. The market share data is used for the allocation of costs to be allocated based on market share per the RPC agreement

The Deposit Activity tab shows the all activity related to RPC member company deposit invoicing per the agreement. Any deposit reallocations or changes are shown and highlighted in this tab.

The CE Pre-Paid tab is a reconciliation between the pre-paid invoiced by Campbell to the RPC committee and the actual costs invoiced to Campbell by the vendor. This pre-paid will be reconciled at year-end 2012.

The CE Grant Summary tab is a summary of grants approved, scheduled milestone payments and actual dates paid by Campbell to Polaris.

The CE Grant Summary tab is a detail of grant payments billed each month as it corresponds to the Summary by Vendor.

The AR Aging tab shows both a summary of receivables outstanding by member company and the details of the invoices making up the total receivables outstanding. The detailed invoice data can be accessed by expanding each members summary line.

The AP Aging tab shows outstanding vendor payables on Campbell Alliance's balance sheet. These payables will be paid timely in accordance with payment terms on executed contracts. Any past due payables will include commentary to explain its status.

The Forecast is composed of the actual year to date invoiced to Campbell Alliance from Vendors plus the forecasted invoices for the remainder of the year. The data is presented on a calendar year basis and on a cash accounting basis. The Forecast can change monthly

The budget is the Budget set at the beginning of the project for each vendor. The budget will not change without approval from the RPC committee

REMS Cost Summary by Vendor	
	2/28/2015

	(28/2016																												
by Vendor loament Phase				VIII												ACTUAL D													
Tender		Type	Norman	Fire (\$100m)	YTO JOE	117 110	Quant 0	NOV DEC	6.3003	(3002 Normal	Budget 72 (Up)	175 474	AN HE	MA	QL CES (1) My	A sky	UN Q2 3003	- M	A35 P	01201	D NOV	94 MI	to proof A SECT	13311	Personal	Budget Fax (Sinfax)	YTD (NOV)	JAN PER MAK	Q13016
	Call Center	Sectionality	128,129	268,500	128,129	128 09	13 131	11/1-11/2	_	2 1 20	<u> </u>			μ_{1}		μ		# /I VI				KHUX	45			_	_		
	2 Fortal	Debrotopy	271166	يا الصلح المناق	275.566	735 17	ال كتات	$U + U \cap$	27.302		7. <u>2</u> J.		\sim $-$	 U U .		+/													-
	Med-Communications	Manage	73,000	20 CHE (180)	230,000	220,000	- L	100	6,600	200,000										-						_	_		-
	Face to Face Meetings	2	1.000	12,500 12,500	71300				77300																				_
ris	Face to Face Meetings	a	-	12,500 12,500 12,500 12,500	-		-								-					-		-							_
	Means Reporting/Tracking	2		25,000 25,000 100,000 82,571																		-							
	Sciences Sa Prescriber Surveys	Mess						67,429	67,631	47,429																			
	Spreament 6	Meas		100,000 100,000			-										-					-							
Allance	rees	riendar	1,881,000	1,865,000 25,000 186,500 138,666	1,840,000	#22,000 274,000 274,000	5,870,000 274	4,000 1NL,000	479,000	1,860,000		2,588			-							_					-		
Marce	Spenies	Dendari	47,154	186,500 118,666	47,554	45,325	41,106 14	(193 7,496 793	34,410	47,554 2,14	0,184	2,088	1,566 337	_	1,031 663		442			-		_		2,586					
Billing & Constantine Cannan	ess.	ALE.	73,283	17,000 (17,781)	73,283	HEDROTO PROGRESSONO PROGRESSON PRO	TO THE	PRINCIPAL PRINCI	GREDACTIC PRVLISHDAS	TIO PRIVILIO POACTIO PI	NUMBER TION PROVIDED BY	Washin Hospichin Heward	DECTED PROVIDEREDACTED PR	VUHINDACTIO PRVIIG	DACTIO PROGRESSIDACTIO PRIVILE	EDACTIC PRVILISIOACTI	PRINCIPORISACTIO PRINCIPO	ESIDACTIO PRIVILEGISSACT	TED PROVIDED ACTION PRO	MUSIBLE ROUSEBA	TID PRIVILEDICTID PROGRESSION	CTED PRIVILEGEACTED PRIV	LEG REDUCTED PROVIDED	HD DACTIO PROVIDE	DACTIO PRIVILIDADE	THO PROVIDENCES PROVIDENCES	EGI SACTIO PRIVILEG	ACTIO PRIVILEGICIIO PRIVILINACTIO PRIVI	CURRECTED PROGRAM
85	euros menings	-genatures	73,483	17,000 (17,741)	71,285	73,483	79,280			73,286				_								_				_	_		-
shows and Minor Contr.			1.001.001	1207201 2007	300 1,011,01	98 822,000 1,346,362 276	1,000 2,200,202	116.161 7.6% 283.25		100000	erren : :	1100	en 100		44.000	, ,	441						+						-
			-		-						.,																		
1 Phase		,		Y2012												ACTUAL													
Tredor		Type	Normani.	Budget Fax (Union)	YTO (DEC)	ALC MP	Ø13213 O	OCT NOV DEC	Q£ 3013	13003 Norma	st. Europei Fax (Unif.	NO 110 (NOV)	MAX PER	MAX	Q12018 APE		UN Q2 3003	XX.	EDG 189	Q1 2013	OCT NOV	OSC Q6 3918	Q242011	13211	Personal	Budget Fax (Union)	YTO (WOW)	AN PER MAK	Q13014
anan)	Call Certier	Deltastegy	124,314	812,000 487,788	124,214	11,056		LEGE 26,563 23,567	111,118	124,214 215,8	6 400,000 184,30	\$ 296,792	21,892 23,07	21,454	68,882 18,637					53,490		19,114 87,187	147,314	221,896	118,009	41,000 (13,029)	115,221	38,310 18,041	54,375
	Stand Management System/CE Portal Setup	Manage Parkets	12,100	230,398 129,292	200,806		- 41	1723 18,870 18,613	20,000	101,806 271,2	16 242,752 29,341	204,196	50,904	18,454	\$5,860 18,454 83,660	18,414	(414 55,381	13,454	18,014 18,014	10,000	18,104 29,007	18,007 57,129 15,250 88,890	167,642	221,301	229,181	120,000 07,000	200,800	38,515 570 18,487 10,700 6,500 10,810	7 57,032 0 27,050
	AND TRANSPORTED !	manage .	14,100	BU,MAN 60,500	29,500		- "	may 8,830	en,400	191,0	re prepared (86,000	177,894	1,100 £5,50	12,625	6,500	44,005	18,750	4,76	10,171	*1,631	£,100	ANATO ELEGO	100335	-46,064	447,465	120,000 (27,821)	127,925	##, NO 13,850	#/Mil
	Marine annual	Technology		10,000 10,000																							-11		-
					-11																				_		-11		-
	Dental Calabase (Ind Party Cala Assessation Vendo	O Dechnology	11 - 1	330,000 330,000	II -	1 1 1		1 1		- 196.0	10 320,000 183,88	116,227		85.092	81.092 17.520	9,000	26,520	6.600	23.263 2.820	22,309	2,820 2,890	2.390 7.099	35.524	120,410	66,890	68.000 3.110	0.09	2.890 2.001 2.816	7.569
	NWSHIE PCDS	fatient	29,074	800,000 773,529	26,576		- 21,	(10) 4,669	26,070	26,030 8,00	212,820 221,83	1 X,202	1,511		1,511 1,818		217 1,093		2,897	2,897	737	764 1,660	7,458	2,584	9,642	63,596 53,552	8,821	2,861	2,861
	CD Translation to Season	fylied																											
	St Face to Face Milgs, Admin.	a		105,000 105,000						- 17,0	1 52,000 34,619	17,865	21,283		23,069 750		790	_	1,561	1,541			2,291	17,001	11,795	12,000 40,265	13,793	8,785	3,793
	Cataloge Option/Mods	in .		800,000 800,000 10,000,000 6,500,000							840,000 840,00	1 X,600,661					1,713,000		_			_							
	3 Grants	3 Gails	1,500,000	10,000,000 6,000,000	1,500,000	1,100,000	8,800,000			1,100,000 1,010	72 13,500,000 5,665,20	18 8,600,665	642,389 3,856,0		2,500,387 1,321,000	94,990	3,413,850	2,008,017	671,390	2,680,207			4,330,486	1,010,772	12,414,333		12,117,718	1,012,121 2,971,616 185,750	100,1313,007
ri .	Sandardued Metros	3	-							18,00	0 - (18,000	18,000			-			18,000		18,000	-		18,000	18,000	18,000	18,000	18,000		_
	Side on fair RFFs; and praint metric recording	2								-																\$1,000 \$1,000	-		
	CE (Metrod) Long Term CE Evaluation (Same as				- 11																				4				
	Incomed By	Metrics	-	80,000 80,000	-				-	-							_	-				-							_
	EMS Service Fees	2	-	131,000 131,000	-				-	- 100,0	00 200,000 66,000	14,100					_	-	34,500	34,500		83,500 85,500	102,000	162,000	812,100	221,000 (907,000)	610,300		-
	topposett to	*		30,000 50,000						_	290,000 250,00			_								_				17,000 17,000	_		-
	DOMESTIC DE	2000		2000							20.00 20.00											_	_			17.000			-
	Increase est 10 Hame as CE (Method Long Term CE 8	of Means									620,000 620,00														4	620,000 620,000			
in and a second	horsonest 4	Messa	-	60,000 60,000							171.000 171.00						-	-							335,009	400,000 (184,029)	356,029	60,260 60,260	80330
	Socionest 5 - Objectives 1 (Other surveillance																								_				
	dipolises); EX viols and deaths in claims database				- 11																				4				
See	eralyes;	Messoc		100,000 100,000							190,000 190,00									-					4	310,000 310,000			
	topeopers 5 - Objectives 5 (Other conventionce																												
	dipotives); Martality rates using state medical exam	mer.			- 11																				4				
	Mildoon	Messax	-	100,000 100,000						-	150,000 150,00							-			-					\$10,000 \$10,000			
	Social ent 5 - Objectives & (Other surveillance				- 11																				4				
	dignitives), NSDUH and MTF publically accessible				- 11							.													4				
	egoris.	Metrics	-	100,000 100,000	-				-	-	190,000 190,00						_	-				-			2,775	130,000 117,231	2,775		
	Noncoment 5 - Objectives 2 and 3 (MADUMS system). New York SENSE Analysis. Active Drug Substitutes in a			1	- 11	1 1 1		1 1			1 1	1 1 1		1		1 1									4	1	11	1 1	
	economic results analysis. Action Ding Substance (e.g.)	and the same of th	11	100.000	ш.	1 1 1		1 1			770.000 770.00	. 1 1 . 1		1		1 1									847.111	#34.500 CH.0333	800.111	1 1	
	Suprament 5 - Objective & Inflessors NATIFFED																										1		$\overline{}$
	(yelen)	Metrics	11 - 1	100,000 100,000	II -	1 1 1		1 1			100,000 100,00			1		1 1					- 1				100,000	400,000 (100,000)	100,000	1 1	
	Successment 6, 7 and 8	Medical	-	100,000 100,000											-					-					418,000	661,000 6,000	459,000		-
	Sastine Prountier Survey	Metrics						89,887	39,337 52,290	250,5	171,790 (81,700				112,179	55,796	227,875	41,409	176	67,587			293,540	255,562	26,166	(24,144)	24,166		
	Debreta Metro: Sendor Hor building FOA Reports?	Meax	12.290	. 02 290	12,292			13.290	12 292	33 290 1422	E 29.50E (36.89)	16226			11.776	27,056	292 60126		16304	24.204			14.228	14228	130,515				
	current fettale Publications	Medica													-										4	40,000 40,000			
	MARIONAL Analysis	Means				1 1				-					-					-	-				2,700	190,000 147,000	Ī		_
Barca	MS Data	rendar	11 -	10,000 10,000						-		1 1 .				1			-	-							1		
Date	Pers	Rendar	373,166	\$10,000 (2,166) \$5,500 \$2,215	372,366			186,083 186,083 5,287	872,366	2,183	00 2,160,000 0 11 180,000 66,131	2,030,666	189,063 189,08	1 188,081	558,250 181,061	180,083 3	1,081 558,290 1601 57,781	184,083	186,063 186,08	37.558	18(08) 159,833	218,811 101,710	1,623,290	2,180,500	1,818,000	1,908,000 (0)	1,758,167	219,811 259,811 219,811 264 462 875	£79,500
tance	Digeops;	Bredor	1207	11.500 1.2.221	11 1297		HARMACTER, BENGEROWSKY,	1.267	1297	\$287 135.8	IN LIGHT BOOK BASES IN LIGHT BOOK PROVING BOOK THE PRO	1 11109	E464 1.73	2.555	36,956 3,112	21,599	101 1 1778	1 1927	916 9131	12.558	165 27,827	2.783 \$3.276	100 827	223,892		180,000 111,809	11 66 673	ACTED PRINCIPACTED PRINCIPACTED PRINC	1 979
and the same of th	Print 1 (199 PRO / budget propert to 2019)	Programme Company				HERDACTIC PRIVILEDACTIC PRIVILEGACTIC PRIV	THE PART OF THE PA	PROFESSION PROFESSION PROFES	AND DESCRIPTION OF THE PERSON NAMED IN COLUMN							NAME AND PROPERTY.	PRINCIPAL PROPERTY.	THE PROPERTY OF THE PERSON NAMED IN	no removable to FE	AL THE	THE PROPERTY AND P	CHAIR PRINCIPAL	AND REAL OF PROVIDE	AND DESCRIPTION OF THE PERSON NAMED IN	Annual resultation		AND DESCRIPTION OF PERSONS	ALTER PRINCIPALITY	ALTERNATION PROVIDE
	COPU 1 (\$18,580 of budget moved to 2018)	Sacration		889,547 (S)	-		-			- NT. A	1 - (44,211	977,474	THE RE		800 KM								10,211	P2.02					-
	SCHELZ(SSS, 500 of budget moved to 2011) SCHELZ	Presiden			-11 -					- 40.11	14 910,000 14K,18 6 130,000 89,63	62,179	200,000 Mil. / M					60.179	_	60.179		_	60.179	00378	116,800	130,000 15,200	114,800		-
	Smot aud! vendor	Quality Management									1				-		-				- -				290,257	610.000 239.745	149,559		
	3 Cansultant	2																							6.733	(6.792)			-
MPDC	Secondary Analysis (MAZIKKS, Inflement)	Metrics	-		-		-		-						-					-		-			117,000	(117,000)	117,000		
alber .	Baseness Campage	External Communications	-				-								-					-		-			305,540	(333,540)	74,711		
contractor of Clinituditic	Mitto Finance Adult	QualityManagement	-		-		-		-						-					-		-			_	- Indian			
	Stander Resiductement	hourber													-							-							
	Scenned 5.4	Medica		100,000 100,000														_							4				
						1 1 1								_		_							1		┹┷┷┺				_
			1,127,221	17,117,145 12,000,0	000 1,127,21	23 887.337 4.042.908	6.600,105	256,201 240,600 126,00	227,117	5.127.221	ST.158 10.812,864 4,21	12,817,338	1,218,790.66 2,150	186.33 126.222.60	4.383.589.59 1.305.887	2 679.006.69	111,212,49 4,562,166	Z.400.191.88	955.86E.6E 296.7	111.00 1.000.016.11	265.962.11 215.557.48	779.950.01 1.296	C22 1.655	13.637.338	15,155,135	28,579,979 (179,5)	18,413,188	1,670,614 5,214,625 626,20	3,041,003

																			_		1												
AN GUREN NA	AUG 187	720 MILEO	NOV DEC	DE2016 Y20	ase:	net Pay 32nd	No (TRO)	M- (1)	100 000	127	A MI	AN 003	1023 - 85.	AUG O	017.61	4 6	A SV DE	0 2235 - 1233	Tribus.	India Atabas	TD (TRID)	ANN - PER	G120	- 44	- MIX-	or or	A Dur	300	0CT	NOV	DEC 063338	Y 2026 B	Normani Budget
					1200		7 77		7		$n - \sigma$, , , , , , , , , , , , , , , , , , ,				7.0						רכים	$\alpha \alpha$		25	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,					
-													_									1				7 #							
-		-			0.00						•••																						
		-				_			-				_		-								_						-	_			
											_										_							_					
	-	_							-																				_	_		_	
		-							-												1		-						-				
												ĺ																					
-									-												_								-		21,000 21,000		
LEGICTED PRIVILENCTED PRIVILEN		-			200,000 100,0	500 -			21,000 21,000	0		21,000 2kg	300	21,000	21,000		21,000	21,000 100,000	300,000	100,000 -	<u> </u>		31,000 21,0	0		21,000 21,000		21,000	21,000				130,000 100,300
COLUMN TO SECURE	The same of the same of	III. NO PRODUCTION PRODUCTION	THE REAL PROPERTY.	III. III. PROGRAMANI III. PROGRAM	- DOG THE PROPERTY OF THE	NAME AND ADDRESS OF THE OWNER, TH	THE PERSON NAMED IN COLUMN TWO	PROTEIN THE PROPERTY.	THE PERSON NAMED IN	THE PERSON NAMED IN	The same of the sa	The Personal Property lies	The state of the last of the l	THE REAL PROPERTY AND ADDRESS OF	COLUMN TWO IS NOT THE OWNER.	The second second	HE PROPERTY OF PROPE	THE PERSON NAMED IN	THE COURSE PROPERTY.	THE PROPERTY OF THE PARTY	The second	JID PRINTING THE PRINTING	ALTER PROPERTY AND A	THE PERSON NAMED IN	DECID PRODUCTS	N. PRODUCTION	The Personal Street Principles	CARROLING PROPERTY.	CHIEF PRINCIPLE INC. THE	THE PERSON NAMED IN	THE PERSON NAMED IN	THE PERSON NAMED IN	AND PROPERTY AND PROPERTY.
	-					-			-				-		-								-						-				
		-			100,000	300,000			21,000 21,000	0		21,000 21,	200		21,000		. 21,00	21,000 10	3,000 100,000	100,000		-	21,000 21,0	0 .		21,000 21,000		21,000	21,000	-	- 21,000 21,1	20 100,000	100,000 100,00
					1701		CHICKET	ACTUM FORE	CARP											17016	PORECAST												12012
QJ 2014 JEL	AUG MP	Q13034 OCT	NOV DEC	Q43234 Y3234	Personal Budg	pei Fav (Unfav	(TRO) YTO (TRO)	AN HE	MAR Q0 300	APK	MIY	JUN CD 3	1011 J.K.	AUG MP	Q1 2015	OCT	NOV DEC	Q42015 Y2015	Porecasi	Budget Fax (Unifer)	YTO (TEG)	JAN PER	MAX Q130	APE.	MILY	JUN QJ 3004	JUL AUG	MP	Q8 3004 QCT	NOV	56C Q63016 1,767 11,600	Y 3036 A	Normani Budget
40,394	8,828 2,625	33,658 3,625	1,076 2,838	Q4 3334 Y2334 13,806 118,009 58,568 229,883	Personal Budg 42,761 64,0 299,876 299,8	00 1,837		1,741	3,700 9,463	1,790	1,700	1,700 13,	1,700	1,700 1,700	11,100	1,700	1,700 1,700	Q6 3015 Y 3015 11,300 63,763 56,722 295,896	45,200	41,200 0	-	1,767 1,767	1,747 11,8	0 1,367	1,767	1,747 11,800	3,797 3,797	1,767	11,800 1,717	7 3,767	1,797 11,800	45,300	48,000 66,000 309,192 249,192
\$7,347 18,007 \$2,625 11,925	(72) M,665	56,951 18,007 78,000 14,500	26,578 26,578	58,140 225,855 86,140 127,855	299,896 299,8 126,986 110,0	00E (X)		8,378 29,378 3,850 26,350	14.174 93.78 2.147 04.09	0 05334	29,574	29,376 88,	722 19,574	28,374 28,379	58,722 27,600	15374	29,374 29,374	58,722 299,896 27,498 126,566	365,863	201,602	1 -	20,161 20,161	30,341 40,4	33,365	20,361	30,341 60,481	20,141 20,141	20,361	60,683 20,160 27,500 9,166	0 20,141	20,141 60,683 9,166 27,698	345,983 3	209,192 209,192
11,101		10,000		12/,505		[26,000]		26,660		1,00				1,000	27,000			100,000		110,000	11			1,000		27,002			2,100	1,000	27,000		110,000 130,000
									-				-								1								-				
28,241 2,890	4,779	7,149 2,890	2,481 2,481	7,853 44,890	48,099 49,0	00 1		491 2,661	2,482 7,585	2,483	2,042	17,462 23	2,662	2,462 2,661	7,083	2,493	3,661 6,921	11,843 48,999	90,009	50,005	1	2,336 2,336	2,536 7,60	2,538	2,538	17,538 22,608	2,156 2,156	2,338	7,606 2,516	6 2,536	7,109 12,181	50,005	32,079 30,879
2,506 71.7	1,418	2,135 646	768 429	2,321 9,442 125 125	12,775 11,3			181	2,217 2,798	1,108	1,108	1,108 3,3	1,108	1,338 1,338	1,01	1,338	1,108 1,108	1,01 12,771	14,000	14,000 0	1 -	1,367 1,367	1,147 8,90	1,367	1,367	1,147 1,500	1,167 1,167	1,567	1,147	7 3,567	1,167 3,500	14,000	14,700 14,700
1,288	-	129	1441	1441 13.700	261 261 12,000 12,0	on .			A11 261	11,000	1	11.000 M	200	16.000	34.000		11.000	11,000 31,000	277	32,000	11		277 27		1 - 1	11.000 11.000	14,000		14.000	11,000	1100	33,000	285 285
	-	_	1 1	10,785			-11			2,000					36,000	t - t					11 1					12,000	14,000			22,000	22,000		
J 4,978,288 600,378		600,879 1,546,685	791,129 298,825	2,5%,429 12,414,551	9,000,485 8,929,	309 (30,879)	90	4,834 1,362,874	111,170 2,112,8	215,A30	1,012,500	328,170 3,629	6,290	- 801,50	808,500	827,706 2	1,094,780 109,890	2,001,836 9,000,68	9,613,289	1,601,209		990,290 875,000	875,000 2,780	90 .	1,500,000	1,500,000		833,533	\$33,533 1,124,0	1,121,000	291,667 2,361,666	5,625,289 10	13,000,000 10,000,000
18,000		18,000		18,000	14,000 14,0	. 00						ĺ	18,000		18,000			18,000	18,000	18,000							18,000		18,000			18,000	18,000 18,000
		-				_			-			_	_		_						4—4		_			_				_	_		
											1 1					l I					II I												
778.000	-	77.500	111100 311100	404.300 \$27.300	67300 2250	997 197 199									_	47300		67 NOT 67 NOT	775.000	221,000	1 1	16.750 16.750	18 797 56.7	7 16 797	16700	16 701 34 705	18700 18700	14705	34.755 14.750	n 1870	19700 16700	773.000	130.000 130.000
	-	-			67,500 225,0 182,000 183,0	000 0			-				21.667	21.667 21.660	63,000	21.007	21.667 21.667	65.000 150.000	112.000	130,000		18,750 18,750 13,811 13,811 4,000 4,000	20,833 52.0	22,833	22,833	20,833 32,699	18,750 18,750 10,833 10,833	22,834	18,710 18,710 12,500 13,810	10.830	18,750 54,250 10,854 82,600	113,000	180,000 180,000
					297,000 183.0	000 (17.000)			14000 14000	130-300	11.000	21.000 118	300					67,000 67,000 68,000 180,000 187,000	182 000	180,000 -		6,000 6,000	30,000 62.0	200,000	11.000	21.000 188.000						183.000	180,000 180,000
104 NA 44 NA		74.790		22.586 5.96.009	238,068 530,0	125 (308,748)			244,540 244,54	110,783	17,411	36,411 276	(834 26,411	11.000	22,300		11,400 57,841	22.386 209.962	193,325	550,825		18,110 48,111	47,814 186,1	111 184	37,411	34,411 279,874	26,411		25,611	22.000	57,841 508,948	300,125	150,325 550,325
854,565 43,500	37,310	74,750	22,584	23,586 554,009	201,012 201,0	113 .		-	_	110,281		14,784 145	DEE.	22,800	22,500		22,584	22,584 206,952	308,863	208,882	4		_	110,284		14,781 161,068	22,300		22,800	22,584	22,581	308,953	201,912 201,912
											1 1					l I					II I												
					490,890 490,8	193 600	11	7,200 87,326	204,47	12	199,258	196	218	33,400	33,400		14,300	14,300 450,330	419,887	439,007		29,907	141,041 186,1	us ·	218,119	218,110		33,400	33,400			419,087	419,887 419,887
											1 1					l I					II I												
					298,899 800,0	100			128,571 128,57	D,817	43,807	42,817 128	371 43,817		42,857			. 290,990	300,000	100,000 -	4	23,818 23,817	42,817 128,1	43,817	42,857	22,857 128,571	D,817		42,857		_	300,000	300,000 800,000
and the second	2,779	2,775		- 2,775	2,775 2,77						1 1		2,779		2,775	l I		2,779	2,775	2,775	II I						2,77%		2,775			2,775	2,775 2,775
			1 7			1	11 -				1			1 —							11				1 -		1 —			1 -			1
	1 1 1		1			- 1	11				1 1					1					11 1	1			1		1			- 1			1
930.006	-		20.101	20.108 940.111	620,500 620,5	100		-	11100 11100		190 110	180	330				18.632	28,622 620,500	695.695	613.500 361.532	4	199,960	1993		227.192	227.592	1.600		X 600		118.692 138.692	495.695 4	417A26
100,000	1 1 1		1 1	100,000	102.000 102.0	100	11 1				290,000	- 210	210,000	30.000	283.000	1	30.000	30,000 340,000	162,000	160,000 -	11 1	1			230,000	230,000	210.000	30,000	283.000	30,300	80,000	102,000	160,000 160,000
ENR.000 ·				455,000	183,000 183,0	. 000			-				183,000		183,000			· 181,000	183,000	181,000 -	11						181,000		183,000			183,000	181,000 181,000
36,566				26,166					-											·			_										
	280,101	130313		130303		80			-	15.990	21.302	23,566 56	288 00.805 800 20.000		60,805			97.081	97.093	97.091	-			15,392	15.960	23.506 36.286	00.80% 70.000 15.000		02.805 02.700			97,090	97.091 97.091
	-		-	2,700 2,700	130,000 60,0 307,800 193,0	(000,000)		1150	20,000 20,000 24,150 57,800	20,000	30,000	40)	20,000	20,000 20,000	60,000			120,000 60,000 207,600	93,000 293,000		-		_	_		20,000 90,000	20,000 20,000	33,000		0 50,000		90,000 290,000	80,000 80,000 110,000 150,000
			2,790	2,700 2,700	AV, 660 193,0	AN (17,900)		LANG	43,450 53,50	80,000	2,000	acon Sci				munit.	mount.	Majana 201,800	440,000	NORCHAN .	-	-		33,000	au,u00	90,000		_	80,000	w 90,300	40,000	ana, and	190,000 190,000
						200 (0)	- 1	9.833 239.833	110.811 679.01	119,811	209,888	115,833 679	.000 110.011	139,813 239,83	679,300	110.810	109.830 109.830	679,502 1,918,00	1,818,000	1908.000	11	119.833 119.833	109,833 679,6	219,833	215.811	229,833 679,699	110.811 110.811	215.834	679,900 119,63	109,830	155,850 679,500	1.918.000 1.	1,818,000 1,808,000
679,000 219,001	215.633 235.634	679,500 215,611	159.831 159.831					770 70.000	8.667 6330	1.667	6.667	6.867 201	200 5.667	1.057 5.057	20.000	5.557	EAST 5.667	20,000 121,511			11	1.867 1.867	E.857 200	0 6.667	6.667	E.SET 22.000	1.667 1.667	6.667				83.000	NI 000 NO 000
£78,500 218,831 00.168 3.000	234,833 234,834 634 525	£79,500 219,811 6,200 2,811	110,811 110,811 18,677 1,376	479,500 1,918,000 17,894 66,191	201111 80.0	00 (21.111)						THE PRIVILEGACTIO	PRIVLEGACTED PRIVLE	GACTED PROVIDENCES PR	VILLEGACTED, PROVILED	SACTIO PRIVILIDACI	TED PRIVILEGICTED PRIVIL	IEACTIO PRIVILIGIACTIO PRI	LIGE BACTIO PRIVILIGES	CTIO-PRIVILIGIDACTIO-PRIVI	GI FOACTIO: PRIVILIGE	TID PRIVEIGNATED PRIVEIG	ACTED PROVIDE BACTED P										
1 679,000 219,031 80368 1,200 WUQACHD PRIVADENTIA PRIVAD	233,833 233,834 839 323 8410 PROMINETE PROMISE	679,000 216,811 6200 2.811 6C110 PRIVILIDACTIO PRIVI	100,000 100,000 10,007 1,000 DEACTED PROVIDENCED PROVID	479,000 1,918,000 17,884 66,191 86CTIO PRIVERGRACTIO PRIVEES	201.512 RO.D. S POACTIO: PROVISIONATIO: P	00 (21.111)	SUEL POACTIO PENVISEACTIO	PRIVATED PRIVATEDACT	TID. PRIVILIDACTID. PR																	ID PRIVIDENCTIO PRIVILIO		VERMITTED PRIVEREDA	CTID PRIVIDACTID PR	T ESET EVERBACTED PROVIDE	S SAT 20300 SOCTED PROVIDENCES PROVI		
23 EFRAGO 238,ES3 25 60.ME 5.202 REVLIGACIOS PREVIDENCIAS	234,633 234,634 434 523 82110, PROVIDE TIE, PROVISIO	678300 119,811 6280 2.311 80715 PROVESSIONED PRINT	199,811 199,811 11,477 1376 HISKOTIO PRIVADICTIO PRIVA	479,000 1,918,000 17.884 46.191 HICTID-PROVENDENCTIO-PRIVED		00 (21.111)	ниционення менеционення	PRIVERGACTED: PRIVERGOACT	TIO PRIVILIDENCTIO PR	NUIGACIES PRIVES					-								_	PRESIDENT PRINCE	The second control of	Ib. PRIVILIBACTIO. PRIVILIO	ACTIO PRIVATED PRI	VEIMOTIO PEVLIEN	CHID. PRIVILIDACIDO PR	EVERNICIES PROVIDE			
VILIGACITE PRIVILENCITO PRIVILE	200,000 200,000 650 525 RCTIC PROVIDE TIE PROVIDE	479.000 235.633 92.00 2.833 00.30 PRIVED ACTIO PRIVI	LIGACTIO PRIVILIGACTIO PRIVILI	MCTID PRIVEIGNACTIO PRIVEI	POACTIO PRIVIDEDICTIO P	00 (21.111)	NAME ADMITTOR PROVIDED ACTOR	PROVIDENCE PROVIDENCE	TED PRIVELEGACING PR	WEIGIACTES PROVED																E. PRIVILISACTIES PRIVILIS	SACTIO PROVIDENTE PRI	VUMCTIO PERVUIDA			ISSCHIS PROVIDENCIES PROVI	REACTION PROVIDED POACTION	
VILIDACTID: PRIVILIDACTID: PRIVILIA 40,993	DIA, REI DIA, REI LES PROVINCIES	actes PRIVILIDACTIO PRIVI	71,530	71,000 114,000	S FONCTIO: PRIVILIBRIDACTIO: P	OS CHAILS			-				an was	41,000 WANT WANT	41,000		um um	89,000 180,000 Na 700 150,000				um um	um as		um	-	ALDOO	NUMCIO PEVUIDA	43,000 81,00	0	BUCTIO PROVIDENCTIO PROVI	SECULIE PROVIDE PRACTIC	180,000 180,000
EVILIDAÇÃO PRIVADAÇÃO PRIVADA	25A,RES 15B,RES ESS 325 SECTED PROVIDENCES PROVIDE 25 379	actes PRIVILIDACTIO PRIVI	73,830 27.800 20.899 4.751	74,830 114,830 80,336 180,237 6,731 6,731	193,000 193,000 124,00	OD GRAID WANGEDACTED PROV		PROVIDENCES PROVIDENCES	41.00 8447	25.60			475 29.545 219				16.779 16.778	89,000 180,000 19,000 524,000 25,000	183,000 265,908			14.779 14.779	16.775 86.8		16773	24.771 44.819	41,000 20.501 20.501 20.501	ZEMS		0	ISSCHIS PROVIDENCIES PROVI	SECULIE PROVIDE PRACTIC	
VILIDACTID: PRIVILIDACTID: PRIVILIA 40,993	200,000 200,000 000 000 000 000 000 000	actes PRIVILIDACTIO PRIVI	71,830 27,880 27,810 27,810 27,711	73,830 114,830 50,338 280,237 6,731 6,731 117,000 117,000	193,000 193,000 124,00	OS CHAILS			-	25.60			ATT 20 MS				am am					H79 H79	14771 847		16771	-	41,000 20.501 20.501	2010	43,000 81,00	0	BUCTIO PROVIDENCTIO PROVI	SECULIE PROVIDE PRACTIC	180,000 180,000
EVILIDAÇÃO PRIVADAÇÃO PRIVADA	219,031 219,030 559 325 20CTIO-PROVENCTIO-PROVEN- 20,037	actes PRIVILIDACTIO PRIVI	71,830 27,880 27,810 27,810 27,711	71,830 114,800 M0.336 180,237 6,711 6,711	193,000 193,000 124,00	OD GRAID WANGEDACTED PROV			41.00 8447	25.60			20 545 20 200 200 200 200 200 200 200 200 200				36.778 36.778 270,000 270,000					14.779 14.779 90,147 90,147	36.771 868 90,367 270,3		16779	-	41,000 26,001 26,007 90,347 90,347	25.65	43,000 81,00	0	BUCTIO PROVIDENCTIO PROVI	SECULIE PROVIDE PRACTIC	180,000 180,000
C 40382	210,031 210,030 838 325 86CTIS- PROVERSCHE: PROVES 28,071	actes PRIVILIDACTIO PRIVI	71,830 27,880 27,810 27,810 27,711	73,830 114,830 50,338 280,237 6,731 6,731 117,000 117,000	2 FOACTSD PROVINCED FO 133,000 133,5 321,000 221,0 321,000 221,0 33,000 20,0 23,000 20,0 2,0,0,7,200 2,540,0	00 (71.11) REVISIONAL TION PROVIDED AS TO SERVICE OF S			41.00 8447	25.60	29.505		485 28.565 209 411 270,000				36.778 36.778 270,500 270,500					16 775 16 775 90,187 90,187	36.771 66.8 80,367 270,		16.771	-	20.000 PROVERSCEND PRIS 41,000 20.001 20.001 90,387 90,387	25.65	43,000 83,00	0	BUCTIO PROVIDENCTIO PROVI	SECULIE PROVIDE PRACTIC	CTED PROVISIONACTED PROVISE 180,000 180,000
WALLONCID MANUSACTIO MINUSA 60 40,863	200,200 200,200 200 200 200,710, PROVANCED, PROVAN 20,170	actes PRIVILIDACTIO PRIVI	71,830 27,880 27,810 27,810 27,711	73,830 114,830 50,338 280,237 6,731 6,731 117,000 117,000	2 FOACTSE PROVESSEDACTSE P 2 10,000 2 10,5 224 596 224 1 18,899 20,0 2,317,296 3,246 27,994 4 4,507,296 4,50 4,50 4,50 4,50 4,50 4,50 4,50 4,50	00 (71.11) REVISIONAL TEST PREVI 000 (21.596) 000 (21.596) 000 (27.596)			41.00 8447	25.60	28.545 270,500 66.000	29.505 88 36, 273,500 1,63	230 4,166 230,600				34.772 34.772 270,300 270,300	19.095 224.996 24,000 811,000 5,317,31 27,994 48,000	264.50E	1,042,000 0		16 778 16 778 90,187 90,187	36.779 86.8 90,367 270,1		90,367	26.771 66.116 90,367 275,500	25.000 MINUSACTED. PMS. 51,000 25.561 25.560 90,167 90,167	29.603	43,000 83,00	0	BUCTIO PROVIDENCTIO PROVI	185,000 1 285,905 2 1,082,500 1	CHO. PRIVILEGED CTSC. PRIVILE 180,000 180,000 293,505 293,505 1,042,000 1,043,000
19. 201 201 201 201 201 201 201 201 201 201	250,000 150,000 850 150 86C 150, PROVIDENCE OF PROVIDE 20,000	actes PRIVILIDACTIO PRIVI	71,830 27,880 27,810 27,810 27,711	73,830 114,830 50,338 280,237 6,731 6,731 117,000 117,000	2 FOACTSD PROVINCED FO 133,000 133,5 321,000 221,0 321,000 221,0 33,000 20,0 23,000 20,0 2,0,0,7,200 2,540,0	00 (71.11) REVISIONAL TEST PREVI 000 (21.596) 000 (21.596) 000 (27.596)			41.00 8447	25.60	28.545 270,500 66.000		230 4,166 230,600				34.775 34.778 270,500 270,500		264.50E			16.772 16.772 90,167 90,167	10,347 270,1		90,367	26.771 46.110 	80,367 90,367	80,367	43,000 83,00	0	BUCTIO PROVIDENCTIO PROVI	SECULIE PROVIDE PRACTIC	CTED PROVINGIBLECTED PROVINGI 180,000 180,000
0 0082 135 135 135 135 135 135 135 135 135 135	JANUAR PROGRAMMA	actes PRIVILIDACTIO PRIVI	71,830 71,830 27,840 27,840 4,731 N(73) N(73) N(3)	73,830 114,830 50,338 280,237 6,731 6,731 117,000 117,000	370ACTES PROVISERDACTES PC 130,000 130,0 130,000 130,0 130,000 130,0 130,000 130,0 130,000 130,0 130,000 130,0 130,000 130,00 130,000 140,00 130,000 140,00 130,000 140,00 130,000 140,00 130,000 140,00 130,000 140,00 130,000 140,00 130,000 140,00 130,000 140,00 130,000 140,00 130,000 140,00 130,000 140,00 130,000 140,00 130,000 140,00 130,000 140,000 130,000 140,000 130,000 140,000 130,000 140,000 130,000 140,000 130,000 140,000 130,000 140,000 130,000 140,000 130,000 140,000 130,00	00 (71.11) REVISIONAL TEST PREVI 000 (21.596) 000 (21.596) 000 (27.596)			41.00 8447	1 7/10/10 0 56/10 2 52/10	29.345 270,300 44.000	29.505 88 36, 273,500 1,63	200 A135 270,000				34.771 54.772 270,500 270,500	10,000 \$24,000 \$1,000 \$11,000 \$2,000,00 \$27,000 \$45,000 \$21,000	264.50E	1,042,000 0		14.772 16.772 90,187 90,187	16.771 4637 80,367 270,0		90,367	26.771 66.116 90,367 275,500	25.00 PALLETTO PRIA 41,000 25.00 25.00 70,167 70,167	90,367	43,000 83,00	0	BUCTIO PROVIDENCTIO PROVI	135,000 1 285,908 2 1,082,000 1,	CHID. PRIVALEGE CHIC. PRIVALES 180,000 180,003 280,005 280,008 1,082,000 1,082,000 281,865 241,848
0.400.00110 PROVIDENTIO PROVIDENTIO PROVIDENTIO PROVIDENTIO PROVIDENTIO PROVIDENTI DI CONTROLO PROVIDENTI	20.371 20.371 20.371	21371 J.36* 21371 J.36* 117,000	71,520 27,620 27,620 27,620 4,721 70,725 26,527 26,527 26,527	77,830 114,800 70,830 114,800 50,330 180,247 6,731 8,733 117,000 117,000 100,840 331,800	370ACTES PROVISERDACTES PC 130,000 130,0 130,000 130,0 130,000 130,0 130,000 130,0 130,000 130,0 130,000 130,0 130,000 130,00 130,000 140,00 130,000 140,00 130,000 140,00 130,000 140,00 130,000 140,00 130,000 140,00 130,000 140,00 130,000 140,00 130,000 140,00 130,000 140,00 130,000 140,00 130,000 140,00 130,000 140,00 130,000 140,00 130,000 140,000 130,000 140,000 130,000 140,000 130,000 140,000 130,000 140,000 130,000 140,000 130,000 140,000 130,000 140,000 130,000 140,000 130,00	00 (78.11) REVILLERANCE TED: FREV 000 (20.895) 000 (213.895) 01 (27.495) 02 (28.895)		25.218 27.396	51.00 22.00 10.10 20.00 256,341 256,34 27,95	1 7/10/10 0 56/10 2 52/10	29.345 270,300 44.000	273,500 2,675 273,500 2,675 243,866 261	200 A135 270,000	28345 28345 270350 275350			270,500 270,500	10,000 \$24,000 \$1,000 \$11,000 \$2,000,00 \$27,000 \$45,000 \$21,000	264.50E	1,042,000 0		90,187 90,187	90,567 270,1		90,367	26.771 46.319 90,367 275,500 213,668 343,688	90,167 90,167	90,367	43,000 83,00	0	2017 200 PROVIDENCE PR	135,000 1 285,908 2 1,082,000 1,	CHES. PROVINCES PROVINCE 180,000 180,000 293,008 293,008 1,082,000 1,082,000

Case: 1:17-md-02804-DAP Doc #: 2313-100 Filed: 08/14/19 8 of 49. PageID #: 369837

Development Phase							ACTUAL							ACTUAL						
Committee Member			YTD (DEC)	JUL	AUG	SEP	Q3 2012	ОСТ	NOV	DEC	Q4 2012	Y2012		YTD (NOV)	JAN	FEB	MAR	01	APR	T
ctavis Group. I.f. (Formerly Watson)			-	, JOE	AUG	JEF	Q3 2012				Q4 2012	-		TID (NOV)	JAIN	FLU	IVIDAN	Q1	AFR	
do Pharmaceuticals Inc.			176,894	56,366	75,413	7,633	139,412	30,195	468	6,819	37,483	176,894		(17,158)	(7,819)	20		(7,799)	37	
nssen Pharmaceuticals, Inc.			176,894	56,366	75,413	7,633	139,412	30,195	468	6.819	37,483	176,894		(17,158)	(7,819)	20		(7,799)	37	
Tallinckrodt, Inc.			176,894	56,366	75,413	7,633	139,412	30.195	468	6.819	37,483	176,894		(17,158)	(7,819)	20		(7,799)	37	
Nylan Technologies, Inc.			176,894	56,366	75,413	7,633	139,412	30,195	468	6,819	37,483	176,894		(17,158)	(7,819)	20		(7,799)	37	
oven Pharmaceuticals, Inc.			176,894	56,366	75,413	7,633	139,412	30,195	468	6,819	37,483	176,894		(17,158)	(7,819)	20		(7,799)	37	
fizer, Inc.			176,894	56,366	75,413	7,633	139,412	30,195	468	6,819	37,483	176,894		(17,158)	(7,819)	20		(7,799)	37	
urdue Pharma, L.P.			176,894	56,366	75,413	7,633	139,412	30,195	468	6,819	37,483	176,894		(17,158)	(7,819)	20		(7,799)	37	1
hodes Pharmaceuticals L.P.			176,894	56,366	75,413	7,633	139,412	30.195	468	6.819	37,483	176,894		(17,158)	(7,819)	20		(7,799)	37	1
oxane Laboratories, Inc.			176,894	56,366	75,413	7,633	139,412	30,195	468	6,819	37,483	176,894		(17,158)	(7,819)	20		(7,799)	37	1
andoz Inc.			176,894	56,366	75,413	7,633	139,412	30,195	468	6,819	37,483	176,894		(17,158)	(7,819)	20		(7,799)	37	
ne PharmaNetwork, LLC			176.894	56,366	75.413	7.633	139,412	30,195	468	6.819	37,483	176,894		(17,158)	(7,819)	20		(7,799)	37	
istaPharm, Inc.			176,894	56,366	75,413	7,633	139,412	30,195	468	6,819	37,483	176,894		(17,158)	(7,819)	20		(7,799)	37	
ctavis Group, I.f. (Formerly Watson)			350,975	112.731	150,826	15,266	278,823	60.390	936	10,825	72,152	350,975		(14,515)	(5,232)	40		(5,192)	74	
npax Laboratories, Inc.			176,894		55,842	83,570	139,412	30,195	468	6,819	37,483	176,894		(17,158)	(7,819)	20		(7,799)	37	
potex			176,894	-	-	83,570	83,570	86.037	468	6.819	93.324	176,894		(17,158)	(7,819)	20		(7,799)	37	
ar Pharmaceuticals			176.895	-	-			-	-	176.895	176.895	176,895		(17.158)	(7,819)	20		(7,799)	37	
nbaxy			-	-	-	-	_	-		-	-	-		159.736	169.076	20		169.096	37	1
osher Smith				-	-	-	-	-		-	-			159,736	-	-		-		
ogenix			-			-	-	-		-	-			-	-					
esher				-	-	-	-	-		-	-			-	-	-		-		
Pya			80.700	32.880	32.637	-	65.517	15.183	-		15.183	80.700								
otal Development Phase Costs			3.085.092	822.000	1.144.262	274.000		554.143	7,495	283,191	844.830	3.085.092		47.586	46.566	357		46,923	662	2
		All6 11/1/12											Allocation							
Operations Phase	Allocation 7/7/12	Allocation 11/1/12					ACTUAL							ACTUAL						
<u> </u>	Allocation 7/7/12	Allocation 11/1/12	YTD (DFC)	IUL	AUG	SEP		ост	NOV	DEC	04 2012	Y2012			IAN	FFB	MAR	01	APR Cost and	АР
Committee Member			YTD (DEC)	JUL	AUG	SEP	ACTUAL Q3 2012	ост	NOV	DEC	Q4 2012	Y2012	3/31/13	ACTUAL YTD (NOV)	JAN	FEB	MAR	Q1	APR Cost and Q1, '13 True-up	Ai 2012 T
Committee Member	3.95%	0.00%		-	-	-	Q3 2012 -	-	-	-	-	-	3/31/13	YTD (NOV)	-	-		-	Q1, '13 True-up	2012 T
Committee Member ctavis Group, I.f. ndo Pharmaceuticals Inc.	3.95% 8.80%	0.00% 8.80%	450,999	- 29,657	357,384	-	Q3 2012 - 387,040	13,740	21,361	- 28,858	63,958	450,999	3/31/13 0.00% 5.74%	YTD (NOV) - 581,878	- 110,724	228,576	28,389	367,689	Q1, '13 True-up 85,218	2012 T
Committee Member ctavis Group, I.f. ndo Pharmaceuticals inc. inssen Pharmaceuticals, inc.	3.95% 8.80% 1.37%	0.00% 8.80% 1.37%	- 450,999 70,293	- 29,657 4,622	- 357,384 55,702	-	Q3 2012 - 387,040 60,324	- 13,740 2,141	21,361 3,329	- 28,858 4,498	- 63,958 9,968	- 450,999 70,293	0.00% 5.74% 1.83%	YTD (NOV) - 581,878 259,352	- 110,724 17,257	- 228,576 35,626	28,389 4,384	- 367,689 57,267	Q1, '13 True-up 85,218 87,232	(156 23,
Committee Member ctavis Group, I.f. ndo Pharmaceuticals inc. inssen Pharmaceuticals, inc. lallindxrodt, inc.	3.95% 8.80% 1.37% 20.16%	0.00% 8.80% 1.37% 20.16%	450,999 70,293 1,033,859	- 29,657 4,622 67,985	- 357,384 55,702 819,257	-	Q3 2012 - 387,040 60,324 887,242	13,740 2,141 31,497	21,361 3,329 48,966	- 28,858 4,498 66,154	- 63,958 9,968 146,617	- 450,999 70,293 1,033,859	3/31/13 0.00% 5.74% 1.83% 22.28%	YTD (NOV) - 581,878 259,352 2,973,380	110,724 17,257 253,822	228,576 35,626 523,982	28,389 4,384 64,608	367,689 57,267 842,412	Q1, '13 True-up 85,218 87,232 914,229	(156 23,
Committee Member ctavis Group, Lf. do Pharmaceuticals Inc. nssen Pharmaceuticals, Inc. tallinckrodt, Inc. tylan Technologies, Inc.	3,95% 8,80% 1,37% 20,16% 14,21%	0.00% 8.80% 1.37% 20.16% 14.21%	450,999 70,293 1,033,859 728,575	- 29,657 4,622 67,985 47,910	357,384 55,702 819,257 577,342	-	Q3 2012 - 387,040 60,324 887,242 625,252	- 13,740 2,141 31,497 22,196	21,361 3,329 48,966 34,507	- 28,858 4,498 66,154 46,619	- 63,958 9,968 146,617 103,323	- 450,999 70,293 1,033,859 728,575	0.00% 5.74% 1.83% 22.28% 15.67%	YTD (NOV) 581,878 259,352 2,973,380 2,090,101	- 110,724 17,257 253,822 178,872	228,576 35,626 523,982 369,258	28,389 4,384 64,608 45,700	367,689 57,267 842,412 593,830	Q1, '13 True-up 85,218 87,232 914,229 641,879	(156 23, 110 76,
Committee Member ctavis Group, I.f. ndo Pharmaceuticals Inc. nssen Pharmaceuticals, Inc. fallinckrodt, Inc. nylan Technologies, Inc. owen Pharmaceuticals, Inc.	3.95% 8.80% 1.37% 20.16% 14.21%	0.00% 8.80% 1.37% 20.16% 14.21% 1.17%	450,999 70,293 1,033,859 728,575 60,031	29,657 4,622 67,985 47,910 3,948	- 357,384 55,702 819,257 577,342 47,570		- 387,040 60,324 887,242 625,252 51,518	13,740 2,141 31,497 22,196 1,829	- 21,361 3,329 48,966 34,507 2,843	28,858 4,498 66,154 46,619 3,841	- 63,958 9,968 146,617 103,323 8,513	- 450,999 70,293 1,033,859 728,575 60,031	3/31/13 0.00% 5.74% 1.83% 22.28% 15.67%	YTD (NOV) - 581,878 259,352 2,973,380 2,990,101 139,701	- 110,724 17,257 253,822 178,872 14,738	228,576 35,626 523,982 369,258 30,425	28,389 4,384 64,608 45,700 3,744	- 367,689 57,267 842,412 593,830 48,907	85,218 87,232 914,229 641,879 38,530	(156 23 110 76 (3,1
Committee Member ctavis Group, I.f. ndo Pharmaceuticals inc. nssen Pharmaceuticals, inc. allinickrodt, inc. ndallinickrodt, inc. ndyan Technologies, inc. oven Pharmaceuticals, inc.	3.95% 8.80% 1.37% 20.16% 14.21% 1.17%	0.00% 8.80% 1.37% 20.16% 14.21% 1.17%	450,999 70,293 1,033,859 728,575 60,031 53,361	29,657 4,622 67,985 47,910 3,948 3,509	- 357,384 55,702 819,257 577,342 47,570 42,285		Q3 2012 - 387,040 60,324 887,242 625,252 51,518 45,794	13,740 2,141 31,497 22,196 1,829 1,626	21,361 3,329 48,966 34,507 2,843 2,527	28,858 4,498 66,154 46,619 3,841 3,414	63,958 9,968 146,617 103,323 8,513 7,567	- 450,999 70,293 1,033,859 728,575 60,031 53,361	3/31/13 0.00% 5.74% 1.83% 22.28% 15.67% 1.11% 0.89%	YTD (NOV) - 581,878 259,352 2,973,380 2,090,101 139,701 106,179	- 110,724 17,257 253,822 178,872 14,738 13,100	228,576 35,626 523,982 369,258 30,425 27,044	28,389 4,384 64,608 45,700 3,744 3,328	- 367,689 57,267 842,412 593,830 48,907 43,473	85,218 87,232 914,229 641,879 38,530 26,462	(156 23, 110 76, (3,0 (7,7)
Committee Member ctavis Group, I.f. do Pharmaceuticals inc. nassen Pharmaceuticals, inc. dallinckrodt, inc. hylan Technologies, inc. oven Pharmaceuticals, inc. fizer, inc. trudue Pharma, L.P.	3.95% 8.80% 1.37% 20.16% 14.21% 1.17% 2.575%	0.00% 8.80% 1.37% 20.16% 14.21% 1.17% 25.75%	450,999 70,293 1,033,859 728,575 60,031 53,361 1,320,158	- 29,657 4,622 67,985 47,910 3,948 3,509 86,811	357,384 55,702 819,257 577,342 47,570 42,285 1,046,128		Q3 2012 - 387,040 60,324 887,242 625,252 51,518 45,794 1,132,940	13,740 2,141 31,497 22,196 1,829 1,626 40,219	21,361 3,329 48,966 34,507 2,843 2,527 62,526	28,858 4,498 66,154 46,619 3,841 3,414 84,473	63,958 9,968 146,617 103,323 8,513 7,567 187,218	450,999 70,293 1,033,859 728,575 60,031 53,361 1,320,158	3/31/13 0.00% 5.74% 1.83% 22.28% 15.67% 1.11% 0.89% 25.36%	YTD (NOV)	110,724 17,257 253,822 178,872 14,738 13,100 324,111	228,576 35,626 523,982 369,258 30,425 27,044 669,085	28,389 4,384 64,608 45,700 3,744 3,328 82,594	367,689 57,267 842,412 593,830 48,907 43,473 1,075,790	85,218 87,232 914,229 641,879 38,530 26,462 923,749	(156 23, 110 76, (3,) (7, (17,
Committee Member ctavis Group, I.f. do Pharmaceuticals inc. inssen Pharmaceuticals, inc. lallinckrodt, inc. lydan Technologies, inc. owen Pharmaceuticals, inc. liter, inc. rdue Pharma, L.P. nodes Pharmaceuticals L.P.	3.95% 8.80% 1.37% 20.16% 14.21% 1.17% 25.75% 7.33%	0.00% 8.80% 1.37% 20.16% 14.21% 1.17% 1.04% 25.75% 7.31%	450,999 70,293 1,033,859 728,575 60,031 53,361 1,320,158 374,549	29,657 4,622 67,985 47,910 3,948 3,509 86,811 24,630	357,384 55,702 819,257 577,342 47,570 42,285 1,046,128 296,803		Q3 2012 - 387,040 60,324 887,242 625,252 51,518 45,794 1,132,940 321,433	- 13,740 2,141 31,497 22,196 1,829 1,626 40,219 11,411	21,361 3,329 48,966 34,507 2,843 2,527 62,526 17,740	28,858 4,498 66,154 46,619 3,841 3,414 84,473 23,966	63,958 9,968 146,617 103,323 8,513 7,567 187,218 53,117	450,999 70,293 1,033,859 728,575 60,031 53,361 1,320,158 374,549	0.00% 5.74% 1.83% 22.28% 15.67% 1.11% 0.89% 25.36% 7.02%	YTD (NOV)	110,724 17,257 253,822 178,872 14,738 13,100 324,111 91,955	228,576 35,626 523,982 369,258 30,425 27,044 669,085 189,830	28,389 4,384 64,608 45,700 3,744 3,328 82,594 23,359	367,689 57,267 842,412 593,830 48,907 43,473 1,075,790 305,144	85,218 87,232 914,229 641,879 38,530 26,462 923,749 248,319	2012 T (156 23, 110 76, (3,0 (7,: (17, (13,0)
Committee Member ctavis Group, I.f. ndo Pharmaceuticals inc. nssen Pharmaceuticals, inc. allinickrodt, inc. Aylan Technologies, inc. oven Pharmaceuticals, inc. fiter, inc. urdue Pharma, I.P. hodes Pharmaceuticals I.P. oxane Laboratories, inc.	3.95% 8.80% 1.37% 20.16% 14.21% 1.17% 1.104% 25.75% 7.31%	0.00% 8.80% 1.37% 20.16% 14.21% 1.17% 1.04% 25.75% 7.31% 9.47%	450,999 70,293 1,033,859 728,575 60,031 53,361 1,320,158 374,549 485,375	29,657 4,622 67,985 47,910 3,948 3,509 86,811 24,630 31,917	357,384 55,702 819,257 577,342 47,570 42,285 1,046,128 296,803 384,624		Q3 2012 387,040 60,324 887,242 625,252 51,518 45,794 1,132,940 321,433 416,541	13,740 2,141 31,497 22,196 1,829 1,626 40,219 11,411 14,787	21,361 3,329 48,966 34,507 2,843 2,527 62,526 17,740 22,989	- 28,858 4,498 66,154 46,619 3,841 3,414 84,473 23,966 31,058	- 63,958 9,968 146,617 103,323 8,513 7,567 187,218 53,117 68,834	- 450,999 70,293 1,033,859 728,575 60,031 53,361 1,320,158 374,549 485,375	0.00% 5.74% 1.83% 22.28% 15.67% 1.11% 0.89% 25.36% 9.84%	YTD (NOV) - 581,878 259,352 2,973,380 2,090,101 139,701 106,179 3,244,768 888,060 1,285,382	110,724 17,257 253,822 178,872 14,738 13,100 324,111 91,955 119,164	228,576 35,626 523,982 369,258 30,425 27,044 669,085 189,830 245,998	28,389 4,384 64,608 45,700 3,744 3,328 82,594 23,359 30,796	367,689 57,267 842,412 593,830 48,907 43,473 1,075,790 305,144 395,958	01, '13 True-up 85,218 87,232 914,229 641,879 38,530 26,462 923,749 248,319 380,545	(156 23, 110 76, (3,) (7, (17, (13,
Committee Member ctavis Group, I.f. ndo Pharmaceuticals Inc. nussen Pharmaceuticals, Inc. lallinckrodt, Inc. Nylan Technologies, Inc. owen Pharmaceuticals, Inc. fizer, Inc. urdue Pharma, L.P. hodes Pharmaceuticals L.P. oxane Laboratories, Inc. andoz Inc.	3.95% 8.80% 1.37% 20.16% 14.21% 1.17% 2.575% 7.31% 9.47%	0.00% 8.80% 1.37% 20.16% 14.21% 1.17% 1.04% 25.75% 7.31% 9.47% 1.22%	450,999 70,293 1,033,859 728,575 60,031 53,361 1,320,158 374,549 485,375 62,596	29,657 4,622 67,985 47,910 3,948 3,509 86,811 24,630 31,917 4,116	357,384 55,702 819,257 577,342 47,570 42,285 1,046,128 296,803 384,624 49,603		Q3 2012 387,040 60,324 887,242 625,252 51,518 45,794 1,132,940 321,433 416,541 53,719	13,740 2,141 31,497 22,196 1,829 1,626 40,219 11,411 14,787 1,907	21,361 3,329 48,966 34,507 2,843 2,527 62,526 17,740 22,989 2,965	28,858 4,498 66,154 46,619 3,841 3,414 84,473 23,966 31,058 4,005	63,958 9,968 146,617 103,323 8,513 7,567 187,218 53,117 68,834 8,877	450,999 70,293 1,033,859 728,575 60,031 53,361 1,320,158 374,549 485,375 62,596	3/31/13 0.00% 5.74% 1.83% 22.28% 15.67% 1.11% 0.89% 25.36% 7.02% 9.84% 1.29%	YTD (NOV) - 581,878 259,352 2,973,380 2,090,101 139,701 106,179 3,244,768 888,060 1,285,382 169,600	110,724 17,257 253,822 178,872 14,738 13,100 324,111 91,955 119,164 15,368	228,576 35,626 523,982 369,258 30,425 27,044 669,085 189,830 245,998 31,725	28,389 4,384 64,608 45,700 3,744 3,328 82,594 23,359 30,796 3,904	367,689 57,267 842,412 593,830 48,907 43,473 1,075,790 305,144 395,958 50,997	85,218 87,232 914,229 641,879 38,530 26,462 923,749 248,319 380,545 50,786	2012 1 (156 23 110 76 (3, (7, (17 (13 20 3,
Committee Member ctavis Group, I.f. ndo Pharmaceuticals inc. nssen Pharmaceuticals, inc. allinickrodt, inc. lydan Technologies, inc. oven Pharmaceuticals, inc. lzer, inc. urdue Pharma, L.P. urdue Pharma, L.P. oxane Laboratories, inc. ndoz Pharmaceuticals L.P. oxane Laboratories, inc. ndoz inc. ndoz inc.	3.95% 8.80% 1.37% 20.16% 14.21% 1.10% 25.75% 9.47% 1.22% 0.08%	0.00% 8.80% 1.37% 20.16% 14.21% 1.17% 1.04% 25.75% 7.31% 9.47% 1.22% 0.08%	450,999 70,293 1,033,859 728,575 60,031 53,361 1,320,158 374,549 485,375 62,596 4,105	29,657 4,622 67,985 47,910 3,948 3,509 86,811 24,630 31,917 4,116 270	357,384 55,702 819,257 577,342 47,570 42,285 1,046,128 296,803 384,624 49,603 3,253		Q3 2012 - 387,040 60,324 887,242 625,252 51,518 45,794 1,132,940 321,433 446,541 53,719 3,523	13,740 2,141 31,497 22,196 1,829 1,626 40,219 11,411 14,787 1,907 125	21,361 3,329 48,966 34,507 2,843 2,527 62,526 17,740 22,989 2,965 194	28,858 4,498 66,154 46,619 3,841 3,414 84,473 23,966 31,058 4,005 263	63,958 9,968 146,617 103,323 8,513 7,567 187,218 53,117 68,834 8,877 582	450,999 70,293 1,033,859 728,575 60,031 53,361 1,320,158 374,549 485,375 62,596 4,105	3/31/13 0.00% 5.74% 1.83% 22.28% 15.67% 0.89% 25.36% 7.02% 9.84% 1.29% 0.00%	YTD (NOV)	110,724 17,257 253,822 178,872 14,738 13,100 324,111 91,955 119,164 15,368 1,008	228,576 35,626 523,982 369,258 30,425 27,044 669,085 189,830 245,998 31,725 2,080	28,389 4,384 64,608 45,700 3,744 3,328 82,594 23,359 30,796 3,904 387	367,689 57,267 842,412 593,830 48,907 43,473 1,075,790 305,144 395,958 50,997 3,475	Q1, '13 True-up 85,218 87,232 914,229 641,879 38,530 26,462 923,749 248,319 380,545 50,786 (3,344)	2012 (15) (15) 23 11) 76 (3) (7) (17 (13) 20 3, (4)
Committee Member ctavis Group, I.f. do Pharmaceuticals Inc. inssen Pharmaceuticals, Inc. tallinckrodt, Inc. ylan Technologies, Inc. lizer, Inc. lizer, Inc. rudue Pharma, L.P. hodes Pharmaceuticals L.P. zoane Laboratories, Inc. indoz Inc. in Pharmaketwork, LLC staPharm, Inc.	3.95% 8.80% 1.37% 20.16% 14.21% 1.17% 2.575% 7.31% 9.47%	0.00% 8.80% 1.37% 20.16% 14.21% 1.17% 1.04% 25.75% 7.31% 9.47% 1.22% 0.08% 0.01%	450,999 70,293 1,033,859 728,575 60,031 53,361 1,320,158 374,549 485,375 62,596 4,105 513	29,657 4,622 67,985 47,910 3,948 3,509 86,811 24,630 31,917 4,116 270 34	357,384 55,702 819,257 577,342 47,570 42,285 1,046,128 296,803 384,624 49,603 3,253 406		03 2012 387,040 60,324 887,242 625,252 51,518 45,794 1,132,940 321,433 416,541 53,719 3,523 440	13,740 2,141 31,497 22,196 1,829 1,626 40,219 11,411 14,787 1,907 125 16	. 21,361 3,329 48,966 34,507 2,843 2,527 62,526 17,740 22,989 2,965 194 24	28,858 4,498 66,154 46,619 3,841 3,414 84,473 23,966 31,058 4,005 263 33	63,958 9,968 146,617 103,323 8,513 7,567 187,218 53,117 68,834 8,877 582	450,999 70,293 1,033,859 728,875 60,031 53,361 1,320,158 374,549 485,375 62,596 4,105 513	3/31/13 0.00% 5.74% 1.83% 22.28% 15.67% 0.89% 25.36% 7.02% 9.84% 1.29% 0.00% 0.00%	YTD (NOV) - 581,878 259,352 2,973,380 2,090,101 139,701 106,179 3,244,768 88,050 1,285,362 169,600 (3,973) (513)	110,724 17,257 253,822 178,872 14,738 13,100 324,111 91,955 119,164 15,368 1,008	228,576 35,626 523,982 369,258 30,425 27,044 669,085 189,830 245,998 31,725 2,080 260	28,389 4,384 64,608 45,700 3,744 3,328 82,594 23,359 30,796 3,904 387 32	367,689 57,267 842,412 593,830 48,907 43,473 1,075,790 305,144 395,958 50,997 3,475 418	Q1, '13 True-up 85,218 87,232 914,229 641,879 38,530 26,462 923,749 248,319 380,545 50,786 (3,344) (418)	(15) (23) 11) 76 (3, (7, (17) (13) 200 3, (4,
Committee Member tavis Group, I.f. do Pharmaceuticals inc. nssen Pharmaceuticals, inc. allinckrodt, inc. allinckrodt, inc. vower Pharmaceuticals, inc. lizer, inc. izer, iz	3.95% 8.80% 1.37% 20.16% 14.21% 1.17% 25.75% 9.47% 1.22% 0.08% 0.01%	0.00% 8.80% 1.37% 20.16% 14.21% 1.04% 25.75% 7.31% 9.47% 1.22% 0.08% 0.01%	450,999 70,293 1,033,859 728,575 60,031 53,361 1,320,158 374,549 485,375 62,596 4,105 513 671,272	29,657 4,622 67,985 47,910 3,948 3,509 86,811 24,630 31,917 4,116 270 34 31,749	357,384 55,702 819,257 577,342 47,570 42,285 1,046,128 296,803 384,624 49,603 3,253		Q3 2012 387,040 60,324 887,242 625,252 51,518 45,794 1,132,940 321,433 416,541 53,719 3,523 440 414,340	13,740 2,141 31,497 22,196 1,829 1,626 40,219 11,411 14,787 1,907 125	21,361 3,329 48,966 34,507 2,843 2,527 62,526 17,740 22,989 2,965 194 24 22,867	28,858 4,498 66,154 46,619 3,841 3,414 84,473 23,966 31,058 4,005 263	63,958 9,968 146,617 103,323 8,513 7,567 187,218 53,117 66,834 8,877 582 73 68,469	450,999 70,293 1,033,859 728,575 60,031 53,361 1,320,158 374,549 485,375 62,596 4,105 513 482,809	3/31/13 0.00% 5.74% 1.83% 22.28% 1.11% 0.89% 7.02% 9.84% 1.29% 0.00% 6.50%	YTD (NOV)	. 110,724 17,257 253,822 178,872 14,738 13,100 324,111 91,955 119,164 15,368 1,008 126 118,534	228,576 35,626 523,982 369,258 30,425 27,044 669,085 189,830 245,998 31,725 2,080	28,389 4,384 64,608 45,700 3,744 3,328 82,594 23,359 30,796 3,904 387 32 31,554	367,689 57,267 842,412 593,830 48,907 43,473 1,075,790 305,144 395,958 50,997 3,475 418	85,218 87,232 914,229 641,879 38,530 26,462 923,749 248,319 380,545 50,786 (3,344) (418) 119,134	(156) 231 110 766 (3, (7, (17, (13) 200 3, (4, (5) (32)
Committee Member ttavis Group, I.f. do Pharmaceuticals Inc. nssen Pharmaceuticals, Inc. allinckrodt, Inc. yain Technologies, Inc. ver, Inc. teer, Inc. teer, Inc. teer, Inc. teer, Inc. does Pharmaceuticals, Inc. teer, Inc. does Pharmaceuticals LP. xone Laboratories, Inc. ndoz Inc. e Pharmaceuticals LP. xone Laboratories, Inc. to Pharmaceuticals LP. xone Laboratories, Inc. to StaPharm, Inc. tavis Group, I.f. (Formerly Watson) past Laboratories, Inc.	3.95% 8.80% 1.37% 20.16% 14.21% 1.17% 1.04% 25.75% 7.31% 9.47% 1.22% 0.08% 0.00%	0.00% 8.80% 1.37% 20.16% 14.21% 1.17% 1.04% 25.75% 7.31% 9.47% 1.22% 0.00% 0.01% 9.41%	450,999 70,293 1,033,859 728,575 60,031 53,361 1,320,158 374,549 485,375 62,596 4,105 513 671,272	29,657 4,622 67,985 47,910 3,948 3,509 86,811 24,630 31,917 4,116 270 34	357,384 55,702 819,257 577,342 47,570 42,285 1,046,128 296,803 384,624 49,603 3,253 406 382,591		03 2012 387,040 60,324 887,242 625,252 51,518 45,794 1,132,940 321,433 446,541 53,719 3,523 440 41,340	13,740 2,141 31,497 22,196 1,829 1,626 40,219 11,411 14,787 1,907 125 16	21,361 3,329 48,966 34,507 2,843 2,527 62,526 17,740 22,989 2,965 194 24 22,867	28,858 4,498 66,154 46,619 3,841 3,414 84,473 23,966 31,058 4,005 263 33	63,958 9,968 146,617 103,323 8,513 7,567 187,218 53,117 68,834 8,877 582 73 68,469	450,999 70,293 1,033,859 728,875 60,031 53,361 1,320,158 374,549 485,375 62,596 4,105 513 482,809	3/31/13 0.00% 5.74% 1.83% 22.28% 15.67% 1.11% 0.89% 25.36% 7.02% 9.84% 1.29% 0.00% 6.50%	YTD (NOV) - 581,878 259,352 2,973,380 2,090,101 139,701 106,179 3,244,768 88,050 1,285,362 169,600 (3,973) (513)	110,724 17,257 253,822 178,872 14,738 13,100 324,111 91,955 119,164 15,368 1,008 126	228,576 35,626 523,982 369,258 30,425 27,044 669,085 189,830 245,998 31,725 2,080 260	28,389 4,384 64,608 45,700 3,744 3,328 82,594 23,359 30,796 3,904 387 32	367,689 57,267 842,412 593,830 48,907 43,473 1,075,790 305,144 395,958 50,997 3,475 418 394,787 525	85,218 87,232 914,229 641,879 38,530 26,462 923,749 248,319 380,545 50,786 (3,344) (418) 119,134	(15) (23) 110 (76) (33, (77, (17) (13) 20) 3, (4), (5)
Committee Member ctavis Group, I.f. do Pharmaceuticals Inc. nssen Pharmaceuticals, Inc. lallindxroft, Inc. yelyan Technologies, Inc. oven Pharmaceuticals, Inc. izer, Inc. izer	3.95% 8.80% 1.37% 20.16% 14.21% 1.17% 1.04% 22.575% 7.31% 9.47% 1.02% 0.08% 0.01%	0.00% 8.80% 1.37% 20.16% 14.21% 1.04% 25.75% 7.31% 9.47% 1.22% 0.08% 0.01% 9.41% 0.00%	450,999 70,293 1,033,859 728,575 60,031 53,361 1,320,158 374,549 485,375 62,596 4,105 513 671,272	29,657 4,622 67,985 47,910 3,948 3,509 86,811 24,630 31,917 4,116 270 34 31,749	357,384 55,702 819,257 577,342 47,570 42,285 1,046,128 296,803 384,624 49,603 3,253 406		03 2012 387,040 60,324 887,242 625,252 51,518 45,794 1,132,940 321,433 446,541 53,719 3,523 440 414,340	13,740 2,141 31,497 22,196 1,829 1,626 40,219 11,411 14,787 1,907 125 16 14,709	21,361 3,329 48,966 34,507 2,843 2,527 62,526 17,740 22,989 2,965 194 24 22,867	28,858 4,498 66,154 46,619 3,841 3,414 84,473 23,966 31,058 4,005 263 33	63,958 9,968 146,617 103,323 8,513 7,567 187,218 53,117 68,834 8,877 582 73 68,469	450,999 70,293 1,033,859 728,575 60,031 53,361 1,320,158 374,549 4,105 513 482,809	3/31/13 0.00% 5.74% 1.83% 22.28% 1.11% 0.89% 7.02% 9.84% 1.29% 0.00% 6.50% 0.00%	YTD (NOV)	. 110,724 17,257 253,822 178,872 14,738 13,100 324,111 91,955 119,164 15,368 1,008 126 118,534	228,576 35,626 523,982 369,258 30,425 27,044 669,085 189,830 245,998 31,725 2,080 260 244,698	28,389 4,384 64,608 45,700 3,744 3,328 82,594 23,359 30,796 3,904 387 32 31,554	367,689 57,267 842,412 593,830 48,907 43,473 1,075,790 305,144 395,958 50,997 3,475 418 394,787	Q1, 13 True-up 85,218 87,232 914,229 641,879 38,530 26,462 923,749 248,319 380,545 50,786 (3,344) 4181 119,134	2012 (15) 23 11: 76 (3) (7,7) (17) (13) 20 (4) (4) (5) (3)
Committee Member ttavis Group, I.f. do Pharmaceuticals Inc. nssen Pharmaceuticals, Inc. lallinckroft, Inc. yayan Technologies, Inc. boven Pharmaceuticals, Inc. lzer, Inc. lzer	3.95% 8.80% 1.37% 20.16% 14.21% 1.17% 1.04% 25.75% 7.31% 9.47% 1.22% 0.08% 0.08% 0.00%	0.00% 8.80% 1.37% 20.16% 1.42% 1.17% 1.04% 25.75% 7.31% 9.47% 1.02% 0.05% 0.00% 0.00%	450,999 70,293 1,033,859 728,575 60,031 53,361 1,320,158 374,549 485,375 62,596 4,105 513 671,272	29,657 4,622 67,985 47,910 3,948 3,509 86,811 24,630 31,917 4,116 270 34 31,749	357,384 55,702 819,257 577,342 47,570 42,285 1,046,128 296,803 384,624 49,603 3,253 406 382,591		03 2012 387,040 60,324 887,242 625,252 51,518 45,794 1,132,940 321,433 446,541 53,719 3,523 440 414,340	13,740 2,141 31,497 22,196 1,829 1,626 40,219 11,411 14,787 1,907 125 16 14,709	21,361 3,329 48,966 34,507 2,843 2,527 62,526 17,740 22,989 2,965 194 24 22,867	28,858 4,498 66,154 46,619 3,841 3,414 84,473 31,058 4,005 263 33 33 30,894	63,958 9,968 146,617 103,323 8,513 7,567 187,218 53,117 68,834 8,877 582 73 68,469	450,999 70,293 1,033,859 728,575 60,031 53,361 1,320,158 374,549 485,375 62,596 4,105 513 482,809	3/31/13 0.00% 5.74% 1.83% 15.67% 1.11% 0.89% 25.36% 7.02% 9.84% 1.29% 0.00% 0.00% 0.00% 0.00% 0.00%	YTD (NOV)	110,724 17,257 253,822 178,872 14,738 13,100 324,111 91,955 119,164 15,368 1,008 126	228,576 35,626 523,982 369,258 30,425 27,044 669,085 189,830 245,998 31,725 2,080 260 244,698	28,389 4,384 64,608 45,700 3,744 3,328 82,594 23,359 30,796 3,904 387 32 31,554 525	367,689 57,267 842,412 593,830 48,907 43,473 1,075,790 305,144 395,958 50,997 3,475 418 394,787 525	85,218 87,232 914,229 641,879 38,530 26,462 923,749 248,319 380,545 50,786 (3,344) (418) 119,134	2012 (15) 23 11) 76 (33, (7, (17) (13) 20 3, (4, (5) (5) (32)
Committee Member ctavis Group, Lf. ndo Pharmaceuticals Inc. nssen Pharmaceuticals, Inc. fallinckrodt, Inc. nylan Technologies, Inc. noven Pharmaceuticals, Inc. (izer, Inc. rurdue Pharma, L.P. hodes Pharmaceuticals LP. oxane Laboratories, Inc. ndoz Inc. te Pharmarework, LLC stathParm, Inc. ctavis Group, Lf. (Formerly Watson) mpas Laboratories, Inc. potex ar	3.95% 8.80% 1.37% 20.16% 14.21% 1.17% 1.04% 25.75% 7.31% 9.47% 1.02% 0.08% 0.00% 0.00%	0.00% 8.80% 1.37% 20.16% 14.21% 1.17% 1.04% 25.75% 7.31% 9.47% 1.22% 0.08% 0.01% 9.41% 0.00% 0.00%	450,999 70,293 1,033,859 728,575 60,031 53,361 1,320,158 374,549 485,375 62,596 4,105 513 671,272	29,657 4,622 67,985 47,910 3,948 3,509 86,811 24,630 31,917 4,116 270 34 31,749	357,384 55,702 819,257 577,342 47,570 42,285 1,046,128 296,803 384,624 49,603 3,253 406 382,591		03 2012 387,040 60,324 887,242 625,252 51,518 45,794 1,132,940 321,433 416,541 53,719 3,523 440 414,340	13,740 2,141 31,497 22,196 1,829 1,626 40,219 11,411 14,787 1,907 125 16 14,709	21,361 3,329 48,966 34,507 2,843 2,527 62,526 17,740 22,989 2,965 194 24 22,867	28,858 4,498 66,154 46,619 3,841 3,414 84,473 23,966 31,058 4,005 263 33	63,958 9,968 146,617 103,323 8,513 7,567 187,218 53,117 68,834 8,877 582 73 68,469	450,999 70,293 1,033,859 728,575 60,031 53,361 1,320,158 374,549 485,375 62,596 4,105 513 482,809	3/31/13 0.00% 5.74% 1.83% 22.28% 15.67% 1.11% 0.99% 25.36% 7.02% 9.84% 1.29% 0.00% 6.50% 0.00% 0.00% 0.00%	YTD (NOV) 581,878 259,352 2,973,380 2,090,101 139,701 106,179 3,244,768 888,060 13,973) (513) 805,520 525 315,488 1,498	110,724 17,257 253,822 178,872 14,738 13,100 324,111 91,955 119,164 15,368 1,008 126	228,576 35,626 523,992 369,258 30,425 27,044 669,085 189,830 245,998 31,725 2,080 260 244,698	28,389 4,384 64,608 45,700 3,744 3,328 82,594 23,359 30,796 3,904 387 32 31,554	367,689 57,267 842,412 593,830 48,907 43,473 1,075,790 305,144 395,958 50,997 3,475 418 394,787 525 - 656 263	Q1, 13 True-up 85,218 87,232 914,229 641,879 38,530 26,462 923,749 248,319 380,545 50,786 (3,344) (418) 119,134 122,808 758	2012 (15 2: (3) (7) (11 2: (3) (7) (12 2: (4) (4) (5) (3)
Committee Member ctavis Group, I.f. do Pharmaceuticals inc. unssen Pharmaceuticals, inc. lallinckrodt, inc. lydan Technologies, inc. oven Pharmaceuticals, inc. liter, inc. urdue Pharma, L.P. nodes Pharmaceuticals L.P. oxane Laboratories, inc. andoz inc. ne PharmaNetwork, LLC starPharm, inc. ttavis Group, I.f. (Formerly Watson) papax Laboratories, inc. papax Laboratories, inc. otoric Group, I.f. (Formerly Watson) papax Laboratories, inc. papax Laboratories, inc. otoric Group, I.f. (Formerly Watson) papax Laboratories, inc.	3.95% 8.80% 1.37% 20.16% 14.21% 1.17% 1.04% 25.75% 9.47% 1.12% 0.08% 0.01% 0.00% 0.00% 0.00%	0.00% 8.80% 1.37% 20.16% 14.21% 1.17% 1.04% 25.75% 7.31% 9.47% 0.08% 0.01% 9.41% 0.00% 0.00% 0.00%	450,999 70,293 1,033,859 728,575 60,031 53,361 1,320,158 374,549 485,375 62,596 4,105 513 671,272	29,657 4,622 67,985 47,910 3,948 3,509 86,811 24,630 31,917 4,116 270 34 31,749	357,384 55,702 819,257 577,342 47,570 42,285 1,046,128 296,803 384,624 49,603 3,253 406 382,591		Q3 2012 387,040 60,324 887,242 625,252 51,518 45,794 1,132,940 321,433 416,541 53,719 3,523 440 414,340	13,740 2,141 31,497 22,196 1,829 1,626 40,219 11,411 14,787 1,907 125 16 14,709	21,361 3,329 48,966 34,507 2,843 2,527 62,526 17,740 22,989 2,965 194 24 22,867	28,858 4,498 66,154 46,619 3,841 3,414 84,473 31,058 4,005 263 33 33 30,894	63,958 9,968 146,617 103,323 8,513 7,567 187,218 53,117 68,834 8,877 582 73 68,469	450,999 70,293 1,033,859 728,575 60,031 53,361 1,320,158 374,549 485,375 62,596 4,105 513 482,009	3/31/13 0.00% 5.74% 1.83% 22.28% 15.67% 1.11% 0.89% 25.36% 9.84% 1.29% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%	YTD (NOV)	110,724 17,257 253,822 178,872 14,738 13,100 324,111 91,955 119,164 15,368 1,008 126	228,576 228,576 35,626 523,982 369,258 30,425 27,044 669,085 189,830 245,998 31,725 2,080 260 244,698	28,389 4,384 64,608 45,700 3,744 3,328 82,594 23,359 30,796 3,904 387 32 31,554 525	367,689 367,689 57,267 842,412 593,830 48,907 43,473 1,075,790 305,144 395,958 50,997 3,475 418 394,787 525 	85,218 87,232 914,229 641,879 38,530 26,462 923,749 248,319 380,545 50,786 (3,344) (418) 119,134 -	2012 (15 2: 111 70 (3) (7) (1: (1: 20 3) (4) (6)
Committee Member ctavis Group, I.f. do Pharmaceuticals Inc. inssen Pharmaceuticals, inc. fallinckrodt, inc. fylan Technologies, Inc. owen Pharmaceuticals, inc. fizer, Inc. rudue Pharma, L.P. hodes Pharmaceuticals L.P. oxane Laboratories, Inc. andoz Inc. te PharmaNetwork, LLC staPharm, Inc. ctavis Group, I.f. (Formerly Watson) papax Laboratories, Inc. papax Laboratories, Inc. papax Laboratories, Inc. papax Laboratories, Inc. potex ar anbaxy poher-Smith gogenix	3.95% 8.80% 1.37% 20.16% 14.21% 1.17% 1.04% 2.575% 7.31% 9.47% 0.00% 0.00% 0.00% 0.00% 0.00%	0.00% 8.80% 1.37% 20.16% 14.21% 1.17% 1.04% 7.31% 9.47% 0.08% 0.01% 9.41% 0.00% 0.00% 0.00% 0.00%	450,999 70,293 1,033,859 728,575 60,031 53,361 1,320,158 374,549 485,375 62,596 4,105 513 671,272	29,657 4,622 67,985 47,910 3,948 3,509 86,811 24,630 31,917 4,116 270 34 31,749	357,384 55,702 819,257 577,342 47,570 42,285 1,046,128 296,803 384,624 49,603 3,253 406 382,591		03 2012 387,040 60,324 887,242 625,252 51,518 45,794 1,132,940 321,433 416,541 53,719 3,523 440 414,340	13,740 2,141 31,497 22,196 1,829 1,626 40,219 11,411 14,787 1,907 125 16 14,709	21,361 3,329 48,966 34,507 2,843 2,527 62,526 17,740 22,989 2,965 194 24 22,867	28,858 4,498 66,154 46,619 3,841 3,414 84,473 31,058 4,005 263 33 33 30,894	63,958 9,968 146,617 103,323 8,513 7,567 187,218 53,117 68,834 8,877 582 73 68,469	450,999 70,293 1,033,859 728,575 60,031 53,361 1,320,158 374,549 485,375 62,596 4,105 513 482,809	3/31/13 0.00% 5.74% 1.83% 22.28% 15.67% 1.11% 0.89% 7.02% 9.44% 0.00% 6.50% 0.00% 0.00% 0.00% 0.00%	YTD (NOV) 581,878 259,352 2,973,380 2,090,101 139,701 106,179 3,244,768 888,060 13,973) (513) 805,520 525 315,488 1,498	110,724 17,257 253,822 178,872 14,738 13,100 324,111 91,955 119,164 15,368 1,008 126	228,576 35,626 523,992 369,258 30,425 27,044 669,085 189,830 245,998 31,725 2,080 260 244,698	28,389 4,384 64,608 45,700 3,744 3,328 82,594 23,359 30,796 3,904 387 32 31,554 525	367,689 57,267 842,412 593,830 48,907 43,473 1,075,790 305,144 395,958 50,997 3,475 418 394,787 525 - 656 263	Q1, 13 True-up 85,218 87,232 914,229 641,879 38,530 26,462 923,749 248,319 380,545 50,786 (3,344) (418) 119,134 122,808 758	2012 (15 2: 11 76 (3 (77 (17) (12) 20 (4 (4) (5) (5)
Committee Member tavis Group, I.f. dob Pharmaceuticals Inc. nssen Pharmaceuticals, Inc. allinckrodt, Inc. lalinckrodt, Inc. lalinckrodt, Inc. lalinckrodt, Inc. lalinckrodt, Inc. lalinckrodt, Inc. lalinckrodt, Inc. lizer, Inc. lizer, Inc. lizer, Inc. lizer, Inc. lordue Pharma, L.P. loodes Pharmaceuticals L.P. loodes Pharmaceuticals L.P. loodes Pharmaceuticals L.P. loodes Pharmaketwork, I.C. staPharm, Inc. lavis Group, I.f. (Formerly Watson) lapax Laboratories, Inc. lootex ir limbary spher-Smith	3.95% 8.80% 1.37% 20.16% 14.21% 1.17% 1.04% 25.75% 9.47% 1.12% 0.08% 0.01% 0.00% 0.00% 0.00%	0.00% 8.80% 1.37% 20.16% 14.21% 1.17% 1.04% 25.75% 7.31% 9.47% 0.08% 0.01% 9.41% 0.00% 0.00% 0.00%	450,999 70,293 1,033,859 728,575 60,031 53,361 1,320,158 374,549 485,375 62,596 4,105 513 671,272	29,657 4,622 67,985 47,910 3,948 3,509 86,811 24,630 31,917 4,116 270 34 31,749	357,384 55,702 819,257 577,342 47,570 42,285 1,046,128 296,803 384,624 49,603 3,253 406 382,591		Q3 2012 387,040 60,324 887,242 625,252 51,518 45,794 1,132,940 321,433 416,541 53,719 3,523 440 414,340	13,740 2,141 31,497 22,196 1,829 1,626 40,219 11,411 14,787 1,907 125 16 14,709	21,361 3,329 48,966 34,507 2,843 2,527 62,526 17,740 22,989 2,965 194 24 22,867	28,858 4,498 66,154 46,619 3,841 3,414 84,473 31,058 4,005 263 33 33 30,894	63,958 9,968 146,617 103,323 8,513 7,567 187,218 53,117 68,834 8,877 582 73 68,469	450,999 70,293 1,033,859 728,575 60,031 53,361 1,320,158 374,549 485,375 62,596 4,105 513 482,009	3/31/13 0.00% 5.74% 1.83% 22.28% 15.67% 1.11% 0.89% 25.36% 9.84% 1.29% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%	YTD (NOV) 581,878 259,352 2,973,380 2,090,101 139,701 106,179 3,244,768 888,060 13,973) (513) 805,520 525 315,488 1,498	110,724 17,257 253,822 178,872 14,738 13,100 324,111 91,955 119,164 15,368 1,008 126	228,576 228,576 35,626 523,982 369,258 30,425 27,044 669,085 189,830 245,998 31,725 2,080 260 244,698	28,389 4,384 64,608 45,700 3,744 3,328 82,594 23,359 30,796 3,904 387 32 31,554 525	367,689 57,267 842,412 593,830 48,907 43,473 1,075,790 305,144 395,958 50,997 3,475 418 394,787 525 656 656	85,218 87,232 914,229 641,879 38,530 26,462 923,749 248,319 380,545 50,786 (3,344) (418) 119,134 -	2012 (15) (25) 11) (6) (3) (7) (41) (20) (4) (4) (5) (32)

2/28/2015

Case: 1:17-md-02804-DAP Doc #: 2313-100 Filed: 08/14/19 9 of 49. PageID #: 369838

Prepayments	Allocation 7/7/12	Allocation 11/1/12					ACTUA	NL .					Allocation 3/31/13	ORECAST						
Committee Member			YTD (OCT)	JUL	AUG	SEP	Q3 2012	ОСТ	NOV	DEC	Q4 2012	Y2012		YTD (TBD)	JAN	FEB	MAR	Q1	APR	APR
Actavis Group, I.f.	3.95%	0.00%	-		-		-	-	-		-	-	0.00%					-		
ndo Pharmaceuticals Inc.	8.80%	8.80%	-		-		-		-			-	5.74%					-		
anssen Pharmaceuticals, Inc.	1.37%	1.37%			-		-	-	-		-	-	1.83%					-		
Mallinckrodt, Inc.	20.16%	20.16%	-		-		-	-	-		-	-	22.28%					-		
Mylan Technologies, Inc.	14.21%	14.21%	-		-		-	-	-		-		15.67%					-		
Noven Pharmaceuticals, Inc.	1.17%	1.17%	-		-		-	-	-		-	-	1.11%					-		
Pfizer, Inc.	1.04%	1.04%	-		-		-	-	-		-		0.89%					-		
urdue Pharma, L.P.	25.75%	25.75%	-		-		-	-	-		-	-	25.36%					-		
hodes Pharmaceuticals L.P.	7.31%	7.31%	-		-		-	-	-		-		7.02%					-		
Roxane Laboratories, Inc.	9.47%	9.47%	-		-		-	-	-		-	-	9.84%					-		
Sandoz Inc.	1.22%	1.22%	-		-		-	-	-		-		1.29%					-		
The PharmaNetwork, LLC	0.08%	0.08%	-		-		-	-	-		-		0.00%					-		
VistaPharm, Inc.	0.01%	0.01%	-		-		-	-	-		-	-	0.00%					-		
Watson Laboratories, Inc.	5.46%	9.41%	-		-		-	-	-		-		6.50%					-		
mpax Laboratories, Inc.	0.00%	0.00%	-		-		-	-	-	-	-	-	0.00%					-		
Apotex	0.00%	0.00%	-		-		-	-	-	-	-		0.00%					-		
Par Pharmaceuticals	0.00%	0.00%	-		-		-	-	-	-	-	-	2.45%					-		
tanbaxy	0.00%	0.00%	-		-		-	-	-	-	-	-	0.01%					-		
Jpsher-Smith	0.00%	0.00%	-		-		-	-	-	-	-	-	0.00%					-		
'ogenix	0.00%	0.00%	-		-		-		-	-		-	0.00%					-		
Vesher	0.00%	0.00%	-		-		-	-	-	-	-	-	0.00%					-		
Total Operations Phase Costs	100.00%	100.00%											100.00%							-

Deposits	Allocation 7/7/12	Allocation 11/1/12				ACTUA	ıL					Allocation 3/31/13	CTUAL						
Committee Member			YTD (DEC)	JUL	AUG SEP	Q3 2012	ост	NOV	DEC	Q4 2012	Y2012		YTD (NOV)	JAN	FEB	MAR	Q1	APR Cost and Q1, '13 True-up	APR 2012 True-up
Actavis Group, I.f.	3.95%	0.00%	-	243,841	(7,253)	236,588	-		(236,588)	(236,588)	-	0.00%	-	-			-		
Endo Pharmaceuticals Inc.	8.80%	8.80%	464,270	471,523	(7,253)	464,270	-		-	-	464,270	5.74%	(202,212)	(2,987)			(2,987)		(199,225)
Janssen Pharmaceuticals, Inc.	1.37%	1.37%	115,220	122,474	(7,253)	115,220	-		-	-	115,220	1.83%	(21,563)	(2,987)			(2,987)		(18,576)
Mallinckrodt, Inc.	20.16%	20.16%	998,663	1,005,917	(7,253)	998,663	-		-	-	998,663	22.28%	18,267	(2,987)			(2,987)		21,253
Mylan Technologies, Inc.	14.21%	14.21%	718,765	726,019	(7,253)	718,765	-		-	-	718,765	15.67%	(3,504)	(2,987)			(2,987)		(517)
Noven Pharmaceuticals, Inc.	1.17%	1.17%	105,812	113,065	(7,253)	105,812	-		-	-	105,812	1.11%	(55,190)	(2,987)			(2,987)		(52,203)
Pfizer, Inc.	1.04%	1.04%	99,697	106,950	(7,253)	99,697	-		-	-	99,697	0.89%	(59,208)	(2,987)			(2,987)		(56,221)
Purdue Pharma, L.P.	25.75%	25.75%	1,261,156	1,268,409	(7,253)	1,261,156	-		-	-	1,261,156	25.36%	(103,676)	(2,987)			(2,987)		(100,689)
Rhodes Pharmaceuticals L.P.	7.31%	7.31%	394,178	401,431	(7,253)	394,178	-		-	-	394,178	7.02%	(73,750)	(2,987)			(2,987)		(70,764)
Roxane Laboratories, Inc.	9.47%	9.47%	495,788	503,041	(7,253)	495,788	-		-	-	495,788	9.84%	(46,536)	(2,987)			(2,987)		(43,549)
Sandoz Inc.	1.22%	1.22%	108,164	115,417	(7,253)	108,164	-		-	-	108,164	1.29%	(49,237)	(2,987)			(2,987)		(46,250)
The PharmaNetwork, LLC	0.08%	0.08%	54,537	61,790	(7,253)	54,537	-		-	-	54,537	0.00%	(54,537)	(2,987)			(2,987)		(51,550)
VistaPharm, Inc.	0.01%	0.01%	51,244	58,497	(7,253)	51,244	-		-	-	51,244	0.00%	(51,244)	(2,987)			(2,987)		(48,257)
Actavis Group, I.f. (Formerly Watson)		9.41%	493,435	314,874	(7,253)	307,620.81	-		185,815	185,815	493,435	6.50%	(196,738)	(2,987)			(2,987)		(193,751)
Impax Laboratories, Inc.	0.00%	0.00%	50,773	-	50,773	50,773	-		-	-	50,773	0.00%	(50,773)	(2,987)			(2,987)		(47,787)
Apotex	0.00%	0.00%	50,773	-	50,773	50,773	-		-	-	50,773	0.00%	(50,773)	(2,987)			(2,987)		(47,787)
Par Pharmaceuticals	0.00%	0.00%	50,773	-	-	-	-		50,773	50,773	50,773	2.45%	60,853	(2,987)			(2,987)		63,840
Ranbaxy	0.00%	0.00%	-	-	-	-	-		-	-	-	0.01%	439	47,787			47,787		(47,348)
Upsher-Smith	0.00%	0.00%	-	-		-	-		-	-	-	0.00%	-	-			-		-
Zogenix	0.00%	0.00%	-	-	-	-	-		-	-	-	0.00%	-	-			-		-
Nesher	0.00%	0.00%	-	-	-	-	-		-	-	-	0.00%	-	-			-		
Total Deposits Costs	94.54%	100.00%	5,513,247	5,513,247	- 0	5,513,247	,		(0)	(0)	5,513,247	100.00%	(939,380) (0))	-	- (0)	- (939,380)

Total	Allocation 7/7/12	Allocation 11/1/12					ACTUAL						Allocation 3/31/13	CTUAL						
Committee Member			YTD (DEC)	JUL	AUG	SEP	Q3 2012	ост	NOV	DEC	Q4 2012	Y2012		YTD (NOV)	JAN	FEB	MAR	Q1	APR Cost and Q1, '13 True-up	APR 2012 True-up
Actavis Group, I.f.	3.95%	0.00%	-	243,841	-	(7,253)	236,588	-	-	(236,588)	(236,588)	-	0.00%	-	-	-	-	-	-	-
Endo Pharmaceuticals Inc.	8.80%	8.80%	1,092,163	557,546	432,797	380	990,722	43,935	21,829	35,677	101,441	1,092,163	5.74%	362,508	99,919	228,596	28,389	356,904	85,254	(355,265)
Janssen Pharmaceuticals, Inc.	1.37%	1.37%	362,407	183,462	131,115	380	314,956	32,336	3,798	11,317	47,451	362,407	1.83%	220,632	6,452	35,645	4,384	46,481	87,269	5,292
Mallinckrodt, Inc.	20.16%	20.16%	2,209,416	1,130,267	894,670	380	2,025,317	61,692	49,435	72,973	184,100	2,209,416	22.28%	2,974,488	243,017	524,002	64,608	831,627	914,265	131,992
Mylan Technologies, Inc.	14.21%	14.21%	1,624,235	830,294	652,755	380	1,483,429	52,391	34,976	53,439	140,806	1,624,235	15.67%	2,069,439	168,067	369,278	45,700	583,045	641,916	75,965
Noven Pharmaceuticals, Inc.	1.17%	1.17%	342,737	173,378	122,983	380	296,741	32,024	3,312	10,661	45,996	342,737	1.11%	67,353	3,933	30,445	3,744	38,121	38,567	(55,257)
Pfizer, Inc.	1.04%	1.04%	329,952	166,824	117,698	380	284,902	31,821	2,996	10,234	45,050	329,952	0.89%	29,813	2,295	27,064	3,328	32,687	26,499	(64,012)
Purdue Pharma, L.P.	25.75%	25.75%	2,758,209	1,411,586	1,121,542	380	2,533,507	70,414	62,995	91,292	224,701	2,758,209	25.36%	3,123,934	313,306	669,104	82,594	1,065,005	923,786	(118,055)
Rhodes Pharmaceuticals L.P.	7.31%	7.31%	945,621	482,426	372,216	380	855,022	41,606	18,208	30,786	90,600	945,621	7.02%	797,151	81,150	189,850	23,359	294,359	248,356	(84,660)
Roxane Laboratories, Inc.	9.47%	9.47%	1,158,057	591,324	460,037	380	1,051,741	44,982	23,457	37,877	106,316	1,158,057	9.84%	1,221,688	108,359	246,018	30,796	385,173	380,582	(23,271)
Sandoz Inc.	1.22%	1.22%	347,655	175,899	125,016	380	301,295	32,102	3,433	10,825	46,360	347,655	1.29%	103,205	4,563	31,745	3,904	40,211	50,823	(42,521)
The PharmaNetwork, LLC	0.08%	0.08%	235,536	118,425	78,666	380	197,471	30,320	663	7,082	38,065	235,536	0.00%	(75,668)	(9,798)	2,100	387	(7,310)	(3,307)	(55,655)
VistaPharm, Inc.	0.01%	0.01%	228,651	114,896	75,819	380	191,095	30,211	493	6,852	37,556	228,651	0.00%	(68,915)	(10,679)	280	32	(10,367)	(381)	(48,770)
Actavis Group, I.f. (Formerly Watson)	•	9.41%	1,327,220	459,354	533,418	8,012	1,000,784	75,099	23,803	227,534	326,436	1,327,220	6.50%	594,268	110,316	244,738	31,554	386,608	119,207	(226,703)
Impax Laboratories, Inc.	0.00%	0.00%	227,668	-	55,842	134,343	190,185	30,195	468	6,819	37,483	227,668	0.00%	(67,406)	(10,805)	20	525	(10,260)	37	(47,787)
Apotex	0.00%	0.00%	227,668	-	-	134,343	134,343	86,037	468	6,819	93,324	227,668	0.00%	(67,931)	(10,805)	20	-	(10,785)	37	(47,787)
Par Pharmaceuticals	0.00%	0.00%	227,668	-		-			-	227,668	227,668	227,668	2.45%	359,183	(10,805)	20	656	(10,129)	192,845	64,461
Ranbaxy	0.00%	0.00%	-	-		-			-	-		-	0.01%	161,674	216,862	20	263	217,145	795	(47,348)
Upsher Smith	0.00%	0.00%	-	-	-			-	-	-		-	0.00%	159,999	-	-	-			-
Zogenix	0.00%	0.00%	-	-		-			-	-	-	-	0.00%		-		-	-		
Nesher	0.00%	0.00%	-	-	-			-		-		-	0.00%	-	-	-	-	-		-
Teva	0.00%	0.00%	80,700	32,880	32,637	-	65,517	15,183	-	-	15,183	80,700	0.00%	-	-	-	-	-		-
Total Costs	94 54%	100.00%	13 725 561	6 672 404	5 207 210	274 000	12 153 614	710 345	250 334	611 267	1 571 947	13 725 561	100.00%	11 965 413	1 305 347	2 598 943	224 222	4 228 513	3 706 550	(939 380)

Case: 1:17-md-02804-DAP Doc #: 2313-100 Filed: 08/14/19 10 of 49. PageID #: 369839

																			ACTUAL			
MAY	JUN	Q2		JUL	AUG	SEP	Q3	OCT	NOV	DEC	Q4		Y2013		YTD (NOV)	JAN	FEB	MAR	Q1 2014	APR and Q1 True-up		MAY
-	-			-		-	-	-	-	-	-		-		-				-			
-		37		(9,396)		-	(9,396)		-	(8,407)	(8,407)		(25,565)				-		-	-		
-	-	37		(9,396)		-	(9,396)	-	-	(8,407)	(8,407)		(25,565)		-	-	-	-	-	-		
-	-	37		(9,396)		-	(9,396)	-	-	(8,407)	(8,407)		(25,565)		-	-	-	-	-	-		
-	-	37		(9,396)		-	(9,396)	-	-	(8,407)	(8,407)		(25,565)				-		-	-		
-	-	37		(9,396)		-	(9,396)	-	-	(8,407)	(8,407)		(25,565)		-	-	-	-	-	-		-
-	-	37		(9,396)		-	(9,396)	-	-	(8,407)	(8,407)		(25,565)		-	-	-		-	-		-
-	-	37		(9,396)		-	(9,396)	-	-	(8,407)	(8,407)		(25,565)		-	-	-	-	-	-		-
-	-	37		(9,396)		-	(9,396)	-	-	(8,407)	(8,407)		(25,565)		-	-	-	-	-	-		-
-	-	37		(9,396)		-	(9,396)	-	-	(8,407)	(8,407)		(25,565)		-	-	-	-	-			-
-	-	37		(9,396)		-	(9,396)	-	-	(8,407)	(8,407)		(25,565)		-	-	-	-	-	-		-
-	-	37		(9,396)		-	(9,396)	-	-	(8,407)	(8,407)		(25,565)		-	-	-	-	-			-
-	-	37		(9,396)		-	(9,396)	-	-	(8,407)	(8,407)		(25,565)		-	-	-	-	-			-
-	-	74		(9,396)		-	(9,396)	-	-	(8,407)	(8,407)		(22,922)		-	-	-	-	-			-
-	-	37		(9,396)		-	(9,396)	-	-	(8,407)	(8,407)		(25,565)		-		-	-	-			-
-	-	37 37		(9,396)		-	(9,396)	-	-	(8,407)	(8,407)		(25,565)		-			-	-			-
- :	- :	37 37		(9,396)		-	(9,396)	-	-	(8,407)	(8,407)		(25,565) 151,329			-	-					
-	-			(9,396) 159,736		-	(9,396) 159,736	-	-	(8,407)	(8,407)		151,329		-	-				-		- :
-	-			159,/36		-	159,736	-	-	151,329	151,329		151,329			-		-	-			-
-	-	-					-		-	151,329	151,329		151,329			-	-		-			-
						-			-	131,323	131,323		131,323		-	-	-			-		
		662	,	0	_					151,329	151,329		198,915						_			
		001								151,525	151,52.	,	130,513									
														Allocation 3/31/14								
														Amocation 3/ 32/ 14					ACTUAL			
MAY	JUN	Q2		JUL	AUG	SEP	Q3	ОСТ	NOV	DEC	Q4		Y2013		YTD (NOV)	JAN	FEB	MAR	Q1 2014	APR and Q1 True-up	2013 True-up	MAY
		-	-	-		-	-					-	-	0.00%	-	-	-	-	-		-	-
27,489	20,399	(22,934)	344,754.92	137,842	54,885	16,896	209,623	15,122	12,377	44,785	72,284	281,907.76	626,663	3.82%		78,666	187,455	23,112	289,234.15	(17,409)	(90,365)	167,911
8,776	6,512	126,388	183,654.73	44,004	17,521	5,394	66,919	4,828	3,951	14,297	23,076	89,994.44	273,649	1.77%	296,519	25,113	59,842	7,378	92,333.26	33,532	(31,169)	77,749
106,674	79,158	1,210,799	2,053,211.19	534,905	212,984	65,566	813,455	58,683	48,031	173,790	280,504	1,093,958.36	3,147,170	22.66%	4,113,156	305,269	727,430	89,689	1,122,388.58	487,982	(56,002)	994,750
75,030	55,676	849,067	1,442,897.36	376,227	149,803	46,116	572,146	41,275	33,783	122,236	197,293	769,439.24	2,212,337	16.28%	2,984,560	214,712	511,640	63,083	789,435.70	367,933	(10,483)	714,925
5,573	3,940	44,989	93,896.02	26,627	10,602	3,264	40,493	2,921	2,391	8,651	13,963	54,456.27	148,352	0.14%		15,196	36,211	4,465	55,871.49	(45,628)	(132,212)	6,328
4,247	3,152	26,070	69,542.69	21,297	8,480	2,610	32,388	2,336	1,912	6,919	11,168	43,555.85	113,099	0.70%	113,515	12,154	28,963	3,571	44,687.78	5,296	(15,832)	30,875
121,418	90,099	1,117,900	2,193,689.74	608,834	242,421	74,628	925,882	70,527	54,669	197,810	323,006	1,248,887.74	3,442,577	24.67%	4,461,836	347,461	827,968	102,085	1,277,513.92	475,937	(78,549)	1,083,133
33,612	24,942	292,977	598,121.19	168,545 236,306	67,110	20,659	256,314	18,491	15,134	54,760	88,385	344,698.28	942,819 1,362,158	10.49% 8.31%		96,188	229,208	28,260	353,656.46	392,122	464,084	460,679
47,126 6.181	34,970 4.587	482,919 65,283	878,876.70 116,279.90	30,996	94,091 12.342	28,965 3.799	359,362 47,137	25,924 3,400	21,219 2,783	76,776 10,070	123,919 16.254	483,281.07 63.390.65	1,362,158	0.55%	(3,635)	134,860 17.689	321,359 42.152	39,622 5.197	495,840.78 65,038.06	94,654 (25.832)	(200,706)	364,758 24,218
- 6,181	4,587	(7,449)	(3,973.48)	30,996	12,342	3,799	4/,13/	3,400	- 2,783	10,070	10,254	63,390.65		0.55%		-	42,152	5,197	- 65,038.06	43,851	78,237	27,087
	- :	(931)	(512.98)	-		-	-	-	-	- :			(3,973)	0.62%	974	-	-			43,851	974	27,087
31,123	23,095	140,400	535.186.72	156,063	62.140	19.129	237,332	18.988	14,013	50,705	83.706	321,038.53	856,225	6.44%	1,217,898	89.065	212,234	26,168	327.466.63	130,032	30,530	282.604
31,123	23,095	140,400	535,186.72	156,063	62,140	19,129	- 237,332	- 18,988	14,013	50,705	83,706	321,038.53	525	0.00%	1,217,898	89,065	- 212,234	26,168	327,466.63	130,032	30,530	282,604
		-	323.00		-		-	-		- :		-	323	1.45%	456,134	-	-		-	102,920	189.798	63,575
11,709	8,689	213,827	214.483.45	58,715	23,379	7.197	89,291	6.441	5,272	19,077	30.790	120,081.13	334,565	2.09%	346,354	33,509	79.848	9.845	123,201.83	25,473	(38,386)	91,838
	34	838	1.100.99	231	92	28	351	25	21	75	121	472.19	1.573	0.00%	(1,310)	132	314	39	484.56	(484)	(1,311)	-
46		250	1,100.55		-	263	263	-	-		-	262.50	263	0.00%	334	-	-	-	-	(404)	334	-
46	-																					
		-	-	-	-	-	-	-	-	-				0.00%	4,550	-	-	3,850	3,850.00	-	-	-
-				-	-	-	-		-	-		-	-	0.00%	4,550		-	3,850	3,850.00	-	-	
-				- - 2,400,592	- - 955,849		-		-	- - 779,950	- - 1,264,470		13,637,158		4,550 - 18,413,187	- - 1,370,014	- - 3,264,624	3,850 - 406,365	3,850.00 - 5,041,003	- - 2,070,378	-	-
-	- - - 355,252	- - 4,540,144	-		- 955,849	- 294,514	- 3,650,954	- 268,962	- 215,558		- 1,264,470	-	-	0.00%	-	-	-	-	5,041,003	2,070,378	-	

Case: 1:17-md-02804-DAP Doc #: 2313-100 Filed: 08/14/19 11 of 49. PageID #: 369840

													Allocation 3/31/13	FORECAST	ACTUAL	FORECAST					
MAY	JUN	Q2		JUL	AUG	SEP	Q3	ОСТ	NOV	DEC	Q4	Y2013		YTD (TBD)	JAN	FEB	MAR	Q1	APR	APR	MAY
		-					-				-		0.00%					-			
		-					-				-	-	5.74%					-			
		-										-	1.83%					-			
		-					•					-	22.28% 15.67%					-			
							-				-		1.11%								
		-									-	-	0.89%					-			
		-									-	-	25.36%					-			
		-					-				-	-	7.02%					-			
		-					-				-	-	9.84%					-			
		-										-	1.29%					-			
		-									-		0.00%					-			
		-											6.50%					-			
		-									-	-	0.00%					-			
		-									-	-	0.00%					-			
		-					-				-	-	2.45%					-			
		-					-				-	-	0.01%					-			
		-	1								-	-	0.00%		-	-		-		+	
													0.00%							+	
-	-			1				-	٠				100.00%		-	-					
													222.3070								
													Allocation 3/31/14					ACTUAL			
MAY	JUN	Q2		JUL	AUG	SEP	Q3	ОСТ	NOV	DEC	Q4	Y2013		YTD (NOV)	JAN	FEB	MAR	Q1 2014	APR and Q1 True-up	2013 True-up	MAY
-		-					-		-		-	-	0.00%	-				-			
-		(199,225)					-		-	-	-	(202,212)	3.82%					-		(85,612)	
-		(18,576)							-	-	-	(21,563)	1.77%							(11,957)	
-		21,253 (517)							-	-	-	18,267 (3,504)	22.66% 16.28%	28,386 36,005				-		28,386 36,005	
		(52,203)								-	-	(55,190)	0.14%					-		(43,973)	
-		(56,221)					-			-	-	(59,208)	0.70%					-		(8,044)	
-		(100,689)								-	-	(103,676)	24.67%					-		(19,288)	
-		(70,764)					-		-	-	-	(73,750)	10.49%	163,669				-		163,669	
-		(43,549)					-			-	-	(46,536)	8.31%					-		(65,953)	
-		(46,250)					-			-	-	(49,237)	0.55%					-		(33,478)	
-		(51,550)							-	-	-	(54,537) (51,244)	0.62%					-		28,464	
		(48,257) (193,751)							-	-	-	(196,738)	0.00% 6.44%	271				-		271	
-		(47,787)					-			-	-	(50,773)	0.00%	-						-	
-		(47,787)					-		-	-	-	(50,773)	1.45%	66,807				-		66,807	
-		63,840					-		-	-	-	60,853	2.09%					-		(15,119)	
-		(47,348)					-		-	-	-	439	0.00%	(439)				-		(439)	
-		-					-		-	-	-	-	0.00%	-				-		-	
-		-							-	-	-	-	0.00%	-				-		-	
_		(939,380)		-							(939,380)	100.00%		2	-	-			- 39,742	-
													Allocation 3/31/14					ACTUAL			
MAY	JUN	Q2		JUL	AUG	SEP	Q3	ост	NOV	DEC	Q4	Y2013		YTD (NOV)	JAN	FEB	MAR	Q1 2014	APR and Q1 True-up	2013 True-up	MAY
						J	- 40				- 4-	.2313	***	()	27.11	120		42.00-7	n unu qı muc-up	2020 1140 40	
27,489	20,399	(222,122)		128,446	54,885	16,896	200,227	15,122	12,377	36,378	63,877	398,886	0.00% 3.82%	527,454	78,666	187,455	23,112	289,234	(17,409)	(175,977)	167,911
27,489 8,776	20,399 6,512	(222,122) 107,849		128,446 34,608	54,885 17,521	16,896 5,394	200,227 57,523	15,122 4,828	12,377 3,951	36,378 5,890	63,877 14,668	398,886 226,521	3.82% 1.77%		78,666 25,113	187,455 59,842	7,378	289,234 92,333	(17,409)	(175,977)	167,911 77,749
106,674	79,158	1,232,089		525,508	212,984	65,566	804,058	4,828 58,683	48,031	165,383	272,097	3,139,871	22.66%		305,269	727,430	89,689	1,122,389	487,982	(27,615)	994,750
75,030	55,676	848,587		366,831	149,803	46,116	562,750	41,275	33,783	113,829	188,886	2,183,267	16.28%		214,712	511,640	63,083	789,436	367,933	25,522	714,925
5,573	3,940	(7,177)		17,231	10,602	3,264	31,097	2,921	2,391	244	5,556	67,597	0.14%	(149,677)	15,196	36,211	4,465	55,871	(45,628)	(176,185)	6,328
4,247	3,152	(30,114)		11,901	8,480	2,610	22,991	2,336	1,912	(1,488)	2,761	28,326	0.70%		12,154	28,963	3,571	44,688	5,296	(23,876)	30,875
121,418	90,099	1,017,247		599,438	242,421	74,628	916,486	70,527	54,669	189,402	314,598	3,313,336	24.67%		347,461	827,968	102,085	1,277,514	475,937	(97,836)	1,083,133
33,612	24,942	222,250		159,148	67,110	20,659	246,917	18,491	15,134	46,353	79,978	843,504	10.49%		96,188	229,208	28,260	353,656	392,122	627,753	460,679
47,126 6,181	34,970 4,587	439,407 19,070		226,910 21,599	94,091 12,342	28,965 3,799	349,966 37,740	25,924 3,400	21,219 2,783	68,369 1,663	115,512 7,847	1,290,057 104,868	8.31% 0.55%		134,860 17,689	321,359 42,152	39,622 5,197	495,841 65,038	94,654 (25,832)	(266,659) (142,420)	364,758 24,218
6,181	۰,۵۷,۳	(58,962)		(9,396)	12,342	3,733	(9,396)	3,400	2,700	(8,407)	(8,407)	(84,075)	0.62%		-	42,152	5,197		43,851	106,701	27,087
-		(49,151)		(9,396)		-	(9,396)		-	(8,407)	(8,407)	(77,322)	0.00%		-	-		-		974	- ,507
31,123	23,095	(53,277)		146,667	62,140	19,129	227,936	18,988	14,013	42,298	75,299	636,566	6.44%		89,065	212,234	26,168	327,467	130,032	30,801	282,604
-		(47,750)		(9,396)		-	(9,396)	-	-	(8,407)	(8,407)	(75,814)	0.00%		-	-	-		-		-
-		(47,750)		(9,396)	-	-	(9,396)	-	-	(8,407)	(8,407)	(76,339)	1.45%		-	-	-	-	102,920	256,605	63,575
11,709	8,689	277,704		49,319	23,379	7,197	79,895	6,441	5,272	10,669	22,383	369,852	2.09%		33,509	79,848	9,845	123,202	25,473	(53,505)	91,838
46	34	(46,472)		(9,165) 159,736	92	28 263	(9,045) 159,999	25	21	(8,332)	(8,286)	153,341 151,592	0.00%	(1,749)	132	314	39	485	(484)	(1,750)	-
	-			-		-	-		-	151,329	151,329	151,329	0.00%		-		3,850	3,850		-	-
-				-				-	-	151,329	151,329	151,329	0.00%		-	-	-	-		-	-
-		-		-		-	-	-	-		-			-	-	-	-	-	-	-	-
479.005	355,252	3,601,42	c	2,400,59	2 955.849	9 294,514	3.650.954	268.962	215.558	931.279	1.415.799	12.896.692									

Case: 1:17-md-02804-DAP Doc #: 2313-100 Filed: 08/14/19 12 of 49. PageID #: 369841

	AC	TUAL									
	JUN	Q2	JUL	AUG	SEP	Q3	ОСТ	NOV	DEC	Q4	Y2014
F	-	-	-							-	-
F									(7,566)	(7,566)	(7,566)
									(7,566)	(7,566)	(7,566)
ı									(7,566)	(7,566)	(7,566)
- 1			-	-	-				(7,566)	(7,566)	(7,566)
		_			-			-	(7,566)	(7,566)	(7,566)
-									(7,566)	(7,566)	(7,566)
		_	-	-	-			-	(7,566)	(7,566)	(7,566)
- 1					-				(7,566)	(7,566)	(7,566)
-	-			-					(7,566)	(7,566)	(7,566)
- 1		-							(7,566)	(7,566)	(7,566)
-	-			-					(7,566)	(7,566)	(7,566)
- 1		-							(7,566)	(7,566)	(7,566)
H		-		-	-				(7,566)	(7,566)	(7,566)
- 1-	-	-	-						(7,566)	(7,566)	(7,566)
H	-	-		-	-		-	-	(7,566)	(7,566)	(7,566)
F		-		-	-				(7,566)	(7,566)	(7,566)
F					-				(7,566)	(7,566)	(7,566)
-		-		_	-				(7,566)	(7,566)	(7,566)
F		-		-	-				(7,566)	(7,566)	(7,566)
-		-	-	-	-			-	143,763	143,763	143,763
-				_	_		_		143,703	-	-
<u> </u>				l.		-			0		
	AC	TUAL									
	JUN	Q2	JUL	AUG	SEP	Q3	ост	NOV	DEC	Q4	Y2014
	JUN	Q2	-	-	-	-				-	-
	JUN 73,303	Q2 - 133,440	32,945	13,679	9,028	- 55,651	76,561	- 58,179	28,498	163,239	641,564
	JUN 73,303 33,942	- 133,440 114,054	- 32,945 17,227	- 13,679 6,334	9,028 4,180	- 55,651 27,741	76,561 35,451	- 58,179 26,939	28,498 13,196	- 163,239 75,586	- 641,564 309,715
	73,303 33,942 434,266	- 133,440 114,054 1,860,996	- 32,945 17,227 195,174	- 13,679 6,334 81,037	9,028 4,180 55,320	- 55,651 27,741 331,530	76,561 35,451 453,571	58,179 26,939 344,669	28,498 13,196 168,830	- 163,239 75,586 967,070	641,564 309,715 4,281,986
	73,303 33,942 434,266 312,106	- 133,440 114,054 1,860,996 1,384,481	- 32,945 17,227 195,174 140,271	- 13,679 6,334 81,037 58,241	9,028 4,180 55,320 38,438	- 55,651 27,741 331,530 236,950	76,561 35,451 453,571 325,981	58,179 26,939 344,669 247,713	28,498 13,196 168,830 121,338	163,239 75,586 967,070 695,031	641,564 309,715 4,281,986 3,105,897
	73,303 33,942 434,266 312,106 2,762	- 133,440 114,054 1,860,996 1,384,481 (168,750)	32,945 17,227 195,174 140,271 1,241	- 13,679 6,334 81,037 58,241 515	9,028 4,180 55,320 38,438 340	55,651 27,741 331,530 236,950 2,097	76,561 35,451 453,571 325,981 2,885	58,179 26,939 344,669 247,713 2,192	28,498 13,196 168,830 121,338 1,074	163,239 75,586 967,070 695,031 6,151	641,564 309,715 4,281,986 3,105,897 (104,630)
	73,303 33,942 434,266 312,106 2,762 13,479	133,440 114,054 1,860,996 1,384,481 (168,750) 33,818	32,945 17,227 195,174 140,271 1,241 6,058	- 13,679 6,334 81,037 58,241 515 2,515	9,028 4,180 55,320 38,438 340 1,660	55,651 27,741 331,530 236,950 2,097 10,233	76,561 35,451 453,571 325,981 2,885 14,078	58,179 26,939 344,669 247,713 2,192 10,698	28,498 13,196 168,830 121,338 1,074 5,240	- 163,239 75,586 967,070 695,031 6,151 30,016	- 641,564 309,715 4,281,986 3,105,897 (104,630) 118,755
	73,303 33,942 434,266 312,106 2,762 13,479 472,850	133,440 114,054 1,860,996 1,384,481 (168,750) 33,818 1,953,372	32,945 17,227 195,174 140,271 1,241 6,058 212,515	- 13,679 6,334 81,037 58,241 515 2,515 88,237	9,028 4,180 55,320 38,438 340 1,660 58,234	55,651 27,741 331,530 236,950 2,097 10,233 358,986	76,561 35,451 453,571 325,981 2,885 14,078 493,871	58,179 26,939 344,669 247,713 2,192 10,698 378,093	28,498 13,196 168,830 121,338 1,074 5,240 183,830	- 163,239 75,586 967,070 695,031 6,151 30,016 1,055,794	- 641,564 309,715 4,281,986 3,105,897 (104,630) 118,755 4,645,666
	73,303 33,942 434,266 312,106 2,762 13,479 472,850 201,113	Q2 - 133,440 114,054 1,860,996 1,384,481 (168,750) 3,818 1,953,372 1,517,998	32,945 17,227 195,174 140,271 1,241 6,058 212,515 90,387	13,679 6,334 81,037 58,241 515 2,515 88,237 37,529	- 9,028 4,180 55,320 38,438 340 1,660 58,234 24,768	55,651 27,741 331,530 236,950 2,097 10,233 358,986 152,684	76,561 35,451 453,571 325,981 2,885 14,078 493,871 210,053	58,179 26,939 344,669 247,713 2,192 10,698 378,093 159,620	28,498 13,196 168,830 121,338 1,074 5,240 183,830 78,187	- 163,239 75,586 967,070 695,031 6,151 30,016 1,055,794 447,860	641,564 309,715 4,281,986 3,105,897 (104,630) 118,755 4,645,666 2,472,198
	73,303 33,942 434,266 312,106 2,762 13,479 472,850 201,113 159,238	Q2 133,440 114,054 1,860,996 1,384,481 (168,750) 33,818 1,953,372 1,517,998 417,943	- 32,945 17,227 195,174 140,271 1,241 6,058 212,515 90,387 71,567	13,679 6,334 81,037 58,241 515 2,515 88,237 37,529 29,715	9,028 4,180 55,320 38,438 340 1,660 58,234 24,768 21,449	55,651 27,741 331,530 236,950 2,097 10,233 358,986 152,684 122,730	76,561 35,451 453,571 325,981 2,885 14,078 493,871 210,053 166,317	58,179 26,939 344,669 247,713 2,192 10,698 378,093 159,620 126,384	28,498 13,196 168,830 121,338 1,074 5,240 183,830 78,187 61,907	163,239 75,586 967,070 695,031 6,151 30,016 1,055,794 447,860 354,608	- 641,564 309,715 4,281,986 3,105,897 (104,630) 118,755 4,645,666 2,472,198 1,391,121
	73,303 33,942 434,266 312,106 2,762 13,479 472,850 201,113 159,238 10,573	Q2 133,440 114,054 1,860,996 1,384,481 (168,750) 33,818 1,953,372 1,517,998 417,943 (99,984)	32,945 17,227 195,174 140,271 1,241 6,058 212,515 90,387 71,567 4,752	13,679 6,334 81,037 58,241 515 2,515 88,237 37,529 29,715 1,973	9,028 4,180 55,320 38,438 340 1,660 58,234 24,768 21,449 1,302	55,651 27,741 331,530 236,950 2,097 10,233 358,986 152,684 122,730 8,027	76,561 35,451 453,571 325,981 2,885 14,078 493,871 210,053 166,317 11,043	58,179 26,939 344,669 247,713 2,192 10,698 378,093 159,620 126,384 12,241	28,498 13,196 168,830 121,338 1,074 5,240 183,830 78,187 61,907 4,110	163,239 75,586 967,070 695,031 6,151 30,016 1,055,794 447,860 354,608 27,394	641,564 309,715 4,281,986 3,105,897 (104,630) 118,755 4,645,666 2,472,198 1,391,121 475
	73,303 33,942 434,266 312,106 2,762 13,479 472,850 201,113 159,238	Q2 133,440 114,054 1,860,996 1,384,481 (168,750) 33,818 1,953,372 1,517,998 417,943 (99,984) 161,000	- 32,945 17,227 195,174 140,271 1,241 6,058 212,515 90,387 71,567	13,679 6,334 81,037 58,241 515 2,515 88,237 37,529 29,715	9,028 4,180 55,320 38,438 340 1,660 58,234 24,768 21,449 1,302 1,456	55,651 27,741 331,530 236,950 2,097 10,233 388,986 152,684 122,730 8,027 8,978	76,561 35,451 453,571 225,981 2,885 14,078 493,871 210,053 166,317 11,043 12,351	58,179 26,939 344,669 247,713 2,192 10,698 378,093 159,620 126,384 12,241 9,385	28,498 13,196 168,830 121,338 1,074 5,240 183,830 78,187 61,907 4,110 4,597	163,239 75,586 967,070 695,031 6,151 30,016 1,055,794 447,860 354,608 27,394 26,334	
	73,303 33,942 434,266 312,106 2,762 13,479 472,850 201,113 159,238 10,573 11,825	Q2 133,440 114,054 1,860,996 1,384,481 (168,750) 33,818 (159,3372 1,517,998 417,943 (99,934) 161,000 974	32,945 17,227 195,174 140,271 1,241 6,058 212,515 90,387 71,567 4,752 5,315	13,679 6,334 81,037 58,241 515 2,515 88,237 37,529 29,715 1,973 2,207	9,028 4,180 55,320 38,438 340 1,660 58,234 24,768 21,449 1,302 1,456	55,651 27,741 331,530 236,950 2,097 10,233 358,986 152,684 122,730 8,027 8,978	76,561 35,451 453,571 325,981 2,885 14,078 493,871 210,053 166,317 11,043 12,351	58,179 26,939 344,669 247,713 2,192 10,698 378,093 159,620 126,384 12,241 9,385	28,498 13,196 168,830 121,338 1,074 5,240 183,830 78,187 61,907 4,110 4,597	163,239 75,586 967,070 695,031 6,151 30,016 1055,794 447,860 354,608 27,394 26,334	641,564 309,715 4,281,986 3,105,897 (104,630) 118,755 4,645,666 2,472,198 1,391,121 475 196,312 974
	73,303 33,942 434,266 312,106 2,762 13,479 472,850 201,113 159,238 10,573	02 133,440 114,054 1,860,996 1,384,481 (168,750) 33,818 1,953,372 1,517,998 (39,994) 161,000 974 566,539	32,945 17,227 195,174 140,271 1,241 6,058 212,515 90,387 71,567 4,752	13,679 6,334 81,037 58,241 515 2,515 88,237 37,529 29,715 1,973	9,028 4,180 55,320 38,438 340 1,660 58,234 24,768 21,449 1,302 1,456	55,651 27,741 331,530 236,950 2,097 10,233 358,986 152,684 122,730 8,027 8,978	76,561 35,451 453,571 325,981 2,885 14,078 493,871 210,053 166,317 11,043 12,351	58,179 26,939 344,669 247,713 2,192 10,698 378,093 159,620 126,384 12,241 9,385	28,498 13,196 168,830 121,338 1,074 5,240 183,830 78,187 61,907 4,110 4,597	163,239 75,586 967,070 695,031 6,151 30,016 1,055,794 447,860 354,608 27,394 26,334	641,564 309,715 4,281,986 3,105,897 (104,630) 118,755 4,645,666 2,472,198 1,391,121 475 196,312 1,265,862
	73,303 33,942 434,266 312,106 2,762 13,479 472,850 201,113 159,238 10,573 11,825	133,440 114,054 1,860,996 1,384,481 (168,750) 33,818 1,953,372 1,517,998 417,943 (99,984) 161,000 974 566,539	32,945 17,227 195,174 140,271 1,241 6,058 212,515 90,387 71,567 4,752 5,315	13,679 13,679 81,037 58,241 515 2,515 88,237 37,529 29,715 1,973 2,207 23,022	9,028 4,180 55,320 38,438 340 1,660 58,234 24,768 21,449 1,302 1,456	55,551 27,741 331,530 236,950 10,233 358,986 152,684 122,730 8,027 8,978	76,561 35,451 453,571 325,981 14,078 493,871 210,053 166,317 11,043 12,351 -	58,179 26,939 344,669 247,713 2,192 10,698 378,093 159,620 126,384 12,241 9,385	28,498 13,196 168,830 121,338 1,074 5,240 183,830 78,187 61,907 4,110 4,597	163,239 75,586 967,070 695,031 6,151 30,016 1,055,794 447,860 354,608 27,394 26,334	641,564 641,564 309,715 4,281,996 3,105,897 (104,630) 118,755 4,645,666 2,472,198 1,391,121 475 196,312 974 1,265,862
	73,303 33,942 434,266 312,106 2,762 13,479 472,850 201,113 159,238 10,573 11,825	133,440 114,054 1,860,996 1,384,481 (168,750) 33,818 1,953,372 1,517,998 417,943 (99,984) 161,000 974 566,539	32,945 17,227 195,174 140,271 1,241 6,058 212,515 90,387 71,567 4,752 5,315 58,900	13,679 6,334 81,037 58,241 515 2,515 88,237 37,529 29,715 1,973 2,207 23,022	9,028 4,180 55,320 38,438 340 1,660 58,234 24,768 21,449 1,302 1,456 - 15,194	5,651 27,741 331,530 286,950 2,097 10,233 358,986 152,684 122,730 8,027 8,978 97,116 	76,561 35,451 453,571 325,981 2,885 14,078 493,871 210,053 166,317 11,043 12,351 128,857	58,179 26,939 344,669 247,713 2,192 10,698 378,093 159,620 126,384 12,241 9,385 - 97,919	28,498 13,196 168,830 121,338 1,074 5,240 183,830 78,187 61,907 4,110 4,597 - 47,964	163,239 75,586 967,070 695,031 6,151 30,016 1,055,794 447,860 354,608 27,394 26,334 - 274,740	641,564 309,715 4,281,986 3,105,897 (104,630) 118,755 4,645,666 2,472,198 1,391,121 475 196,312 974 1,265,862 466,924
	73,303 33,942 434,266 312,106 2,762 13,479 472,850 201,113 159,238 10,573 11,825	02 133,440 114,054 1,860,996 1,384,481 (168,750) 33,818 1,953,372 1,517,998 417,943 (39,984) 161,000 974 566,539 	32,945 17,227 195,174 140,271 1,241 6,058 212,515 90,387 71,567 4,752 5,315 58,900	13,679 13,679 81,037 58,241 515 2,515 88,237 37,529 29,715 1,973 2,207 23,022 5,179 7,482	9,028 4,180 55,320 38,438 340 1,660 58,234 24,768 21,449 1,302 1,456 - 15,194 - 3,418 4,938	55,651 27,741 331,530 2,695 2,097 10,233 358,986 152,684 122,730 8,027 8,078 - 97,116 - 21,071 30,438	76,561 35,451 453,571 325,981 22,885 14,078 493,871 210,053 166,317 11,043 12,351 	58,179 26,939 344,669 247,713 2,192 10,698 378,093 159,620 126,384 12,241 9,385 - - 97,919	28,498 13,196 168,830 121,338 1,074 5,240 183,830 78,187 61,907 4,110 4,597	163,239 75,586 967,070 695,031 6,151 30,016 1,055,794 447,860 27,394 26,334 - 274,740 - 61,806 89,283	641,564 641,564 309,715 4,281,986 3,105,897 (104,630) 118,755 4,645,666 2,472,198 1,391,121 475 196,312 974 1,265,862 466,924 361,941
	73,303 33,942 434,266 312,106 2,762 13,479 472,850 201,113 159,238 10,573 11,825	133,440 114,054 1,860,996 1,384,481 (168,750) 33,818 1,953,372 1,517,998 417,943 499,984) 161,000 974 566,539 384,047 119,018 (1,795)	32,945 17,227 195,174 140,271 1,241 6,058 212,515 90,387 71,567 4,752 5,315 58,900	. 13,679 6,334 81,037 58,241 515 2,515 88,237 37,529 29,715 1,973 2,207 23,022 5,179 7,482	9,028 4,180 55,320 38,438 340 1,660 58,234 24,768 21,449 1,302 1,456 - 15,194 - 3,418 4,938	55,651 27,741 331,530 26,6550 2,097 10,233 388,986 152,684 122,730 8,027 8,978 	76,561 35,451 453,571 25,981 2,885 14,078 493,871 210,053 166,317 11,043 12,351 18,857 28,988 41,675	58,179 26,939 344,669 247,713 2,192 10,698 378,093 159,620 126,384 12,241 9,385 - 97,919 22,028 31,821	28,498 13,196 168,830 121,338 1,074 5,240 133,830 78,187 61,907 4,110 4,597 - 47,964 10,790 15,587	163,239 75,586 967,070 695,031 6,151 30,016 1,055,794 447,860 354,608 27,394 26,334 - 274,740 - 61,806 89,283	641,564 309,715 4,281,986 3,105,897 (104,630) 118,755 4,645,666 2,472,198 1,391,121 475 196,312 974 1,265,862 466,924 361,941 (1,310)
	73,303 33,942 434,266 312,106 2,762 13,479 472,850 201,113 159,238 10,573 11,825	133,440 114,054 1,860,996 1,880,481 (168,750) 33,818 1,953,372 1,517,998 417,943 (99,984) 161,000 974 566,539 384,047 119,018 (1,795)	32,945 17,227 195,174 140,271 1,241 6,058 212,515 90,387 71,567 4,752 5,315 58,900 12,474 18,019	13,679 6,334 81,037 58,241 515 2,515 88,237 37,529 29,715 1,973 2,207 23,022 5,179 7,482	9,028 4,180 55,320 38,438 340 1,660 58,234 24,768 21,449 1,302 1,456 - 15,194 - 3,418 4,938	5,551 27,741 331,530 286,950 2,097 10,233 358,986 152,684 122,730 8,978 97,116 - 21,071 30,438	76,561 35,451 453,571 325,981 2,885 14,078 493,871 210,053 166,317 11,043 12,351 128,857 	58,179 26,939 344,669 247,713 2,192 10,698 378,093 159,620 126,384 12,241 9,385 97,919 - 22,028 31,821	28,498 13,196 168,830 121,338 1,074 5,240 183,830 78,187 61,907 4,110 4,597 47,964 - 10,790 15,587	163,239 75,586 967,070 695,031 6,151 30,016 1,055,794 447,860 354,608 27,394 26,334 274,740 	641,564 309,715 4,281,986 3,105,897 (104,630) 118,755 4,645,666 2,472,198 1,391,121 475 196,312 974 1,265,862 66,924 361,941 (1,310) 334
	73,303 33,942 434,266 312,106 2,762 13,479 472,850 201,113 159,238 10,573 11,825	133,440 114,054 1,860,996 1,384,481 (168,750) 33,818 1,953,372 1,517,998 417,943 (99,984) 161,000 974 566,539 	32,945 17,227 195,174 140,271 1,241 6,058 212,515 93,317 71,567 4,752 5,315 5,315 5,315 5,319	13,679 6,334 81,037 58,241 515 2,515 88,237 37,529 29,715 1,973 2,207 23,022 5,179 7,482	9,028 4,180 55,320 38,438 340 1,660 58,234 21,449 1,305 1,456 	5,651 27,741 311,530 26,650 2,097 10,233 358,986 152,684 122,730 8,027 8,978 - 97,116 - 21,071 30,438 -	76,561 35,451 453,571 225,981 2,885 14,078 493,871 210,053 166,317 11,043 12,351 18,857 28,988 41,875	58,179 26,939 344,669 247,713 2,192 10,698 378,093 159,620 12,241 9,385 97,919 22,028 31,821 700	28,498 13,196 168,830 121,338 1,074 5,240 183,830 78,187 61,907 4,110 4,597 	163,239 75,586 967,070 695,031 6,151 30,016 1,055,794 447,860 354,608 27,394 26,334	641,564 309,715 4,281,986 3,105,897 (104,630) 118,755 4,645,666 2,472,198 1,391,121 475 196,312 974 1,265,862 466,924 361,941 (1,310) 334 4,555
	73,303 33,942 434,266 312,106 2,762 13,479 472,850 201,113 159,238 10,573 11,825	133,440 114,054 1,860,996 1,384,481 (168,750) 33,818 1,953,372 1,517,998 417,943 (99,984) 161,000 974 566,539 384,047 119,018 (1,795) 334	32,945 17,227 195,174 140,271 12,241 6,058 212,515 90,387 71,567 4,752 5,315 58,900	13,679 6,334 81,037 58,241 515 2,515 88,237 37,529 29,715 1,973 2,207 23,022 5,179 7,482	9,028 4,180 55,320 38,438 340 1,660 58,234 24,768 21,449 1,302 1,456 15,194 	55,651 27,741 331,530 286,950 2,097 10,233 358,986 152,684 122,730 8,027 8,978 97,116 	76,551 35,451 453,571 325,981 2,885 14,078 493,871 210,053 166,317 11,043 12,351 128,857 28,988 41,875	58,179 26,939 344,669 247,713 2,192 10,698 378,093 159,620 126,384 12,241 9,385 - 97,919 - 22,028 31,821	28,498 13,196 168,830 121,338 1,074 5,240 183,830 78,187 61,907 4,110 4,597 47,964 - 10,790 15,587	163,239 75,586 967,070 655,031 6,151 30,016 1,055,794 447,860 354,608 27,394 26,334 27,394 61,806 89,283	641,564 641,564 309,715 4,281,986 3,105,897 (104,630) 118,755 4,645,666 2,472,198 1,391,121 475 196,312 974 1,265,862

1,464,233

Case: 1:17-md-02804-DAP Doc #: 2313-100 Filed: 08/14/19 13 of 49. PageID #: 369842

JUN	Q2	JUL	AUG	SEP	Q3	ост	NOV	DEC	Q4	Y2014
JOIL	- 42	JOL	AUG	JLF	- 45	001	NOV	DLC		12014
	-								-	
	-								-	
	-				-				-	-
	-								-	-
	-				-				-	-
	-								-	-
	-				-				-	-
	-				-					-
	-								-	
									-	-
	-				-				-	-
	-				-				-	-
	-				-				-	•
	-				-					•
	-								-	
									-	_
	-				-					-
	-				-				-	-
	-	-								
							<u> </u>			
AC	TUAL									
JUN	Q2	JUL	AUG	SEP	Q3	ост	NOV	DEC	Q4	Y2014
					-				-	
—	(85,612)				-					(85,612)
	(11,957)				-					(11,957)
	28,386								-	28,386
	36,005				-				-	36,005
	(43,973)								-	(43,973)
	(8,044)								-	(8,044)
	(19,288)				-				-	(19,288)
	163,669							1	-	163,669
	(65,953) (33,478)				-				-	(65,953)
	28,464				-				-	(33,478) 28,464
	-				-				-	-
	271								-	271
									-	-
	66,807				-				-	66,807
	(15,119)				-				-	(15,119)
	(439)				-				-	(439)
	-									-
	-				-					
	39,742	-								39,742
-			·			•		•		
^-	TUAL									
JUN	Q2	JUL	AUG	SEP	Q3	ОСТ	NOV	DEC	Q4	Y2014
-	-		-	-		-	-	-	-	-
73,303	47,828	32,945	13,679	9,028	55,651	76,561	58,179	20,931	155,672	548,385
33,942	102,098	17,227	6,334	4,180	27,741	35,451	26,939	5,629	68,019	290,192
434,266 312,106	1,889,383 1,420,486	195,174 140,271	81,037 58,241	55,320 38,438	331,530 236,950	453,571 325,981	344,669 247,713	161,263 113,771	959,504 687,465	4,302,806 3,134,336
2,762	(212,723)	1,241	515	340	2,097	2,885	2,192	(6,493)	(1,415)	(156,169)
13,479	25,774	6,058	2,515	1,660	10,233	14,078	10,698	(2,326)	22,450	103,145
472,850	1,934,085	212,515	88,237	58,234	358,986	493,871	378,093	176,264	1,048,228	4,618,812
201,113	1,681,667	90,387	37,529	24,768	152,684	210,053	159,620	70,620	440,293	2,628,301
159,238	351,990	71,567	29,715	21,449	122,730	166,317	126,384	54,340	347,041	1,317,602
10,573	(133,462)	4,752	1,973	1,302	8,027	11,043	12,241	(3,456)	19,828	(40,569)
11,825	189,465 974	5,315	2,207	1,456	8,978	12,351	9,385	(2,969) (7,566)	18,767 (7,566)	217,210 (6,593)
123,373	566,810	58,900	23,022	15,194	97,116	128,857	97,919	40,397	267,173	1,258,566
-	-	-	-		-	-	-	(7,566)	(7,566)	(7,566)
27,754	450,854	12,474	5,179	3,418	21,071	28,988	22,028	3,224	54,240	526,165
40,093	103,899	18,019	7,482	4,938	30,438	41,875	31,821	8,020	81,717	339,256
-	(2,234)	-	-	-	-	-	-	(7,566)	(7,566)	(9,316)
-	334	-	-	-	-	-	-	(7,566)	(7,566)	(7,232)
	-	-	-	-	-	- :	700	(7,566)	(6,866)	(3,016)
<u> </u>		-		-			- :	143,763	143,763	143,763
	-	-	-	-	-	-	-			

Case: 1:17-md-02804-DAP Doc #: 2313-100 Filed: 08/14/19 14 of 49. PageID #: 369843

Phase 1 - Development																					
Subteam		Y2012			Y2013			Y2014			Y2015			Y2016			Y2017			Total	
	Forecast	Budget	Fav (Unfav)	Forecast	Budget Fav (Un	nfav)	Forecast	Budget	Fav (Unfav)	Forecast	Budget	Fav (Unfav)	Forecast	Budget	Fav (Unfav)	Forecast	Budget	Fav (Unfav)	Forecast	Budget	Fav (Unfav)
Technology	632,079	648,233	16,154	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	632,079	648,233	16,154
Patient	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CE	75,000	125,000	50,000	0	0	0	0	0	0	0) (0	0	0	0	0	C	0	75,000	125,000	50,000
Metrics	67,429	200,000	132,571	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	67,429	200,000	132,571
Vendor	1,907,556	2,051,500	143,944	2,586	0	(2,586)	0	0	0	100,000	100,000	0	100,000	100,000	0	100,000	100,000	0	2,210,141	2,351,500	141,359
Prescriber	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Legal	REDACTED: PRIVIR	EDACTED: PRIVILRE	DACTED: PRIVILIRE	EREDACTED: PRIVILE	EDACTED: PRIVILREDACTED	D: PRIVIE	REDACTED: PRIVILR	EDACTED: PRIVIL	REDACTED: PRIV	REDACTED: PRIVIL	REDACTED: PRIVI	IREDACTED: PRIV	REDACTED: PRIVILRED	DACTED: PRIVIL	REDACTED: PRIV	REDACTED: PRIVIL F	REDACTED: PRIVIL	REDACTED: PRIV	DACTED: PRIVILEGE	DACTED: PRIVILEGI	EDACTED: PRIVILEGED
Operations	75,285	37,500	(37,785)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	75,285	37,500	(37,785)
Subtotal	3,085,093	3,287,233	202,140	47,586	- (47,58	86)	-	-	-	100,000	100,000	-	100,000	100,000	-	100,000	100,000	-	3,432,678	3,587,233	154,555

Phase 2 - Operations																					
Subteam		Y2012			Y2013		Y21	014		Y201	.5		Y20	16		Y20	117			Total	
	Forecast	Budget	Fav (Unfav)	Forecast	Budget	Fav (Unfav)	Forecast	Budget	Fav (Unfav)	Forecast	Budget	Fav (Unfav)	Forecast	Budget	Fav (Unfav)	Forecast	Budget	Fav (Unfav)	Forecast	Budget	Fav (Unfav)
Technology	245,019	1,482,598	1,237,579	768,770	1,109,402	340,632	520,216	470,120	(50,096)	518,223	503,288	(14,935)	447,137	447,137	7 (456,171	456,171	0	2,955,537	4,468,716	1,513,179
Patient	26,074	825,000	798,926	8,984	232,820	223,836	9,567	86,594	77,027	13,036	13,563	527	14,277	14,277	7 (14,991	14,991	-	44,625	1,187,245	1,142,620
CE	0	655,000	655,000	137,381	137,381	0	868,966	696,574	(172,392)	307,499	445,000	137,501	425,000	425,000		425,000	425,000	-	1,006,346	2,783,955	1,777,609
CE-Grants	3,500,000	10,000,000	6,500,000	9,030,772	12,754,619	3,723,847	12,416,533	10,668,590	(1,747,943)	9,000,485	8,929,509	(70,976)	9,615,289	9,615,289		10,000,000	10,000,000	-	24,947,305	61,968,007	37,020,702
Metrics	91,626	2,850,000	2,758,374	309,788	1,778,142	1,468,354	2,710,266	3,799,100	1,088,834	3,850,883	3,366,573	(484,310)	3,451,532	3,370,974	(80,558)	3,451,532	3,352,554	(98,978)	3,111,680	18,517,343	15,405,663
Vendor	375,453	435,500	60,047	2,296,381	2,540,496	244,115	1,984,191	2,098,000	113,809	2,021,511	1,998,000	(23,511)	1,998,000	1,998,000	(0)	1,998,000	1,998,000	(0)	4,656,025	11,067,996	6,411,971
Prescriber	889,047	889,047	(0)	888,082	1,080,000	191,918	114,800	130,000	15,200	178,000	178,000	-	130,000	130,000		130,000	130,000	-	1,891,930	2,537,047	645,117
Legal	REDACTED: PRIVIE	REDACTED: PRIVIL	REDACTED: PRIVILE	REREDACTED: PRIVILE	REDACTED: PRIVIL	REDACTED: PRIVI	REDACTED: PRIVIL	REDACTED: PRIVILI	REDACTED: PRIV	REDACTED: PRIVILR	EDACTED: PRIVILI	REDACTED: PRIVI	REDACTED: PRIVIL	REDACTED: PRIVIL	IREDACTED: PRIV	REDACTED: PRIVIL	REDACTED: PRIVIL R	REDACTED: PRIV	DACTED: PRIVILEG	EDACTED: PRIVILEG	EDACTED: PRIVILEGE
Operations	0	0	-	0	0	-	0	0	-	0	0	-	0	(0	0	-	0	0	0
Quality Management	0	0	-	0	0	-	190,257	450,000	259,743	352,991	324,996	(27,995)	265,908	265,908	3	265,908	265,908	-	190,257	1,306,812	1,116,555
Extermal Communications	0	0	-	0	0	-	103,540	0	(103,540)	3,557,396	3,346,000	(211,396)	1,082,000	1,082,000) (1,082,000	1,082,000	0	103,540	5,510,000	5,406,460
Subtotal	5,127,221	17,137,145	12,009,925	13,637,158	19,632,860	5,995,702	19,158,335	18,578,978	(579,357)	19,995,023	19,284,929	(710,094)	17,609,143	17,528,585	(80,558)	18,003,602	17,904,624	(98,978)	39,344,246	110,067,121	70,722,875

sudget Changes Summary								
uuget Changes Summary	2012 DEV	2012 OPER	2013	2014	2015	2016	2017	
riginal Budget	3,249,483	17,633,025	19,036,980	18,578,978	19,336,929	17,628,585	18,004,624	Notes
hanges	37,750	-	-	-	-	-	-	Approved by RPC vote 7/13/12 for additional funding for GMS (Polaris) budget to enable GMS implementation to meet FDA CE deadline.
		(595,880)	595,880	-	-		-	Approved by RPC vote 8/29/12 to move \$595,880 from 2012 to 2013 for DHCPL 2
	-	-	-	-	48,000	-	-	Approved by RPC vote 12/10/14 to add \$48,000 CE Grantee Reimbursement to April, 2015
mended Total	3,287,233	17,037,145	19,632,860	18,578,978	19,384,929	17,628,585	18,004,624	
ariance		(100,000)	-	-	-	-	-	_

· · · · · · · · · · · · · · · · · · ·							Net Effect - Fa	iv (Unfav)	
Vendor	Task	Affected Period		Location on Summary by Vendor	Change Date	2014	2015	2016	2017
Ashfield	Call Center	Jan to Dec 2014	January reflects \$18,095 covering January and February costs. Reduced fees when IVR implementation occurs in February. Reduced amount to start in March 2014. An additional adjustment to make is to incorporate the IVR setup fee. This will be \$13,710 for month of changeover in February. We then anticipate costs to drop to \$3,215 per month thereafter.	Line 25				,	
Polaris	Grant Management System / CE Portal Setup	Jan to Dec 2014	Moved \$86,000 from CE Portal Setup to Grant Management System line increasing each month by \$7,166	Line 26 and 28					
Polaris	CE Grants	Feb 2014 to Jan 2015	Removed estimated grant extensions forecasted in Dec and Jun 2014 for a total of \$3,765,720. Reallocated funds outlined below total \$3,893,150. EG-000101 Milestone 1 \$348,852.50 3/2/14 EG-000101 Milestone 2 \$247,037.50 3/15/14 EG-000101 Milestone 3 \$296,445 8/15/14 EG-001101 Milestone 4 \$98,815 3/14/15 EG-0011501 Milestone 4 \$98,815 3/14/15 EG-011501 Milestone 1 \$316,750 3/2/14 EG-011501 Milestone 2 \$226,250 2/21/14 EG-011501 Milestone 3 \$271,500 6/13/14 EG-011501 Milestone 3 \$271,500 6/13/14 EG-011501 Milestone 4 \$90,500 9/26/14 EG-014601 Milestone 4 \$50,500 9/26/14 EG-014601 Milestone 1 \$700,000 3/2/14 EG-014601 Milestone 2 \$200,000 4/15/14 EG-014601 Milestone 2 \$200,000 4/15/15 EG-014601 Milestone 3 \$600,000 10/14/14 EG-014601 Milestone 4 \$200,000 4/15/15 2015 grant budgeted amount for 2014. Estimated 2015 grant payments reduced by amounts below. 2014 Cycle Milestone 1 in May 2014 (\$44,600) 2014 Cycle Milestone 2 in Sep 2014 (\$31,858) 2014 Cycle Milestone 4 in Oct 2015 (\$12,743)	Line 35					
ассме	REMS Service Fees	Jan to Dec 2014	No invoices received in Jan. Reallocated total amount from Jan-Dec to Feb-Dec @ \$14,454 per month.	Line 39					
TBD	Independent Audit by 3rd Party of CE	Jan to Dec 2014	Audit not expected to happen in 1st half, reallocated total amount (\$130,000) from Jan-Dec to Jul-Dec, 2014 @ \$21,666 per month	Line 40					
TBD	Assessment 3B	Apr to Dec 2014, Jan to Dec 2015	We will not likely have a vendor under contract until Q3 2014. We currently have \$420k distributed evenly from April — December 2014 and \$320k distributed evenly throughout the entire 2015 year. Revised so that \$300k is distributed evenly from September — December 2014; added the remaining \$120k from 2014 to the \$300k currently allocated to 2015 and distributed the \$420k evenly throughout the entire 2015 year.	Line 42					
HealthCore	Assessment 4	Jan 2014 to May 201	Updated milestone payments based on recently executed contract with vendor. April 2014 - \$146,780; May 2014 - \$188,405; June 2014 - \$68,480; July 2014 - \$27,250; January 2015 - \$22,584; March 2015 - \$110,284; April 2015 - \$10,892; May 2015 - \$66,192; January 2016 - \$22,584; March 2016 - \$110,284; April 2016 - \$10,892; May 2016 - \$66,192	Line 43					

							Net Effect - Fa	ıv (Unfav)	
Vendor	Task	Affected Period	Reason	Location on Summary by Vendor	Change Date	2014	2015	2016	2017
		Jan to Dec 2014, 201	Objectives 1, 5, and 6 were split into individual lines. Total budget of \$800k was allocated between induvidual lines. Forecast reallocations are listed below: Objective 1 2014: Evenly distributed \$150,000 across October – December. 2015: Evenly distributed \$300,000 between January and July. 2016: Evenly distributed \$300,000 between January and July.						
TBD	Assessment 5 (Objectives 1, 5, 6)	and 2016	2014: Evenly distributed \$150,000 across October – December. 2015: Evenly distributed \$300,000 between January and July. 2016: Evenly distributed \$300,000 between January and July. Dijective 6	Line 44, 45 and 46					
			2014: March - \$10,000; May - \$15,000. 2015: Evenly distributed \$100,000 between January and July. 2016: Evenly distributed \$100,000 between January and July.						
RMPDC	Assessment 5 (Objectives 2, 3)	Jan to Jul 2014	Reallocated amounts scheduled from Jan-Jul to Mar-Jul to reflect contracting timing	Line 47					
Inflexxion	Assessment 5 (Objective 4)	Jan/Feb 2014	Moved \$100,000 expected to be billed in Jan to Feb	Line 48					
IMS	Assessment 6, 7 and 8	Jan to Jul 2014	Assessments 6, 7 and 8 are combined into one line as the tasks have been rolled into one study performed by a single vendor. Overall fees from 2014 plus 2015 are now expected to be \$612k and fall according to milestones. Allocations have been revised such that a milestone payment of \$306k falls in March 2014, a milestone payment of \$153k falls in July 2014, and a milestone payment of \$158k falls in July 2015. Allocations for 2016 have been revised such that one milestone payment falls in July 2016 for \$185,000.	Line 49					
ims	Assessment 7	Jan to Jul 2014	Assessments 6, 7 and 8 are combined into one line as the tasked have been rolled into one study performed by a single vendor.	N/A					
IMS	Assessment 8	Jan to Jul 2014	Assessments 6, 7 and 8 are combined into one line as the tasked have been rolled into one study performed by a single vendor.	N/A					
Constantine Cannon	Legal	REDACTED: PRIVILEGED		REDACTED: PRIVILEGED					
TBD	Audit Vendor	Jan to Dec 2014	Reallocated amounts scheduled from Jan-Dec to Apr-Dec (\$50,000 per month) to reflect delay in vendor selection to allow evaluation of additional candidate	Line 63					
Polaris	Grant Management System	Mar to Apr 2014	Invoice not received, expected to bill with March invoices	Line 26					
Cenveo	Printing PCDs	Mar 2014	invoices not previously received for November to January added in March	Line 31					
TBD	PCD translation to Spanish	Mar to Apr 2014	Moved \$25k from March to April as we are waiting for information from the FDA before work can start.	Line 32					
TBD	CE Face to Face Meeing	Mar 2014	Reduced amount from \$12k to \$8k for actual expenses incurred.	Line 33					
Polaris	CE Grants	Mar and May 2014	Moved \$296,445 from March to May for updated schedule for 2012 Grant Extensions	Line 35					
TBD	Admin for RFPs and grant metric reporting	Feb to Mar 2014	Moved \$20,000 from February to March for invoice not received.	Line 37					
ACCME	REMS Service Fees	Feb to Dec 2014	No invoices received in February. Reallocated total amount evenly between April to December at \$15,899 per month.	Line 39					
TBD	Assessment 5 - Objectives 6 (Other surveillance objectives); NSDUH and MTF publically accessible reports	Mar to June 2014, 2015 and 2016	Revised to \$5,550 in June for 2014, 2015 and 2016 based on draft Change Order.	Line 46					
RMPDC	Assessment 5 - Objectives 2 and 3 (RADARS system): Pre/Post REMS Analysis: Active Drug Substance (e.g. ER morphine versus IR morphine, etc.)	Mar to Dec 2014	Revised fee schedule to match draft SOW.	Line 47					

							Net Effect - I	Fav (Unfav)	
Vendor	Task	Affected Period	Reason	Location on Summary by Vendor	Change Date	2014	2015	2016	2017
Inflexxion	Assessment 5 - Objective 4 (Inflexxion NAVIPPRO)	Feb to Mar 2014	Moved \$100k from February to March for invoice not received.	Line 48					
IMS	Assessment 6, 7 and 8	Mar and May 2014	Moved \$306k from March to May based on estimated SOW execution and schedule of invoicing.	Line 49					
Constantine Cannon	Legal	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILE	GED				
Ashfield	Call Center	Mar-Apr 2014	Moved \$3,215 March Fee to April for invoice not received	Line 25					
Polaris	Grant Management System	Mar-Apr 2014	Moved \$19,007.43 March Fee to April for invoice not received	Line 26					
Cenveo	Printing PCDs	Mar-Apr 2014	Moved \$774 March Fee to April for invoice not received	Line 31					
TBD	PCD translation to Spanish	Apr-May 2014	Moved \$25,000 April fee to May	Line 32					
Polaris	CE Grants	Mar-Apr 2014	Moved \$511,273 billing of two grants to April due to payment report not being received in time to bill on March 15.	Line 35					
TBD	Admin for RFPs and grant metric reporting	Mar 2014	Removed \$20,000 from March and \$30,000 from April forecast for funding not utilized.	Line 37					
ACCME	REMS Service Fees	Mar-Dec 2014	Reallocated total amount evenly from April to December for no invoices received. Revised fee will be \$17,666 per month.	Line 39					
RMPDC	Assessment 5-Objectives 2 and 3	Apr-May 2014	Moved \$79,008 to May as first milestone date will be after April 15.	Line 47	1				
Inflexxion	Assessment 5-Objective 4	2014-2016	Reallocated milestone payments based on executed SOW. Total cost in each year is \$160,000 higher than budgeted.	Line 48					
IMS	Assessment 6, 7 and 8	2014-2015	Reallocated milestone payments based on executed SOW.	Line 49	1				
UBC	Umbrella Metrics Vendor	Mar-Apr 2014	Moved \$42,190 to April for invoice not received	Line 51					
TBD	Annual Audit Vendor	Apr-Dec 2014	Reallocated total amount evenly from May to December. Revised fee will be \$56,250 per month.	Line 61					
Ashfield	Call Center	Apr, 2014	Actual costs for April were \$22k higher than forecasted	Line 25					
McKesson	Web Communications	Apr, 2014	Change order for website updates billed in April increasing cost by \$7,525.	Line 27					
ACCME	REMS Service Fees	Apr, 2014	Estimated costs \$210k higher than forecasted	Line 39					
Inflexxion	Assessment 5 (Objective 4)	Apr-Jun, 2014	Per contract terms, June costs billed in April for an increase in April of \$200k and a reduction in June of \$200k	Line 48					
UBC	Umbrella Metrics Vendor	Apr, 2014	Actual invoice received \$24,145, forecasted cost was \$66,537 for a reduction of \$42,392	Line 50					
Ashfield	Call Center	May to Jun, 2014	Moved \$12k to June for invoice not received.	Line 25	1				
McKesson	Web Communications	May to Jun, 2014	Reduced May to \$0 for invoice not received. Increased June to \$12,100 for invoice received.	Line 27					
тво	PCD Translation to Spanish	May to Jun, 2014	Moved \$25K from May to June to allow for PCD translation if needed. Costs will continue to be pushed on a monthly basis until RPC is able to evaluate if PCD changes and accompanying translation will be needed	Line 32					
TBD	Admin for RFPs and grant metric reporting	June to Dec, 2014	Budget for this line item potentially not needed in 2014 or only at end of 2014, so reforecast full \$45k from June to December	Line 37					
HealthCore	Assessment 4	May to Jun, 2014	Moved \$188,405 from May to June for invoice not received.	Line 43					
UBC	Assessment 5, Objective 6	June, 2015	Removed \$5,550 due to 2014 payment covering 2015.	Line 46					
RMPDC	Assessment 5, Objective 2 and 3	2015 and 2016	Aligned monthly amounts to SOW schedule. Reduced 2015 by \$147k, reduced 2016 by \$111k.	Line 47					
RMPDC	Assessment 5 - Objectives 2 and 3 (RADARS system): Pre/Post REMS Analysis: Active Drug Substance (e.g. ER morphine versus IR morphine, etc.)	May to Jun, 2014	Moved \$920,008 from May to June for invoice not received.	Line 47					
Inflexxion	Assessment 5, Objective 4	2014, 2015 and 2016	Moved all milestone payments ahead by 1.5 months to account for advanced billing per SOW terms except \$100,000 remains in June, 2014	Line 48					
IMS	Assessment 6, 7 and 8	May to Jun, 2014	Move \$153,000 from May to June for invoice not received.	Line 49	1				
ивс	Umbrella Metrics Vendor	May to Dec, 2014	Aligned monthly amounts to SOW schedule. Reduced 2014 by \$65k.	Line 51					
TBD	Additional Analysis	May, 2014	Removed \$30,000 for funds not used.	Line 53	1				
ClinAudits	Annual Audit Vendor	May to Dec, 2014	Initial billing covers first two months expected invoices. Beginning July, monthly cost of \$56,250 reduced to \$36,616.	Line 61					
TBD	PCD translation to Spanish	Jun to Aug 2014	Moved \$25,000 from June to August for invoice not received	Line 32		-			-
L	/		,		1		1	1	

					ĺ		Net Effect - Fa	ıv (Unfav)	
/endor	Task	Affected Period	Reason	Location on Summary by Vendor	Change Date	2014	2015	2016	2017
			Move \$16,000 from August to November for next scheduled F2F						
/A	CE Face to Face Meeing	Aug to Nov 2014	meeting.	Line 33		-	-	-	-
BD	Independent Audit by 3rd Party of CE	Jul to Dec 2014	Move \$21,667 per month from July - August to September - December	Line 40		-	-	-	
HealthCore	Assessment 4	2014 to 2016	Reallocated milestones for FDA Reports 3 and 4 based on SOW. Original milestones forecasted between 2014 and 2016. Revised milestones forecasted between 2014 and 2015. Added forecast for FDA Report 5 and Milestone 1 for FDA Report 6 for \$232,536. FDA Reports 5 and 6 are forecasted with the same timeline and cost as FDA Report 4 with Milestone payments of \$29,584 in November, 2015 and \$209,952 in 2016. Net change to 2014 is an increase of \$210,989. 2015 and 2016 are neutral.	Line 43		(210,989)			_
						, ,,,,,,,,			
UBC	Assessment 5 - Objective 6 (Other surveillance objectives:' NSDUH and MTF publically accessible	Jun to Jul 2014	Moved \$5,550 from June to July for invoice not received	Line 46		-	_	_	-
JBC	Umbrella Metrics Vendor	Jun to Jul 2014	Moved \$42,831 from June to July for invoice not received	Line 51		-	-	-	-
BD	Additional Analysis	Jun, 2014	Removed \$30,000 for funds not used.	Line 53		30,000			
Constantine Cannon	Legal	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVIL	EREDACTED: PF	REDACTED: PRIV	REDACTED: PR R	EDACTED: PRIF	REDACTED: PR
			Increase June by \$40,980 and reduce October by \$40,980 for prebilled						
PDRN	DHCPL 3	Jun to Oct 2014	postage	Line 60		-	-	-	-
ClinAudits	Annual Audit Vendor	June	Increase June by \$10,159 for invoice received.	Line 61		(10,159)	-	-	-
Ashfield	Call Center	Jul to Aug 2014	Moved \$3,215 from July to August for invoice still in approval process.	Line 25		_			_
CCME	REMS Service Fees	Jul to Aug 2014	Moved \$61,500 from July to August for invoice and received.	Line 39					
JBC	Assessment 5 - Objective 6 (Other surveillance objectives:' NSDUH and MTF publically accessible	Jul to Aug 2014	Moved \$5,550 from July to August for invoice not received.	Line 46		-	-	-	
JBC	Umbrella Metrics Vendor	Jul to Aug 2014	Moved \$63,113 from July to August for invoice not received.	Line 51		-	-	-	-
BD	Journal Article Publications	Jul to Oct 2014	Reallocated from July - September to August - October for work not yet completed.	Line 52		_	_	_	_
linAudits	Annual Audit Vendor	Jul to Aug 2014	Moved \$36,616 from July to August for invoice not received.	Line 61		-	_		_
Campbell Alliance	Vendor Expenses	Jul 2014	Actual expenses \$4,966 less than expected for month.	Line 56		4,966.00	-	-	
	,		Increase Septmber to December by \$13,750 per month for CE			,			
inda Kitlinski	CE Consultant	Sep to Dec 2014	consultant.	Line 62		(55,000.00)			
AADARS/Inflexxion	Assessment Report Re-analysis	Sep 2014	Increase September by \$1,000,000 for estimated costs associated with additional assessment reports for the FDA	Line 63		(1,000,000.00)			
Ashfield	Call Center	Aug 2014	Catch up invoices from prior months	Line 25		(2,398.00)	-	_	-
AcKesson .	Web Communications	Aug 2014	Actual invoice \$2,667 less than forecasted.	Line 27		2,667.00	-	-	-
Polaris	Grant Management System	Aug to Sep 2014	Moved \$20,297 from August to September for invoice not received	Line 26		-	-	-	-
Cenveo	Printing PCDs	Aug 2014	Increase August by \$793 for actual invoice received	Line 31		(739.00)	-	-	-
BD	PCD translation to Spanish	Aug to Sep 2014	Moved \$25,000 from August to September for invoice not received	Line 32		-	-	-	
Polaris	Central Database (3rd Party Data Aggregation Vendor)	Aug to Sep 2014	Moved \$2,390 from August to September for invoice not received	Line 30		-	-	-	
ACCME	REMS Service Fees	Aug to Sep 2014	Moved \$123,000 from August to September for invoice not received	Line 39		_			
No.	Assessment 5 - Objectives 6 (Other	g to 3cp 2014	Reduce August 2014 from \$5,550 to \$2,775 for actual invoice received.						
JBC	surveillance objectives); NSDUH and	2014 to 2016	Increase July 2015 by \$2,775 and reduce July 2016 by \$2,775 for updated forecast.	Line 46		2,775.00	(2,775.00)	2,775.00	2,775.00
JBC	Umbrella Metrics Vendor	Aug 2014	Increase August by \$67,402 for actual invoice received. Invoice matches current contract schedule.	Line 51		(70,177.00)	-	-	-
Campbell Alliance	Expenses	Aug 2014	Reduce August by \$11,384 for actual cost	Line 56		11,384.00	-	-	-
TBD	Journal Article Publications	Aug to Nov 2014	Reallocated from \$20,000 per month in August to October to \$20,000 per month in September to November	Line 52		,			
50	pournal Article Publications	nug to 1909 2014	Reallocate remaining fee between September and December for	LITE JA	+		-	-	
ClinAudits	Annual Audit Vendor	Aug to Dec 2014	\$54,924 per month	Line 61	1				

							Net Effect - F	av (Unfav)	
Vendor	Task	Affected Period	Reason	Location on Summary by Vendor	Change Date	2014	2015	2016	2017
	Secondary Analysis (RADARS,		Reduced September by \$883,000 based on actual estimates for report						
nflexxion/RMPDC	Inflexxion)	Sep 2014	changes by Inflession (\$95,000) and RMPDC (\$22,000)	Line 63		883,000.00	-	-	
	Assessment 5 - Objectives 2 and 3 (RADARS system): Pre/Post REMS Analysis: Active Drug Substance (e.g. ER morphine versus IR								
RMPDC	morphine, etc.) Assessment 5 - Objective 4	Oct to Nov 2014	Move \$20,103 from October to November for updated schedule.	Line 47		-		-	
nflexxion	(Inflexxion NAVIPPRO System)	Sep to Oct 2014	Move \$30,000 from September to October for updated schedule	Line 48		-	-	-	
Cenveo	Printing PCDs	Sep to Oct 2014	Moved \$625 from September to October for invoice not received	Line 31		-	-	-	
TransPerfect	PCD translation to Spanish	Sep to Oct 2014	Removed \$25,000 from September, increased October by \$125 for actual cost per contract.	Line 32		24,875.00	-	-	
			Reallocated 2014 grants based on actual milestone payments in LOAs. Increased 2015 budget by \$1,180,157 for 2014 budget being below						
Polaris	CE Grants	Sep to Oct 2014	expected costs.	Line 35		244,613.00	224,536.00	(472,063.00)	(472,063.00)
ACCME	REMS Service Fees	Sep to Oct 2014	Moved \$184,500 from September to October for invoice not received	Line 39		-	-	-	
	Assessment 3b (Same as CE		Reallocated \$300,000 from Oct - Dec at \$100,000 per month. Reduced						
TBD	(Metrics) Long Term CE	Sep to Dec 2014	Sep to \$0.	Line 42		-	-	-	
TBD	Journal Article Publications	Sep to Dec 2014	Moved \$20,000 per month from Sep - Nov to Oct - Dec	Line 52	1	-	-	-	
				1					
ClinAudits	Annual Audit Vendor	Sep to Oct 2014	Moved \$31,351 from September to October for actual invoice received			-	-	-	
Campbell Alliance	Expenses	Sep 2014	Reduced September by \$11,475 for actual expenses	Line 56		11,475.00	-	-	
inda Kitlinski	CE Consultant	Sep to Dec 2014	Reallocated \$55,000 from Oct 2014-Mar 2015 at \$9,166.67 per month	Line 62		27,500.00	(27,500.00)	-	
nflexxion/RMPDC	Secondary Analysis (RADARS, Inflexxion)	Sep to Oct 2014	Moved \$117,000 from September to October for invoice not received	Line 63					
IIII CANOI WIN DC	inication	REDACTED:	violed \$117,000 from September to October for invoice not received	Line 05				I.	
Constantine Cannon	Legal	PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVI	EREDACTED: PIF	REDACTED: PRIVI	REDACTED: PR	REDACTED: PR	REDACTED: PR
TRD.	Assessment 5 - Objectives 1 (Other surveillance objectives); ER visits and deaths in claims database	Oct to Doc 2014	Reallegated face to CTE 000 per month in New and Dec	Line 44					
IBU	analysis; Assessment 5 - Objectives 5 (Other	Oct to Dec 2014	Reallocated fees to \$75,000 per month in Nov and Dec	Line 44		-	-	-	
	surveillance objectives); Mortality rates using state medical examiner								
TBD	databases	Oct to Dec 2014	Reallocated fees to \$75,000 per month in Nov and Dec	Line 45		-	-	-	
nflexxion	Assessment 5 - Objective 4								
HIICAAIUH	(Inflexxion NAVIPPRO System)	Nov to Dec 2014	Reduced Nov and Dec by \$30,000 per month	Line 48		60,000.00	-	-	
	(Inflexxion NAVIPPRO System) Awareness Campaign	Nov to Dec 2014 Nov to Dec 2014	Reduced Nov and Dec by \$30,000 per month Added \$414,946 in Nov and Dec for new vendor on Awareness Campaign	Line 48 Line 64		60,000.00		-	
Ogilvy + Mather	Awareness Campaign	Nov to Dec 2014	Added \$414,946 in Nov and Dec for new vendor on Awareness Campaign Moved \$2,076 from Oct to Nov for invoice not received. Costs for the call center have decreased for 2015 and 2016 due to both actual transition from live call center to IVR as well as a more accurate cost estimate based on the executed IVR SOW (prior forecasts were anticipated based on estimates provided by potential IVR vendors which	Line 64				-	
	, ,		Added \$414,946 in Nov and Dec for new vendor on Awareness Campaign Moved \$2,076 from Oct to Nov for invoice not received. Costs for the call center have decreased for 2015 and 2016 due to both actual transition from live call center to IVR as well as a more accurate cost estimate based on the executed IVR SOW (prior forecasts were				20,600	19,800	(46,000
Ogilvy + Mather	Awareness Campaign Call Center	Nov to Dec 2014 Oct to Nov 2014	Added \$414,946 in Nov and Dec for new vendor on Awareness Campaign Moved \$2,076 from Oct to Nov for invoice not received. Costs for the call center have decreased for 2015 and 2016 due to both actual transition from live call center to IVR as well as a more accurate cost estimate based on the executed IVR SOW (prior forecasts were anticipated based on estimates provided by potential IVR vendors which were later negotiated down). Adjust forecast per anticipated GMS updates beyond the Polaris SOW. Potential updates include re-design of the CE Search Page per O&M recommendations and CE Provider interface enhancements to improve user-friendliness. Combined with CE Portal Set up line and reduced 2015 budget to \$65,000 with reduction of all future costs as no	Line 64 Line 25					
Ogilvy + Mather	Awareness Campaign	Nov to Dec 2014	Added \$414,946 in Nov and Dec for new vendor on Awareness Campaign Moved \$2,076 from Oct to Nov for invoice not received. Costs for the call center have decreased for 2015 and 2016 due to both actual transition from live call center to IVR as well as a more accurate cost estimate based on the executed IVR SOW (prior forecasts were anticipated based on estimates provided by potential IVR vendors which were later negotiated down). Adjust forecast per anticipated GMS updates beyond the Polaris SOW. Potential updates include re-design of the CE Search Page per O&M recommendations and CE Provider interface enhancements to improve user-friendliness. Combined with CE Portal Set up line and reduced 2015 budget to \$65,000 with reduction of all future costs as no additional changes are anticipated at this time.	Line 64			20,600	19,800	(46,000
Ogilvy + Mather Ashfield Polaris McKesson	Awareness Campaign Call Center Grant Management System Web Communications	Oct to Nov 2014 2015 to 2017 Oct 2014 and 2017	Added \$414,946 in Nov and Dec for new vendor on Awareness Campaign Moved \$2,076 from Oct to Nov for invoice not received. Costs for the call center have decreased for 2015 and 2016 due to both actual transition from live call center to IVR as well as a more accurate cost estimate based on the executed IVR SOW (prior forecasts were anticipated based on estimates provided by potential IVR vendors which were later negotiated down). Adjust forecast per anticipated GMS updates beyond the Polaris SOW. Potential updates include re-design of the CE Search Page per O&M recommendations and CE Provider interface enhancements to improve user-friendliness. Combined with CE Portal Set up line and reduced 2015 budget to \$65,000 with reduction of all future costs as no additional changes are anticipated at this time. Increased Oct 2014 by \$5,773 for Custom Development. Increased 2017 by \$110k as part of the annual budget review.	Line 25 Line 26 Line 27					
Ogilvy + Mather Ashfield Polaris	Awareness Campaign Call Center Grant Management System	Nov to Dec 2014 Oct to Nov 2014 2015 to 2017	Added \$414,946 in Nov and Dec for new vendor on Awareness Campaign Moved \$2,076 from Oct to Nov for invoice not received. Costs for the call center have decreased for 2015 and 2016 due to both actual transition from live call center to IVR as well as a more accurate cost estimate based on the executed IVR SOW (prior forecasts were anticipated based on estimates provided by potential IVR vendors which were later negotiated down). Adjust forecast per anticipated GMS updates beyond the Polaris SOW. Potential updates include re-design of the CE Search Page per O&M recommendations and CE Provider interface enhancements to improve user-friendliness. Combined with CE Portal Set up line and reduced 2015 budget to \$65,000 with reduction of all future costs as no additional changes are anticipated at this time. Increased Oct 2014 by \$5,773 for Custom Development. Increased 2017	Line 64 Line 25 Line 26		(414,946.00)			(249,192

Cenveo TransPerfect TBD Polaris MedBiquitous TBD	Printing PCDs PCD Translation to Spanish CE Face to Face Meeing CE Grants Standardized Metrics Admin for RFPs and grant metric reporting	Oct to Nov 2014 2015 to 2017 2014 2017 2017 2014 2017 to 2016	Moved \$565 from Oct to Nov for invoice not received. Adjust forecast per annual review. The 2016 forecast is \$36,000 less than last year's 2016 forecast due to being able to use this year's REMS modification costs for updated numbers. Adjust forecast per annual review Adjust forecast per annual review Adjust forecast per annual review. Reduce 2014 grant cycle to \$8.9M and 2015 grant cycle to \$8.75M. Adjust forecast per annual review	Location on Summary by Vendor Line 31 Line 32 Line 33	Change Date	2014	(263)	(6,295) (277)	(14,700) (291)
TransPerfect TBD Polaris MedBiquitous	PCD Translation to Spanish CE Face to Face Meeing CE Grants Standardized Metrics Admin for RFPs and grant metric	2015 to 2017 2014 2017 2017	per annual review. The 2016 forecast is \$36,000 less than last year's 2016 forecast due to being able to use this year's REMS modification costs for updated numbers. Adjust forecast per annual review Adjust forecast per annual review. Adjust forecast per annual review adjust forecast per annual review. Reduce 2014 grant cycle to \$8.9M and 2015 grant cycle to \$8.75M.	Line 32 Line 33		- -	(263)		
TransPerfect TBD Polaris MedBiquitous	PCD Translation to Spanish CE Face to Face Meeing CE Grants Standardized Metrics Admin for RFPs and grant metric	2015 to 2017 2014 2017 2017	costs for updated numbers. Adjust forecast per annual review Adjust forecast per annual review Adjust forecast per annual review. Reduce 2014 grant cycle to \$8.9M and 2015 grant cycle to \$8.75M.	Line 32 Line 33		- - -	(263)		
TBD Polaris MedBiquitous	CE Face to Face Meeing CE Grants Standardized Metrics Admin for RFPs and grant metric	2014 2017 2017	Adjust forecast per annual review Adjust forecast per annual review. Reduce 2014 grant cycle to \$8.9M and 2015 grant cycle to \$8.75M.	Line 33		-	(263)	(277)	(291)
Polaris MedBiquitous TBD	CE Grants Standardized Metrics Admin for RFPs and grant metric	2017 2017	Adjust forecast per annual review. Reduce 2014 grant cycle to \$8.9M and 2015 grant cycle to \$8.75M.			-	_		(231)
MedBiquitous IBD	Standardized Metrics Admin for RFPs and grant metric	2017	and 2015 grant cycle to \$8.75M.	Line 35				-	(52,000)
TBD	Admin for RFPs and grant metric		Adjust forecast per annual review			(208)	1,499,075	972,064	(10,000,000)
		2014 +- 2016		Line 36		-	-	-	(18,000)
ACCME		2014 to 2016	Remove all forecasted funds as CE subteam has determined task is no longer needed."	Line 37		45,000	20,000	20,000	_
ACCME		Oct to Dec 2014 and	Updated 2014 allocation based on ACCME schedule of activities provided and estimated activity fees from approved grant proposals.						
	REMS Service Fees	2017	Updated 2017 per annual budget review.	Line 39		(298,002)	-	-	(225,000)
	Independent Audit by 3rd Party of		Moved \$43,334 from Oct to Nov for invoice not received. The CE Subteam does not anticipate the need to have CE audited by an independent 3rd party, outside of ACCME or other Accrediting						
TBD	CE	Oct to Nov 2014	Organizations until 2017.	Line 40		130,000	-	-	(130,000)
UBC	Assessment 3a	2017	Adjust forecast per annual review	Line 41		-	-	-	(180,000)
UBC	Assessment 3b (Same as CE (Metrics) Long Term CE	2014 to 2017	Aligned fees to those in not-yet executed SOW	Line 42		191,258	(130,324)	(230,324)	(550,324)
HealthCore	Assessment 4	2017	Adjust forecast per annual review	Line 43		-	-	-	(209,952)
	Assessment 5 - Objectives 1 (Other surveillance objectives); ER visits and deaths in claims database								
HealthCore	analysis;	2014 to 2017	Aligned fees to those in not-yet executed SOW	Line 44		150,000	(150,930)	(119,887)	(419,887)
тво	Assessment 5 - Objectives 5 (Other surveillance objectives); Mortality rates using state medical examiner databases	2017	Adjust forecast per annual review	Line 45		-	-	-	(300,000)
UBC	Assessment 5 - Objectives 6 (Other surveillance objectives); NSDUH and MTF publically accessible reports	2017	Adjust forecast per annual review	Line 46		-	-	-	(2,775)
	Assessment 5 - Objectives 2 and 3 (RADARS system): Pre/Post REMS Analysis: Active Drug Substance (e.g. ER morphine versus IR								
RMPDC	morphine, etc.)	2017	Adjust forecast per annual review	Line 47		-	-	-	(637,524)
Inflexxion	Assessment 5 - Objective 4 (Inflexxion/NAVIPPRO)	2014 to 2017	Adjust forecast per annual review	Line 48		-	-	-	(560,000)
MS	Assessment 6, 7 and 8	2017	Aligned fees to those in not-yet executed SOW	Line 49		-	(32,000)	-	(185,000)
JBC	Umbrella Metrics Vendor	2015 to 2017	Added fees per amendment to address assessment 5.6	Line 51		-	(2,400)	(2,400)	(97,091)
TBD .	Journal Article Publications	Oct to Nov 2014	Moved \$20,000 from Oct to Dec for invoice not received	Line 52		-	-	-	(60,000)
TBD	Additional Analysis	2017	Adjust forecast per annual review	Line 53	+	-	-	-	(150,000)
Campbell Alliance	Fees	2017	Adjust forecast per annual review	Line 54	+	-	-	-	(1,918,000)
Campbell Alliance	Expenses	Oct 2014 and 2017	Decreased by \$27,169 for actual expenses. Adjust 2017 forecast per annual review	Line 55		27,169	-	-	(180,000)
Constantine Cannon	Legal	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVIL	E REDACTED: PFF	REDACTED: PRIVI	REDACTED: PRR	EDACTED: PRIRI	DACTED: PRIV
PDRN	DCHPL 3	Oct to Nov 2014	Moved \$89,020 from Oct to Nov for invoice not received. Adjust forecast per annual review.	Line 60		-	-	-	(130,000)
ClinAudits	Annual Audit Vendor	2014 to 2017	Revised fees in light of Subteam decision for less frequent vendor audits			134,866	215,004	199,092	(265,908)
Lindudits Linda Kitlinski	CE Consultant	Oct to Dec 2014	and revised per audit fee estimates based on initial audit fees Reallocated costs to \$13,750 in Nov, Dec	Line 61 Line 62		134,866	215,004	199,092	(205,908)
Linda Kitiinski Topche	PMO Finance Audit	Dec 2014	Increased December from \$0 to \$30K for full amount of proposal received	Line 62		(30,000)	-	-	=

					[Net Effect - F	av (Unfav)	
Vendor	Task	Affected Period	Reason	Location on Summary by Vendor	Change Date	2014	2015	2016	2017
			While the current Ogilvy & Mather SOW only covers the initial costs, a rationale for 2015 costs is that it is a soft number estimate for upfront activity which depends on the results of the discovery phase. A rationale for 2016-2017 costs is that even though the CE/EC/Vendor						
Ogilvy + Mather	Awareness Campaign	2014 to 2017	Subteams determined that is it too early to estimate right now, the maintenance expected is usually 1/3 or less than upfront activity.	Line 65		100.000	(3,346,000)	(1,082,000)	(1,082,000)
McKesson	Web Communications	Nov to Dec 2014	invoice expected to be received in Dec billed in Nov due to delayed billing in Nov.	Line 27		(5,866.00)		_	
TBD	CE Face to Face Meeing	Nov 2014	Actual expenses \$1661	Line 33		26,339.00	_	-	
Polaris	CE Grants	Nov to Dec 2014	Milestone Payment of \$273,475 moved to Nov to accommodate 90 days advance billing.	Line 35				-	
ACCME	REMS Service Fees	Nov 2014	Actual fees for Nov \$331k	Line 39		(60,000.00)	-	-	
UBC	Assessment 3a	Nov to Dec 2014	Moved \$7,000 from Nov to Dec for invoice not received.	Line 41		-	_	-	
UBC	Assessment 3b (Same as CE (Metrics) Long Term CE	Nov to Dec 2014	Moved \$51,402 from Nov to Dec for invoice not received.	Line 42		-	_	_	
RMPDC	Assessment 5 - Objectives 5 (Other surveillance objectives); Mortality rates using state medical examiner databases	Nov to Dec 2014	Reduced \$75,000 from Nov and Dec due to updated proposal received from vendor.	Line 45		150,000.00	-	-	
									I
TBD	Journal Article Publications		5 Reallocated costs to \$20,000 in Dec, Jan and Feb.	Line 52		40,000.00	(40,000.00)	-	
TBD	Additional Analysis	Nov 2014	Moved \$30,000 from Nov to Dec for invoice not received	Line 53		-	-	-	
PDRN	DCHPL 3	Nov 2014	Reduced by \$15,200 for actual invoice costs.	Line 60		15,200.00	-	-	
Linda Kitlinski	CE Consultant	Nov to Mar 2014	Reduced November to 0 as no invoice was received. Revised December to \$15,000 and moved \$12,500 to 2015. Costs in 2015 are divided evenly at \$13k over Jan, Feb and Mar.	Line 62		12,500.00	(12,500.00)	-	
Ogilvy + Mather	Awareness Campaign	Nov to Dec 2014	Moved \$18,922 from Nov to Dec for invoice not received.	Line 64			,	-	
Campbell Alliance	Expenses	2015 to 2017	Moved \$100k from Operations to Development for F2F meetings	Lines 17 and 56		Œ	=	-	<u> </u>
<u>HealthCore</u>	Assessment 5 - Objectives 1 (Other surveillance objectives); ER visits and deaths in claims database analysis;	Dec 2014 to Jan 2015	Moved \$117,246 from Jan to Dec for work expected to be completed in searly December	Line 44		(117,246.00)	117,246.00	-	
RMPDC	Assessment 5 - Objectives 2 and 3 (RADARS system): Pre/Post REMS Analysis: Active Drug Substance (e.g. ER morphine versus IR morphine, etc.)	Dec 2014	Increase Dec by \$12,072.28 for Audit fees". Could you revise to "Increase Dec by \$12,072.28 for fees related to participation in audit conducted by ClinAudits.	Line 47		(12,072,28)			
RIMPDC	Central Database (3rd Party Data	Dec 2014	conducted by ClinAudits.	Line 47		(12,072.28)	-	-	
Polaris	Aggregation Vendor)	Dec 14	Actual invoice \$4,253 less than forecast	Line 30		4,253	-	-	<u> </u>
Delarie	CE Crant-	Doc 14	Grant EG-00291 payment moved from Dec to Jan to accommodate 90	Line 25		445.000	(115,920)		ĺ
Polaris	CE Grants	Dec 14	days advanced billing Dec 2014 actual invoice \$4,000 more than forecast, reduced 2015 to remove monthly cost and allocate \$67,500 in October for 2015 fees at a	Line 35		115,920	(115,920)	-	
ACCME	REMS Service Fees	Dec 14 to Dec 15	reduced cost of \$500 per activity.	Line 39		(4,000)	157,500	-	<u> </u>
UBC	Assessment 3a	Dec 14, Jan 15	\$17k moved to January for invoice not received	Line 41		17,000	(17,000)	-	
UBC	Assessment 3b (Same as CE (Metrics) Long Term CE Eval)	Dec 14, Jan 15	\$109k moved to January for invoice not received	Line 42		108,743.00	(108,743.00)	-	
HealthCore	Assessment 5 - Objectives 1 (Other surveillance objectives); ER visits and deaths in claims database	Dec 14, Jan 15	\$117k moved to January for invoice not received	Line 44			(117,246.00)	-	
DMDDC	Assessment 5 - Objectives 2 and 3 RADARS system): Pre/Post REMS Analysis: Active Drug Substance e.g. ER morphine versus IR	Dog 14	December reduced by \$130 or unall for this took is full invested to 200	Mino 47		12,072.00			
RMPDC TBD	morphine, etc.) Journal Article Publications	Dec 14 Dec 14, Mar 15	December reduced by \$12k as work for this task is fully invoiced in 2014 Reallocated to \$20k per month in Jan-Mar from Dec-Feb.	Line 47 Line 52	1	20,000.00	(20,000.00)	-	

							Net Effect - F	av (Unfav)	
lendor	Task	Affected Period	Reason	Location on Summary by Vendor	Change Date	2014	2015	2016	2017
		REDACTED:							
onstantine Cannon	Legal	PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIV	ILE REDACTED: PI	FREDACTED: PRIVE	REDACTED: PR	REDACTED: PRI	REDACTED: P
linAudits	Annual audit vendor	Dec 14	Reduced by \$8846 for actual invoice received	Line 61		8,846.00		-	
nda Kitlinski	CE Consultant	Dec 14	Reduced by \$8269 for actual invoice received	Line 62		8,269.00		-	
gilvy & Mather	Awareness Campaign	Dec 14, Jan 15	\$211k moved to January for actual invoice received	Line 64		211,396.00	(211,396.00)	-	
pche (sub-contractor of ClinAudits)	PMO Finance Aduit	Dec 14, Feb 15	\$30k moved to February for updated schedule	Line 65		30,000.00	(30,000.00)	-	
mpbell Alliance	Expenses	Dec 14	Reduced Dec by \$10,424 for actual cost	Line 56		10,424.00	_	_	
D	CE Face to Face Mtgs, Admin	Mar 15, Apr 15	Move \$12,000 from March to April for updated schedule	Line 33		,			
shfield (Alliance)	Call Center	Jan-Feb 2015	Moved \$3700 from Jan to Feb for invoice not received	Line 25	Jan 2015	_		_	
BC	Assessment 3a	Jan-Feb 2015	Moved \$23000 from Jan to Feb for invoice not received	Line 41	Jan 2015				
JC	Assessment 3b (Same as CE	Jan-1 eu 2013	Widved \$23000 from Jan to Feb for invoice not received	Line 41	Jan 2013	1			
С	(Metrics) Long Term CE Eval)	Jan-Feb 2015	Moved \$147893 from Jan to Feb for invoice not received	Line 42	Jan 2015	-	-	-	
	Assessment 5 - Objectives 5 (Other surveillance objectives); Mortality rates using state medical examiner	5 1 2045	Anna Caraca Cara						
MPDC	databases	Jan-Feb 2015	Moved \$42858 from Jan to Feb for invoice not received	Line 47	Jan 2015	-		-	
		5 1 2045	Reallocated from \$20k per month in Jan-Mar to \$20k per month in Feb-		2045				
ID	Journal Article Publications	Jan-Feb 2015	Apr	Line 52	Jan 2015	-	-	-	
BD	Additional Analysis	Jan-Feb 2015	Moved \$24150 from Jan to Feb for invoice not received	Line 53	Jan 2015	1	-	-	
impbell Alliance	Expenses	Jan-Feb 2015	Reduced by \$6488 for actual cost	Line 56	Jan 2015		6,488	-	
		REDACTED:							
nstantine Cannon	Legal	PRIVILEGED	REDACTED: PRIVILEGED			REDACTED: PRIVE	REDACTED: PR	REDACTED: PR	REDACTED: P
nAudits	Annual audit vendor	Jan-Feb 2015	Moved \$29545 from Jan to Feb for invoice not received	Line 61	Jan 2015	-	-	-	
da Kitlinski	CE Consultant	Jan-Feb 2015	Moved \$11652 from Jan to Feb for invoice not received	Line 62	Jan 2015	-	=	-	
ilvy & Mather	Awareness Campaign	Jan-Feb 2015	Moved \$581896 from Jan to Feb for invoice not received	Line 64	Jan 2015	-	-	-	
IC .	Grantee Reimbursement	Apr-May 2015	Moved \$48000 from Apr to May for updated schedule	Line 66	Jan 2015	-	1	-	
MPDC	Assessment 5 - Objectives 2 and 3 (RADARS system): Pre/Post REMS Analysis: Active Drug Substance (e.g. ER morphine versus IR morphine, etc.)	Feb 2015 to Aug 2017	Reallocated funds based on executed SOW	Line 47	Jan 2015	_	239,598	161,310	142,89
olaris	Grant Management System/CE Portal Setup	Feb to Mar 2015	Moved \$35,000 from Feb to Mar for updated schedule	Line 26	Jan 2015			_	
		June 2015, 2016,							
MPDC	Assessment 5.4	2017	Added \$241,868 to June 2015, 2016 and 2017 for assessment 5.4.	Line 67	Jan 2015		241,868	241,868	241,86
hfield (Alliance)	Call Center	Feb 2015	Decrease by \$1,637 for actual invoice	Line 25	Feb 2015		1,637	241,000	241,00
cKesson	Web Communications	Feb 2015	Increase by \$11,550 for custom updates	Line 27	Feb 2015		(11,550)		
	Printing PCDs	Feb-Mar 2015	Move \$1,108 from Feb to Mar for no invoice received	Line 31	Feb 2015		(11,550)	-	
nveo	Printing PCDs	rep-iviar 2015			Feb 2015			-	
			Move milestone 3 payment for EG-000251 from July to Feb for updated						
olaris	CE Grants	2015-2016	schedule and Milestone 4 from Feb to Mar 2015	Line 35	Feb 2015		-	-	
BC .	Assessment 3a	Feb-Mar 2015	Move \$29,000 from Feb to Mar for no invoice received	Line 41	Feb 2015		-	-	
	Assessment 3b (Same as CE								
BC .	(Metrics) Long Term CE Eval)	Feb-Mar 2015	Move \$196,424 from Feb to Mar for no invoice received	Line 42	Feb 2015		-	-	
MPDC	Assessment 5 - Objectives 5 (Other surveillance objectives); Mortality rates using state medical examiner databases	Feb-Mar 2015	Move \$85,714 from Feb to Mar for no invoice received	Line 45	Feb 2015		_	-	
	Assessment 5 - Objectives 2 and 3 (RADARS system): Pre/Post REMS Analysis: Active Drug Substance (e.g. ER morphine versus IR								
ИPDC	morphine, etc.)	Feb-Dec 2015	Reallocated according to service order	Line 47	Feb 2015		-	-	
D	Journal Article Publications	Feb-May 2015	Shifted from Feb-Apr to Mar-May for no activity	Line 52	Feb 2015		_	-	
D	Additional Analysis	Feb-Mar 2015	Moved \$24,150 from Feb to Mar for invoice not received	Line 53	Feb 2015		_	-	
mpbell Alliance	Expenses	Feb 2015	Increase expenses by \$29,998 for F2F costs from December	Line 56	Feb 2015		(29,998)	-	
	·	REDACTED:					, , , , ,		
nstantine Cannon	Legal	PRIVILEGED	REDACTED: PRIVILEGED		1	REDACTED: PRIVE	REDACTED: PR	REDACTED: PR	REDACTED: P
inAudits	Annual audit vendor	Feb-Mar 2015	Moved \$33,854 from Feb to Mar for invoice not received	Line 61	Feb 2015		-	-	
inda Kitlinski	CE Consultant	Feb-Mar 2015	Reallocated remaining fee between Mar and Apr @ \$19,159 per month.	Line 62	Feb 2015		-	-	

Case: 1:17-md-02804-DAP Doc #: 2313-100 Filed: 08/14/19 23 of 49. PageID #: 369852

REMS Changes to Forecast in Summary by Vendor Tab

							Net Effect - Fav (Unfav)			
Vendor	Task	Affected Period	Reason	Location on Summary by Vendor	Change Date	2014	2015	2016	2017	
Ogilvy & Mather	Awareness Campaign	Feb-Apr 2015	Reallocated Feb to Apr as Feb - \$0, Mar - \$256,241 and Apr as \$1,137,155. Change is due to (1) invoice not received by cutoff date for and (2) to account for timing of potential forecasted fees when 2015 SOW is finalized.	Line 64	Feb 2015				_	
Topche (sub-contractor of ClinAudits)	PMO Finance Aduit	Feb 2015	Reduced by \$2,006 for actual invoice	Line 65	Feb 2015		2,006			

Case: 1:17-md-02804-DAP Doc #: 2313-100 Filed: 08/14/19 24 of 49. PageID #: 369853

REMS Changes to Forecast in Summary by Vendor Tab

								Net Effect - F	av (untav)	4
•	Vendor	Task	Affected Period	Reason	Location on Summary by Vendor	Change Date	2014	2015	2016	2017

Case: 1:17-md-02804-DAP Doc #: 2313-100 Filed: 08/14/19 25 of 49. PageID #: 369854

REMS Changes to Forecast in Summary by Vendor Tab

						Net Effect - F	av (Unfav)		
Vendor	Task	Affected Period	Location on Summary by Vendor	Change Date	2014	2015	2016	2017	

Case: 1:17-md-02804-DAP Doc #: 2313-100 Filed: 08/14/19 26 of 49. PageID #: 369855

REMS Changes to Forecast in Summary by Vendor Tab

								Net Effect - F	av (untav)	4
•	Vendor	Task	Affected Period	Reason	Location on Summary by Vendor	Change Date	2014	2015	2016	2017

Case: 1:17-md-02804-DAP Doc #: 2313-100 Filed: 08/14/19 27 of 49. PageID #: 369856

REMS Changes to Forecast in Summary by Vendor Tab

						Net Effect - F	av (Unfav)		
Vendor	Task	Affected Period	Location on Summary by Vendor	Change Date	2014	2015	2016	2017	

Case: 1:17-md-02804-DAP Doc #: 2313-100 Filed: 08/14/19 28 of 49. PageID #: 369857

REMS Changes to Forecast in Summary by Vendor Tab

						Net Effect - F	av (Unfav)		
Vendor	Task	Affected Period	Location on Summary by Vendor	Change Date	2014	2015	2016	2017	

Case: 1:17-md-02804-DAP Doc #: 2313-100 Filed: 08/14/19 29 of 49. PageID #: 369858

REMS Changes to Forecast in Summary by Vendor Tab

								Net Effect - F	av (untav)	4
•	Vendor	Task	Affected Period	Reason	Location on Summary by Vendor	Change Date	2014	2015	2016	2017

Case: 1:17-md-02804-DAP Doc #: 2313-100 Filed: 08/14/19 30 of 49. PageID #: 369859

REMS Changes to Forecast in Summary by Vendor Tab

								Net Effect - F	av (untav)	4
•	Vendor	Task	Affected Period	Reason	Location on Summary by Vendor	Change Date	2014	2015	2016	2017

Case: 1:17-md-02804-DAP Doc #: 2313-100 Filed: 08/14/19 31 of 49. PageID #: 369860

REMS Changes to Forecast in Summary by Vendor Tab

						Net Effect - F	av (Unfav)		
Vendor	Task	Affected Period	Location on Summary by Vendor	Change Date	2014	2015	2016	2017	

ACTAVIS / WATSON ENDO GENERIC PROD / ENDO LABS JANSSEN PHARM MALLINCKRODT MYLAN NOVEN PURDUE PHARMA
ENDO GENERIC PROD / ENDO LABS JANSSEN PHARM MALLINCKRODT MYLAN NOVEN PURDUE PHARMA
ENDO GENERIC PROD / ENDO LABS JANSSEN PHARM MALLINCKRODT MYLAN NOVEN PURDUE PHARMA
MALLINCKRODT MYLAN NOVEN PURDUE PHARMA
MYLAN NOVEN PURDUE PHARMA
NOVEN PURDUE PHARMA
PURDUE PHARMA
RHODES PHARM
ROXANE
SANDOZ
THE PHARMANETWORK
VISTA
PFIZER
IMPAX
APOTEX PAR PHARM
RANBAXY PHARM
UPSHER-SMITH
ZOGENIX
NESHER
NEGITER

	Prior Yea	r Allocation %
	IMS Market Share Estimate**	Adjusted Market Share Estimate
b c d e f g j k	6.41% 3.81% 1.76% 22.55% 16.21% 0.14% 24.55% 10.44%	6.44% 3.82% 1.77% 22.66% 16.28% 0.14% 24.67% 10.49%
l m	8.27% 0.55%	8.31% 0.55%
p q	0.61% 0.00%	0.62% 0.00%
s t	0.70% 0.00%	0.70% 0.00%
u v	1.44% 2.08%	1.45% 2.09%
w x	0.00%	0.00% 0.00%
y z	0.00%	0.00% 0.00%
Z	99.53%	100.00%

RPC Member Deposit Activity
Case: 1:17-md-02804-DAP Doc #: 2313-100 Filed: 08/14/19 33 of 49. PageID #: 369862

						Deposit Account	Activity		
				7/12/2012	9/1/2012	12/1/2012	1/1/2013	4/15/2013	4/1/2014
				2012 Deposit	Reallocation to	Reallocation to add Par and Combine	Reallocation to add	2012 IMS Actual Data Deposit	2013 IMS Actual Data Deposit
RPC Member	Operations Market Share	Funds Received	Denosit Requirement	Requirements	•	Watson/Actavis		Reallocation	
Actavis Group, I.f.	0.00%	\$0		\$243,841	-\$7,253				\$0
Endo Pharmaceuticals Inc.	3.82%	\$176,446	•	\$471,523	-\$7,253		-\$2,987		-\$85,612
Janssen Pharmaceuticals, Inc.	1.77%	\$81,701	· ·	\$122,474	-\$7,253				-\$11,957
Mallinckrodt, Inc.	22.66%	\$1,045,316	' '	\$1,005,917	-\$7,253				\$28,386
Mylan Technologies, Inc.	16.28%	\$751,267	\$751,267	\$726,019	-\$7,253	\$0	-\$2,987	-\$517	\$36,005
Noven Pharmaceuticals, Inc.	0.14%	\$6,649	\$6,649	\$113,065	-\$7,253	\$0	-\$2,987	-\$52,203	-\$43,973
Pfizer, Inc.	0.70%	\$32,445	\$32,445	\$106,950	-\$7,253	\$0	-\$2,987	-\$56,221	-\$8,044
Purdue Pharma, L.P.	24.67%	\$1,138,192	\$1,138,192	\$1,268,409	-\$7,253	\$0	-\$2,987	-\$100,689	-\$19,288
Rhodes Pharmaceuticals L.P.	10.49%	\$484,096	\$484,096	\$401,431	-\$7,253	\$0	-\$2,987	-\$70,764	\$163,669
Roxane Laboratories, Inc.	8.31%	\$383,299	\$383,299	\$503,041	-\$7,253	\$0	-\$2,987	-\$43,549	-\$65,953
Sandoz Inc.	0.55%	\$25,449	\$25,449	\$115,417	-\$7,253	\$0	-\$2,987	-\$46,250	-\$33,478
The PharmaNetwork, LLC	0.62%	\$28,464	\$28,464	\$61,790	-\$7,253	\$0	-\$2,987	-\$51,550	\$28,464
VistaPharm, Inc.	0.00%	\$0	\$0	\$58,497	-\$7,253	\$0	-\$2,987	-\$48,257	\$0
Actavis (Formerly Watson Laboratories, Inc.)	6.44%	\$296,969	\$296,969	\$314,874	-\$7,253	\$185,815	-\$2,987	-\$193,751	\$271
Impax Laboratories, Inc.	0.00%	\$0	\$0	\$0	\$50,773	\$0	-\$2,987	-\$47,787	\$0
Apotex	1.45%	\$66,807	\$66,807	\$0	\$50,773	\$0	-\$2,987	-\$47,787	\$66,807
Par Pharmaceuticals	2.09%	\$96,507	\$96,507	\$0	\$0		-\$2,987		-\$15,119
Ranbaxy	0.00%	\$0		\$0	\$0		\$47,787	-\$47,348	
Upsher-Smith Laboratories	0.00%	\$0		\$0	\$0				\$0
Zogenix	0.00%	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
					ı	T		T	1
Total Deposit	100.00%	\$4,613,609	\$4,613,609	\$5,513,247	\$0	\$0	\$0	-\$939,380	\$39,742
			1						
DECLUBED DEDOCIT		Ć0 ECE 217	CO ECE 217						

REQUIRED DEPOSIT	\$8,565,317	\$8,565,317
VARIANCE	-\$3,951,708	-\$3,951,708

COMMENTS:

CE Grant Summary by Grant

2/28/2015

Grant ID	Grantee	Total Amount	Milestone 1:	Executuion of	of Letter of	Milestone 2: S	tart of First	Activity and	Milestone	3: Mid-term	of Grant	Milestone	4: Completion	on of Last
			Amount	Due	Paid	Amount	Due	Paid	Amount	Due	Paid	Amount	Due	Paid
EG-000101	Boston U	1,857,500.00	650,125.0	12/18/2012	12/18/2012	464,375.00	3/1/2013	2/27/2013	557,250.0	0 11/1/2013	3 11/1/2013	185,750.00	6/1/2014	4 6/2/2014
EG-000115	American College of Physicians, Inc.	1,434,430.00	502,050.50	1/30/2013	1/30/2013	358,607.50	6/1/2013	5/29/2013	430,329.0	3/1/2014	3/3/2014	143,443.00	4/1/2015	;
EG-000146	California Academy of Family Physicians	5,997,640.00	2,099,174.0	1/30/2013	1/30/2013	1,499,410.00	4/1/2013	4/1/2013	1,799,292.0	0 10/1/2013	3 10/1/2013	599,764.00	4/30/2014	4 4/30/2014
EG-000204	Utah Medical Association Foundation	838,899.00	293,614.6	2/14/2013	2/14/2013	209,724.75	10/1/2013	10/1/2013	251,669.7	0 4/1/2014	4/1/2014	83,889.90	4/1/2015	;
EG-000206	Association for Hospital Medical Education	379,800.00	132,930.0	1/30/2013	1/30/2013	94,950.00	8/1/2013	8/1/2013	113,940.0	0 11/15/2013	3 11/15/2013	37,980.00	5/1/2014	4 5/1/2014
EG-000228	University of Washington	799,577.00	279,851.9	12/3/2013	12/4/2013	199,894.25	1/1/2014	1/2/2014	239,873.1	0 6/16/2014	4 6/18/2014	79,957.70	12/31/2014	4 1/2/2015
EG-000239	Temple University	498,755.00	174,564.2	12/3/2013	12/4/2013	124,688.75	1/1/2014	1/2/2014	149,626.5	7/31/2014	8/1/2014	49,763.00	2/2/2015	5 2/2/2015
EG-000240	Montefiore	1,977,300.00	692,055.0	12/3/2013	12/4/2013	494,325.00	1/4/2014	1/2/2014	593,190.0	0 4/4/2014	4/1/2014	197,730.00	7/5/2014	4 7/2/2014
EG-000244	AAPM	599,280.00	209,748.0	12/3/2013	12/4/2013	149,820.00	2/2/2014	2/3/2014	179,784.0	8/2/2014	8/1/2014	59,928.00	2/1/2015	5 2/2/2015
EG-000248	University of Cincinnati	324,705.00	113,646.7	12/3/2013	12/4/2013	81,176.25	3/1/2014	3/3/2014	97,411.5	9/15/2014	9/15/2014	32,470.50	4/14/2015	;
EG-000249	Univ of Nebraska Board of Regents	1,105,290.00	390,000.00	12/3/2013	12/4/2013	400,000.00	3/13/2014	3/14/2014	200,000.0	3/23/2015	5	115,290.00	3/31/2016	j .
EG-000251	University of North Texas	420,822.00	147,287.70	12/3/2013	12/4/2013	105,205.50	3/16/2014	3/14/2014	126,246.6	0 10/5/2015	5	42,082.20	5/1/2015	;
EG-000101 Ext	Boston U	988,150.00	345,852.50	3/21/2014	3/20/2014	247,037.50	4/1/2014	4/1/2014	296,445.0	8/1/2014	8/1/2014	98,815.00	2/28/2015	5 2/27/2015
EG-000115 Ext	American College of Physicians, Inc.	905,000.00	316,750.0	3/6/2014	3/6/2014	226,250.00	3/15/2014	3/14/2014	271,500.0	5/30/2014	5/29/2014	90,500.00	9/12/2014	4 9/15/2014
EG-000146 Ext	California Academy of Family Physicians	2,000,000.00	700,000.00	3/6/2014	3/6/2014	500,000.00	4/15/2014	4/15/2014	600,000.0	0 10/1/2014	10/1/2014	200,000.00	4/15/2015	;
EG-000267	Trustees of Boston University	1,093,900.00	382,865.0	10/10/2014	10/23/2014	273,475.00	2/28/2015	2/26/2015	328,170.0	8/28/2015	5	109,390.00	2/28/2016	j .
EG-000285	Pri-Med Institute, LLC	1,195,217.00	418,325.9	10/26/2014	10/23/2014	298,804.25	11/22/2014	11/21/2014	358,565.1	0 4/1/2019	5	119,521.70	6/19/2015	;
EG-000269	University of Washington	785,400.00	274,890.0	10/23/2014	10/23/2014	196,350.00	1/1/2015	1/2/2015	235,620.0	7/1/2019	5	78,540.00	1/1/2016	j .
EG-000259	CO*RE	3,655,634.00	1,279,471.9	10/23/2014	10/23/2014	913,908.50	11/1/2014	11/21/2014	1,096,690.2	5/1/2019	5	365,563.40	1/31/2016	j .
EG-000260	Florida Medical Association	45,613.00	15,964.5	10/30/2014	10/23/2014	11,403.25	10/25/2014	11/21/2014	13,683.9	0 4/30/2015	5	4,561.30	11/30/2015	;
EG-000291	Postgraduate Institute for Medicine	1,159,200.00	405,720.00	10/23/2014	10/23/2014	289,800.00	12/6/2014	12/5/2014	347,760.0	2/1/2019	2/1/2015	115,920.00	3/14/2015	;
EG-000270	Dannemiller, Inc.	757,730.00	265,205.50	10/26/2014	10/23/2014	189,432.50	12/1/2014	12/5/2014	227,319.0	0 6/1/2015	5	75,773.00	12/1/2015	j

Total Grants Approved 28,819,842.00

CE Grant Summary by Month

2/28/2015

Grants are billed to RPC 90 days in advance of when each payment is due. This report represents the date payment will be billed to RPC.

RPC Invoice Status Categories

Actual - Milestone has been billed to RPC

Firm - Milestone is scheduled on an executed LOA

Tentative - Milestone forecasted as part of the annual budget and subject to change

<u>Month</u>	<u>Milestone</u>	<u>Amount</u>	RPC Invoice Status	
	Additional Milestone 1 for 2012 Grants (2012 total			
anuary	budget increased to \$10.5M from \$10M)	177,894.15		
lanuary	EG-000101 (2012 Grant Cycle) Milestone 2	464,375.00	Actual	
anuary	Subtotal	642,269.15	-	642,269.1
ebruary	EG-000115 (2012 Grant Cycle) Milestone 2	358,607.50	Actual	
- ebruary	EG-000146 (2012 Grant Cycle) Milestone 2	1,499,410.00	Actual	
February	Subtotal	1,858,017.50	-	1,858,017.5
March	No Activity	-		
March	Subtotal	-	-	
April	Aggregated Milestone 1 and 2 for 2013 Grants as allocated below: EG-000228 Milestone 1 \$279,851.95 EG-000239 Milestone 1 \$174,564.25 EG-000240 Milestone 1 \$209,748.00 EG-000241 Milestone 1 \$113,646.75 EG-000242 Milestone 1 \$113,646.75 EG-000251 Milestone 1 \$147,287.70 EG-000251 Milestone 2 \$199,894.25 EG-000240 Milestone 2 \$124,688.75 EG-000240 Milestone 2 \$149,820.00 EG-000248 Milestone 2 \$149,820.00 Milestone 2 \$267,942.10	3,325,000.00	Actual	
April	Subtotal	3,325,000.00	-	3,325,000.0
May	EG-000206 (2012 Grant Cycle) Milestone 2	94,950.00	Actual	
Мау	Subtotal	94,950.00	-	94,950.0
une	No Activity			
lune	Subtotal	-	-	

CE Grant Summary by Month

/20	าก	11
/28/	ZU	12

July	EG-000146 (2012 Grant Cycle) Milestone 3	1,799,292.00	Actual	
July	Subtotal	2,009,016.75	-	2,009,016.75
August	EG-000206 (2012 Grant Cycle) Milestone 3	113,940.00	Actual	
August	EG-000101 (2012 Grant Cycle) Milestone 3	557,250.00	Actual	
August	Subtotal	671,190.00	-	671,190.00
September	No Activity	-		
September	Subtotal	-	-	
October	No Activity			
October	Subtotal	-	-	
November	No Activity			
November	Subtotal	-	-	
December	EG-000115 (2012 Grant Cycle) Milestone 3	430,329.00	Actual	
December	Subtotal	430,329.00	-	430,329.00
2013	Total	9,030,772.40	-	9,030,772.40

<u> 2014 - </u>	Duuget	Approv	reu by	MFC

Month	Milestone	<u>Amount</u>	RPC Invoice Status	
January	EG-000251 (2013 Grant Cycle) Milestone 2	105,205.50	Actual	
	EG-000249 (2013 Grant Cycle) Milestone 2 total payment due is \$400,000.00, pre-payment billed in			
January	April, 2013 will cover \$267,942.10.	132,057.90	Actual	
January	EG-000240 (2013 Grant Cycle) Milestone 3	593,190.00	Actual	
January	EG-000204 (2012 Grant Cycle) Milestone 3	251,669.70	Actual	
January	Subtotal	1,082,123.10	-	1,082,123.10
February	EG-000146 (2012 Grant Cycle) Milestone 4 EG-000206 (2012 Grant Cycle) Milestone 4 EG-000101 (2012 Grant Extension Cycle) Milestone 1 EG-000115 (2012 Grant Extension Cycle) Milestone 1 EG-000146 (2012 Grant Extension Cycle) Milestone 1 EG-000101 (2012 Grant Extension Cycle) Milestone 2 EG-000115 (2012 Grant Extension Cycle) Milestone 2 EG-000146 (2012 Grant Extension Cycle) Milestone 2	599,764.00 37,980.00 345,852.50 316,750.00 700,000.00 247,037.50 226,250.00 500,000.00	Actual Actual Actual Actual Actual Actual Actual Actual Actual	
February	Subtotal	2,973,634.00	Actual	2,973,634.00
March March	EG-000101 (2012 Grant Cycle) Milestone 4 Subtotal	185,750.00 185,750.00	- Actual -	185,750.00

1	ำ	0	/2	n	1	
./	_	0,	<i>'</i> _	U	T	J

April April April April	EG-000228 (2013 Grant Cycle) Milestone 3 EG-000115 (2012 Grant Extension Cycle) Milestone 3 EG-000240 (2013 Grant Cycle) Milestone 4 Subtotal	239,873.10 271,500.00 197,730.00 709,103.10	Actual Actual Actual -	197,730.00
May	EG-000239 (2013 Grant Cycle) Milestone 3	149,491.50	Actual	
May	EG-000101 (2012 Grant Extension Cycle) Milestone 3	296,445.00	Actual	
May	EG-000244 (2013 Grant Cycle) Milestone 3	179,784.00	Actual	
May	Aggregated Milestone 1 and 2 for 2014 Grants as allocated below: EG-000267 Milestone 1 \$382,865.00 EG-000285 Milestone 1 \$418,325.95 EG-000269 Milestone 1 \$274,890.00 EG-000259 Milestone 1 \$1,279,471.90 EG-000260 Milestone 1 \$15,964.55 EG-000291 Milestone 1 \$405,720.00 EG-000270 Milestone 1 \$265,205.50 EG-000259 Milestone 2 \$413,055.30	3,455,498.20	Actual	
May	Subtotal	4,081,218.70	Actual	4,081,218.70
iviay	Subtotal	4,001,210.70	_	4,001,210.70
June	EG-000115 (2012 Grant Extension Cycle) Milestone 4	90,500.00	Actual	
June	EG-000248 (2013 Grant Cycle) Milestone 3	97,411.50	Actual	
June	Subtotal	187,911.50	_	187,911.50
July	EG-000146 (2012 Grant Extension Cycle) Milestone 3	600,000.00	Actual	
July	Check Processing Fees	372.89	Actual	
July	Subtotal	600,372.89	-	600,372.89
August	No Activity			
August	Subtotal	-	-	600,372.89
Contouchon	No. A aki. iku.			
September	No Activity Subtotal			
September	Subtotal	-	-	-
October	EG-000228 (2013 Grant Cycle) Milestone 4	79,957.73	Firm	
October	EG-000285 (2014 Grant Cycle) Milestone 2	298,804.25	Actual	
October	EG-000269 (2014 Grant Cycle) Milestone 2	196,350.00	Firm	
October	EG-000259 (2014 Grant Cycle) Milestone 2	500,850.20	Actual	
October	EG-000260 (2014 Grant Cycle) Milestone 2	11,403.25	Actual	
October	EG-000291 (2014 Grant Cycle) Milestone 2	289,800.00	Firm	
October	EG-000270 (2014 Grant Cycle) Milestone 2	189,432.50	Firm	
October	EG-000239 (2013 Grant Cycle) Milestone 2	(112.50)	Firm	
October	Subtotal	1,566,485.43	-	1,566,485.43
November	Check Processing Fees	282.78	Firm	
November	EG-000244 (2013 Grant Cycle) Milestone 4	59,928.00	Firm	
November	EG-000267 (2014 Grant Cycle) Milestone 2	273,475.00	Firm	

2	/28	/2015	

November November	EG-000239 (2013 Grant Cycle) Milestone 4 EG-000291 (2014 Grant Cycle) Milestone 3 Subtotal	49,673.00 347,760.00 731,118.78	Firm Firm -	731,118.78
December December December	EG-000101 (2012 Grant Extension Cycle) Milestone 4 EG-000249 (2013 Grant Cycle) Milestone 3 Subtotal	98,815.00 200,000.00 298,815.00	Firm Firm -	298,815.00
2014	Total	12,416,532.50	-	12,505,532.29

2015 - Budget Approved by RPC				
			RPC Invoice	
<u>Month</u>	<u>Milestone</u>	<u>Amount</u>	Status	
January	Check Processing Fees	535.86	Firm	
January	EG-000146 (2012 Grant Extension Cycle) Milestone 4	200,000.00	Firm	
January	EG-000291 (2014 Grant Cycle) Milestone 4	115,920.00	Firm	
January	EG-000248 (2013 Grant Cycle) Milestone 4	32,470.50	Firm	
January	EG-000115 (2012 Grant Cycle) Milestone 4	143,443.00	Firm	
January	EG-000204 (2012 Grant Cycle) Milestone 4	83,889.90	Firm	
January	EG-000285 (2014 Grant Cycle) Milestone 3	358,565.10	Firm	
January	Subtotal	934,824.36	-	934,824.30
February	EG-000259 (2014 Grant Cycle) Milestone 3	1,096,690.20	Firm	
February	Cancellation for ACCME fees	(7,500.00)	Firm	
February	Correction to EG-000239 Milestone 4	0.08	Firm	
February	EG-000260 (2014 Grant Cycle) Milestone 3	13,683.90	Firm	
February	Subtotal	1,102,874.18	-	1,102,874.18
March	EC 000270 (2004 Court Coult) Milestons 2	227 240 00	5 1	
March	EG-000270 (2014 Grant Cycle) Milestone 3	227,319.00	Firm	
March	EG-000251 (2013 Grant Cycle) Milestone 3	126,246.60	Firm	
March	EG-000251 (2013 Grant Cycle) Milestone 4	42,082.20	Firm	
March	EG-000285 (2014 Grant Cycle) Milestone 4	119,521.70	Firm	
March	Subtotal	515,169.50	-	515,169.50
April	EG-000269 (2014 Grant Cycle) Milestone 3	235,620.00	Firm	
April	Subtotal	235,620.00	-	
May	Aggregated Milestone 1 for 2015 Grants	3,062,500.00	Tentative	
May	Subtotal	3,062,500.00	-	3,062,500.00
June	EG-000267 (2014 Grant Cycle) Milestone 3	328,170.00	Firm	
June	Subtotal	328,170.00	-	328,170.00
July	No Activity		Firm	
July	Subtotal	-	-	

2/28/2015

August	No Activity	-		
August	Subtotal	-	-	-
September	EG-000260 (2014 Grant Cycle) Milestone 4	4,561.30	Firm	
September	EG-000270 (2014 Grant Cycle) Milestone 4 EG-000270 (2014 Grant Cycle) Milestone 4	75,773.00	Firm	
September	1/3 of Milestone 2 for 2015 Grants	729,166.00		
September	Subtotal	809,500.30	-	809,500.30
September	Subtotal	005,500.50		005,500.50
October	1/3 of Milestone 2 for 2015 Grants	729,166.00	Tentative	
October	EG-000269 (2014 Grant Cycle) Milestone 4	78,540.00	Firm	
October	Subtotal	807,706.00	-	807,706.00
		551,155155		551,155155
November	1/3 of Milestone 2 for 2015 Grants	729,167.00	Tentative	
November	EG-000259 (2014 Grant Cycle) Milestone 4	365,563.40	Firm	
November	Subtotal	1,094,730.40	-	1,094,730.40
		,,		,,
December	EG-000267 (2014 Grant Cycle) Milestone 4	109,390.00	Firm	
December	Subtotal	109,390.00	-	109,390.00
		•		•
2015	Total	9,000,484.74	_	8,764,864.74
			=	
2016 - Budget Approved by RPC				
			RPC Invoice	
Month	<u>Milestone</u>	Amount	RPC Invoice Status	
		Amount	Status	
Month January	1/3 of Milestone 3 for 2015 Grants	Amount 875,000.00	Status Tentative	
		Amount	Status	
January	1/3 of Milestone 3 for 2015 Grants	Amount 875,000.00	Status Tentative	990,290.00
January January January	1/3 of Milestone 3 for 2015 Grants EG-000249 (2013 Grant Cycle) Milestone 4 Subtotal	875,000.00 115,290.00 990,290.00	Status Tentative Firm -	990,290.00
January January January February	1/3 of Milestone 3 for 2015 Grants EG-000249 (2013 Grant Cycle) Milestone 4 Subtotal 1/3 of Milestone 3 for 2015 Grants	875,000.00 115,290.00 990,290.00	Status Tentative Firm -	·
January January January	1/3 of Milestone 3 for 2015 Grants EG-000249 (2013 Grant Cycle) Milestone 4 Subtotal	875,000.00 115,290.00 990,290.00	Status Tentative Firm -	990,290.00 875,000.00
January January January February February	1/3 of Milestone 3 for 2015 Grants EG-000249 (2013 Grant Cycle) Milestone 4 Subtotal 1/3 of Milestone 3 for 2015 Grants Subtotal	875,000.00 115,290.00 990,290.00 875,000.00	Tentative Firm - Tentative -	·
January January January February March	1/3 of Milestone 3 for 2015 Grants EG-000249 (2013 Grant Cycle) Milestone 4 Subtotal 1/3 of Milestone 3 for 2015 Grants Subtotal 1/3 of Milestone 3 for 2015 Grants	875,000.00 115,290.00 990,290.00 875,000.00 875,000.00	Tentative Firm - Tentative - Tentative - Tentative	875,000.00
January January January February February	1/3 of Milestone 3 for 2015 Grants EG-000249 (2013 Grant Cycle) Milestone 4 Subtotal 1/3 of Milestone 3 for 2015 Grants Subtotal	875,000.00 115,290.00 990,290.00 875,000.00	Tentative Firm - Tentative -	·
January January January February February March March	1/3 of Milestone 3 for 2015 Grants EG-000249 (2013 Grant Cycle) Milestone 4 Subtotal 1/3 of Milestone 3 for 2015 Grants Subtotal 1/3 of Milestone 3 for 2015 Grants Subtotal	875,000.00 115,290.00 990,290.00 875,000.00 875,000.00	Tentative Firm - Tentative - Tentative - Tentative	875,000.00
January January January February February March March	1/3 of Milestone 3 for 2015 Grants EG-000249 (2013 Grant Cycle) Milestone 4 Subtotal 1/3 of Milestone 3 for 2015 Grants Subtotal 1/3 of Milestone 3 for 2015 Grants Subtotal No Activity	875,000.00 115,290.00 990,290.00 875,000.00 875,000.00	Tentative Firm - Tentative - Tentative - Tentative	875,000.00
January January January February February March March	1/3 of Milestone 3 for 2015 Grants EG-000249 (2013 Grant Cycle) Milestone 4 Subtotal 1/3 of Milestone 3 for 2015 Grants Subtotal 1/3 of Milestone 3 for 2015 Grants Subtotal	875,000.00 115,290.00 990,290.00 875,000.00 875,000.00	Tentative Firm - Tentative - Tentative - Tentative	875,000.00
January January January February February March March April	1/3 of Milestone 3 for 2015 Grants EG-000249 (2013 Grant Cycle) Milestone 4 Subtotal 1/3 of Milestone 3 for 2015 Grants Subtotal 1/3 of Milestone 3 for 2015 Grants Subtotal No Activity Subtotal	875,000.00 115,290.00 990,290.00 875,000.00 875,000.00 875,000.00	Tentative Firm - Tentative - Tentative - Tentative -	875,000.00
January January January February February March March April April	1/3 of Milestone 3 for 2015 Grants EG-000249 (2013 Grant Cycle) Milestone 4 Subtotal 1/3 of Milestone 3 for 2015 Grants Subtotal 1/3 of Milestone 3 for 2015 Grants Subtotal No Activity Subtotal Aggregated Milestone 1 for 2016 Grants	875,000.00 115,290.00 990,290.00 875,000.00 875,000.00 875,000.00 375,000.00	Tentative Firm - Tentative - Tentative - Tentative -	875,000.00 875,000.00
January January January February February March March April	1/3 of Milestone 3 for 2015 Grants EG-000249 (2013 Grant Cycle) Milestone 4 Subtotal 1/3 of Milestone 3 for 2015 Grants Subtotal 1/3 of Milestone 3 for 2015 Grants Subtotal No Activity Subtotal	875,000.00 115,290.00 990,290.00 875,000.00 875,000.00 875,000.00	Tentative Firm - Tentative - Tentative - Tentative -	875,000.00
January January January February February March March April April May	1/3 of Milestone 3 for 2015 Grants EG-000249 (2013 Grant Cycle) Milestone 4 Subtotal 1/3 of Milestone 3 for 2015 Grants Subtotal 1/3 of Milestone 3 for 2015 Grants Subtotal No Activity Subtotal Aggregated Milestone 1 for 2016 Grants Subtotal	875,000.00 115,290.00 990,290.00 875,000.00 875,000.00 875,000.00 375,000.00	Tentative Firm - Tentative - Tentative - Tentative -	875,000.00 875,000.00
January January January February February March March April April May May	1/3 of Milestone 3 for 2015 Grants EG-000249 (2013 Grant Cycle) Milestone 4 Subtotal 1/3 of Milestone 3 for 2015 Grants Subtotal 1/3 of Milestone 3 for 2015 Grants Subtotal No Activity Subtotal Aggregated Milestone 1 for 2016 Grants Subtotal No Activity	875,000.00 115,290.00 990,290.00 875,000.00 875,000.00 875,000.00 375,000.00	Tentative Firm - Tentative - Tentative - Tentative -	875,000.00 875,000.00
January January January February February March March April April May	1/3 of Milestone 3 for 2015 Grants EG-000249 (2013 Grant Cycle) Milestone 4 Subtotal 1/3 of Milestone 3 for 2015 Grants Subtotal 1/3 of Milestone 3 for 2015 Grants Subtotal No Activity Subtotal Aggregated Milestone 1 for 2016 Grants Subtotal	875,000.00 115,290.00 990,290.00 875,000.00 875,000.00 875,000.00 375,000.00	Tentative Firm - Tentative - Tentative - Tentative -	875,000.00 875,000.00
January January January February February March March April April May May	1/3 of Milestone 3 for 2015 Grants EG-000249 (2013 Grant Cycle) Milestone 4 Subtotal 1/3 of Milestone 3 for 2015 Grants Subtotal 1/3 of Milestone 3 for 2015 Grants Subtotal No Activity Subtotal Aggregated Milestone 1 for 2016 Grants Subtotal No Activity	875,000.00 115,290.00 990,290.00 875,000.00 875,000.00 875,000.00 375,000.00	Tentative Firm - Tentative - Tentative - Tentative -	875,000.00 875,000.00

1201	ำก	11
/28/	ZU	כבי

July	Subtotal	-	-	
August	No Activity	_		
August	Subtotal		_	
September	1/3 of Milestone 2 for 2016 Grants	833,333.00	Tentative	
September	Subtotal	833,333.00	-	833,333.00
October	1/3 of Milestone 2 for 2016 Grants	833,333.00		
October	1/3 of Milestone 4 for 2015 Grants	291,666.00		
October	Subtotal	1,124,999.00	-	1,124,999.00
November	1/3 of Milestone 2 for 2016 Grants	833,334.00	Tentative	
November	1/3 of Milestone 4 for 2015 Grants	291,666.00		
November	Subtotal	1,125,000.00	-	1,125,000.00
NOVELIIMEI	Subtotal	1,125,000.00		1,123,000.00
December	1/3 of Milestone 4 for 2015 Grants	291,667.00	Tentative	
December	Subtotal	291,667.00	-	291,667.00
		•		
2016	Total	9,615,289.00	_	9,615,289.00
2017 - Budget Not Yet Approved by RPC				
			RPC Invoice	
<u>Month</u>	<u>Milestone</u>	Amount	RPC Invoice Status	
		Amount	Status	
January	1/3 of Milestone 3 for 2016 Grants	<u>Amount</u> 1,000,000.00	Status	1 000 000 00
		Amount	Status	1,000,000.00
January January	1/3 of Milestone 3 for 2016 Grants	<u>Amount</u> 1,000,000.00 1,000,000.00	Status Tentative	1,000,000.00
January	1/3 of Milestone 3 for 2016 Grants Subtotal	<u>Amount</u> 1,000,000.00	Status Tentative	1,000,000.00
January January February	1/3 of Milestone 3 for 2016 Grants Subtotal 1/3 of Milestone 3 for 2016 Grants	1,000,000.00 1,000,000.00 1,000,000.00	Status Tentative	
January January February	1/3 of Milestone 3 for 2016 Grants Subtotal 1/3 of Milestone 3 for 2016 Grants	1,000,000.00 1,000,000.00 1,000,000.00	Status Tentative - Tentative -	
January January February February	1/3 of Milestone 3 for 2016 Grants Subtotal 1/3 of Milestone 3 for 2016 Grants Subtotal	1,000,000.00 1,000,000.00 1,000,000.00 1,000,000.00	Status Tentative - Tentative -	
January January February February March	1/3 of Milestone 3 for 2016 Grants Subtotal 1/3 of Milestone 3 for 2016 Grants Subtotal 1/3 of Milestone 3 for 2016 Grants Subtotal	1,000,000.00 1,000,000.00 1,000,000.00 1,000,000.00 1,000,000.00	Status Tentative - Tentative -	1,000,000.00
January January February February March March	1/3 of Milestone 3 for 2016 Grants Subtotal 1/3 of Milestone 3 for 2016 Grants Subtotal 1/3 of Milestone 3 for 2016 Grants Subtotal No Activity	1,000,000.00 1,000,000.00 1,000,000.00 1,000,000.00 1,000,000.00	Status Tentative - Tentative -	1,000,000.00
January January February February March March	1/3 of Milestone 3 for 2016 Grants Subtotal 1/3 of Milestone 3 for 2016 Grants Subtotal 1/3 of Milestone 3 for 2016 Grants Subtotal	1,000,000.00 1,000,000.00 1,000,000.00 1,000,000.00 1,000,000.00	Status Tentative - Tentative -	1,000,000.00
January January February February March March April	1/3 of Milestone 3 for 2016 Grants Subtotal 1/3 of Milestone 3 for 2016 Grants Subtotal 1/3 of Milestone 3 for 2016 Grants Subtotal No Activity Subtotal	Amount 1,000,000.00 1,000,000.00 1,000,000.00 1,000,000.00 1,000,000.00 1,000,000.00	Status Tentative - Tentative - Tentative -	1,000,000.00
January January February February March March April April	1/3 of Milestone 3 for 2016 Grants Subtotal 1/3 of Milestone 3 for 2016 Grants Subtotal 1/3 of Milestone 3 for 2016 Grants Subtotal No Activity Subtotal Aggregated Milestone 1 for 2017 Grants	Amount 1,000,000.00 1,000,000.00 1,000,000.00 1,000,000.00 1,000,000.00 3,500,000.00	Status Tentative - Tentative - Tentative -	1,000,000.00
January January February February March March April	1/3 of Milestone 3 for 2016 Grants Subtotal 1/3 of Milestone 3 for 2016 Grants Subtotal 1/3 of Milestone 3 for 2016 Grants Subtotal No Activity Subtotal	Amount 1,000,000.00 1,000,000.00 1,000,000.00 1,000,000.00 1,000,000.00 1,000,000.00	Status Tentative - Tentative - Tentative -	1,000,000.00
January January February February March March April April May	1/3 of Milestone 3 for 2016 Grants Subtotal 1/3 of Milestone 3 for 2016 Grants Subtotal 1/3 of Milestone 3 for 2016 Grants Subtotal No Activity Subtotal Aggregated Milestone 1 for 2017 Grants Subtotal	Amount 1,000,000.00 1,000,000.00 1,000,000.00 1,000,000.00 1,000,000.00 3,500,000.00	Status Tentative - Tentative - Tentative -	1,000,000.00
January January February February March March April April May May	1/3 of Milestone 3 for 2016 Grants Subtotal 1/3 of Milestone 3 for 2016 Grants Subtotal 1/3 of Milestone 3 for 2016 Grants Subtotal No Activity Subtotal Aggregated Milestone 1 for 2017 Grants Subtotal No Activity	Amount 1,000,000.00 1,000,000.00 1,000,000.00 1,000,000.00 1,000,000.00 3,500,000.00	Status Tentative - Tentative - Tentative -	1,000,000.00
January January February February March March April April May	1/3 of Milestone 3 for 2016 Grants Subtotal 1/3 of Milestone 3 for 2016 Grants Subtotal 1/3 of Milestone 3 for 2016 Grants Subtotal No Activity Subtotal Aggregated Milestone 1 for 2017 Grants Subtotal	Amount 1,000,000.00 1,000,000.00 1,000,000.00 1,000,000.00 1,000,000.00 3,500,000.00	Status Tentative - Tentative - Tentative -	1,000,000.00
January January February February March March April April May May	1/3 of Milestone 3 for 2016 Grants Subtotal 1/3 of Milestone 3 for 2016 Grants Subtotal 1/3 of Milestone 3 for 2016 Grants Subtotal No Activity Subtotal Aggregated Milestone 1 for 2017 Grants Subtotal No Activity	Amount 1,000,000.00 1,000,000.00 1,000,000.00 1,000,000.00 1,000,000.00 3,500,000.00	Status Tentative - Tentative - Tentative -	1,000,000.00

2/28/2015

August	No Activity			
August	Subtotal	-	-	-
September	1/3 of Milestone 2 for 2017 Grants	833,333.00	Tentative	
September	Subtotal	833,333.00	-	833,333.00
October	1/3 of Milestone 2 for 2017 Grants	833,333.00	Tentative	
October	1/3 of Milestone 4 for 2016 Grants	333,333.00	Tentative	
October	Subtotal	1,166,666.00	-	1,166,666.00
November	1/3 of Milestone 2 for 2017 Grants	833,333.00	Tentative	
November	1/3 of Milestone 4 for 2016 Grants	333,334.00	Tentative	
November	Subtotal	1,166,667.00	-	1,166,667.00
December	1/3 of Milestone 4 for 2016 Grants	333,334.00	Tentative	
December	Subtotal	333,334.00	-	333,334.00
2017	Total	10,000,000.00		10,000,000.00

Days Past Due

Campbell Alliance

■ INVENTIV HEALTH

		<u>Current</u>	<u>1-30 Days</u>	<u>31-60 Days</u>	61-90 Days	91+ Days
Apotex Corp	Total: Endo Pharmaceuticals, Inc.	\$ 36,700	\$ 3,224	\$ -	\$ -	
ndo Pharmaceuticals, Inc.	Total: Endo Pharmaceuticals, Inc.	\$ -	\$ -	\$ -	\$ -	
mpax Laboratories, Inc.	Total: Janssen Pharmaceuticals, Inc.	\$ (7,566)	\$ -	\$ -	\$ -	
anssen Pharmaceuticals, Inc.	Total: Janssen Pharmaceuticals, Inc.	\$ 21,941	\$ 7,289	\$ -	\$ -	
Iallinckrodt	Total: Mallinckrodt (Covidien)	\$ 325,072	\$ -	\$ -	\$ -	
Aylan Inc.	Total: Mylan Inc.	\$ 159,467	\$ -	\$ -	\$ -	
lesher	Total: Noven Pharmaceuticals, Inc.	\$ -	\$ -	\$ -	\$ -	
oven Pharmaceuticals, Inc.	Total: Noven Pharmaceuticals, Inc.	\$ (6,493)	\$ -	\$ -	\$ -	
ar Pharmaceuticals	Total: Pfizer, Inc.	\$ 23,117	\$ -	\$ -	\$ -	
fizer, Inc.	Total: Pfizer, Inc.	\$ 2,612	\$ -	\$ -	\$ -	
urdue Pharma	Total: Purdue Pharma	\$ 327,161	\$ -	\$ -	\$ -	
anbaxy Pharmaceuticals, Inc.	Total: Rhodes Pharmaceuticals L.P.	\$ (7,566)	\$ -	\$ -	\$ -	
nodes Pharmaceuticals L.P.	Total: Rhodes Pharmaceuticals L.P.	\$ 152,215	\$ -	\$ -	\$ -	
oxane Laboratories, Inc.	Total: Roxane Laboratories, Inc.	\$ 77,448	\$ 35,084	\$ -	\$ -	
andoz Inc.	Total: Sandoz Inc.	\$ 14,306	\$ -	\$ -	\$ -	
ne PharmaNetwork, LLC	Total: The PharmaNetwork, LLC	\$ (1,805)	\$ -	\$ -	\$ -	
osher-Smith Laboratories	Total: VistaPharm, Inc.	\$ (2,212)	\$ -	\$ -	\$ -	
staPharm, Inc.	Total: VistaPharm, Inc.	\$ (7,566)	\$ -	\$ -	\$ -	
atson	Total: Watson Pharmaceuticals, Inc.	\$ -	\$ -	\$ 10,288	\$ -	
ogenix, Inc.	Total: Watson Pharmaceuticals, Inc.	\$ (3,076)	\$ -	\$ -	\$ -	
PC Total		1,103,755	45,596	10,288		

Case: 1:17-md-02804-DAP Doc #: 2313-100 Filed: 08/14/19 43 of 49. PageID #: 369872



Invoice Date Terms Date DPD PO # <u>Amount</u> Current 1-30 Days 31-60 Days 61-90 Days 91+ Days **APO100 Apotex Corp** 01/24/15 RPC-001U REMS Program Management Suppor 3640 12/10/14 45 16 (2,176.14)- (2,176.14) RPC-001U REMS Program Management Suppor 3678 12/10/14 45 01/24/15 16 2,043.34 - 2,043.34 RPC-001U REMS Program Management Suppor 3724 12/22/14 45 02/05/15 4 3,356.37 3,356.37 RPC-001U REMS Program Management Suppor 3770 01/13/15 45 02/27/15 -18 4,491.32 4,491.32 RPC-001U REMS Program Management Suppor 3814 01/13/15 45 02/27/15 -18 32,208.23 32,208.23 Total: Apotex Corp **Apotex Corp** 39,923.12 36,699.55 3,223.57 0.00 0.00 0.00 END100 Endo Pharmaceuticals, Inc. RPC-001C REMS Program Management Suppor 3712 12/22/14 45 02/05/15 10001402 Total: Endo Pharmaceuticals, Inc. 0.00 0.00 0.00 0.00 0.00 Endo Pharmaceuticals, Inc. IMP001 Impax Laboratories, Inc. RPC-001T REMS Program Management Suppor 12/10/14 45 01/24/15 16 (4,490.59)(4,490.59)0.00 4700001554 RPC-001T REMS Program Management Suppor 3677 12/10/14 45 01/24/15 16 (3,075.86)(3,075.86)0.00 4700001554 Total: Impax Laboratories, Inc. Impax Laboratories, Inc. (7,566.45) (7,566.45) 0.00 0.00 0.00 0.00 JAN300 Janssen Pharmaceuticals, Inc. RPC-001D REMS Program Management Suppor 3664 12/10/14 45 01/24/15 16 993020160 3,184.67 3,184.67 RPC-001D REMS Program Management Suppor 3713 12/22/14 45 02/05/15 4 993020160 4,104.67 4,104.67 RPC-001D REMS Program Management Suppor 3756 01/13/15 45 02/27/15 -18 993020160 2,685.20 2,685.20 RPC-001D REMS Program Management Suppor 3805 01/13/15 45 02/27/15 -18 993020160 19,256.17 19,256.17 Total: Janssen Pharmaceuticals, Inc. 29,230.71 21,941.37 7,289.34 0.00 0.00 0.00 Janssen Pharmaceuticals, Inc. MAL100 Mallinckrodt REMS Program Management Suppor 39,782.52 RPC-001E 3757 01/13/15 45 02/27/15 -18 10426881-000 39.782.52 RPC-001E REMS Program Management Suppor 3806 01/13/15 45 02/27/15 -18 10426881-000 285,289.28 285,289.28 Total: Mallinckrodt Mallinckrodt 325,071.80 325,071.80 MYL100 Mylan Inc. RPC-001F REMS Program Management Suppor 01/13/15 45 02/27/15 -18 4300009571 19,515.65 19,515.65 RPC-001F REMS Program Management Suppor 3807 01/13/15 45 02/27/15 -18 4300009571 139,951.07 139,951.07 Total: Mylan Inc. 159,466.72 159,466.72 Mylan Inc. NES100 Nesher RPC-001Z REMS Program Management Suppor 3642 12/10/14 45 01/24/15 16 57398 OP RPC-001Z REMS Program Management Suppor 3683 12/10/14 45 01/24/15 16 57398 OP Total: Nesher Nesher **NOV200** Noven Pharmaceuticals, Inc. RPC-001G REMS Program Management Suppor 3632 12/10/14 45 01/24/15 16 57398 OP (4,260.24)(4,260.24)RPC-001G REMS Program Management Suppor 3667 12/10/14 45 01/24/15 16 57398 OP (2,566.36)(2,566.36)RPC-001G REMS Program Management Suppor 3716 12/22/14 02/05/15 4 57398 OP 334.05 334.05 Total: Noven Pharmaceuticals, Inc. Noven Pharmaceuticals, Inc. (6,492.55)(6,492.55)**PAR100** Par Pharmaceuticals

Case: 1:17-md-02804-DAP Doc #: 2313-100 Filed: 08/14/19 44 of 49. PageID #: 369873

[] INVENTIV HEALTH Invoice Date Terms Date DPD PO # Amount Current 1-30 Days 31-60 Days 61-90 Days 91+ Days RPC-0001V REMS Program Management Suppor 3771 01/13/15 45 02/27/15 -18 2.829.05 2.829.05 RPC-0001V REMS Program Management Suppor 01/13/15 45 02/27/15 -18 20.287.74 20.287.74 Total: Noven Pharmaceuticals, Inc. Par Pharmaceuticals 23,116.79 23,116.79 PFI100 Pfizer, Inc. RPC-001S REMS Program Management Suppor 3768 01/13/15 45 02/27/15 -18 N-3198821 319.67 319.67 RPC-001S REMS Program Management Suppor 3813 01/13/15 45 02/27/15 -18 N-3198821 2,292.40 2,292.40 Total: Pfizer, Inc. Pfizer, Inc 2,612.07 2,612.07 PDP100 Purdue Pharma RPC-001J REMS Program Management Suppor 01/13/15 45 02/27/15 -18 4500067225 40,038.25 40,038.25 RPC-001J REMS Program Management Suppor 3808 01/13/15 02/27/15 -18 4500067225 287,123.21 287,123.21 Total: Purdue Pharma **Purdue Pharma** 327,161.46 327,161.46 RPI100 Ranbaxy Pharmaceuticals, Inc. RPC-001W REMS Program Management Suppor 3655 12/10/14 45 01/24/15 16 (4,490.59)(4,490.59)RPC-001W REMS Program Management Suppor 3680 12/10/14 45 01/24/15 16 (3,075.86)(3,075.86)Total: Ranbaxy Pharmaceuticals, Inc. Ranbaxy Pharmaceuticals, Inc. (7,566.45) (7,566.45) RHO100 Rhodes Pharmaceuticals L.P. RPC-001K REMS Program Management Suppor 3762 01/13/15 45 02/27/15 -18 4500067179 18,157.07 18,157.07 RPC-001K REMS Program Management Suppor 3809 01/13/15 45 02/27/15 -18 4500067179 134,058.37 134,058.37 Total: Rhodes Pharmaceuticals L.P. Rhodes Pharmaceuticals L.P. 152,215.44 152,215.44 ROX200 Roxane Laboratories, Inc. RPC-001L REMS Program Management Suppor 3635 12/10/14 45 01/24/15 16 8,788.38 8,788.38 RPC-001L REMS Program Management Suppor 3671 12/10/14 45 01/24/15 16 26,295.18 26,295.18 RPC-001L REMS Program Management Suppor 3763 01/13/15 45 02/27/15 -18 9,478.12 9,478.12 RPC-001L REMS Program Management Suppor 3810 01/13/15 45 02/27/15 -18 67,969.68 67,969.68 Total: Roxane Laboratories, Inc. Roxane Laboratories, Inc. 112,531.36 77,447.80 35,083.56 **SAN400** Sandoz Inc. RPC-001M REMS Program Management Suppor 3636 12/10/14 45 01/24/15 16 7750489038 (3,608.93)(3,608.93)RPC-001M REMS Program Management Suppor 3672 12/10/14 01/24/15 16 7750489038 (1,125.77)(1,125.77)RPC-001M REMS Program Management Suppor 3720 12/22/14 02/05/15 4 7750489038 1,278.56 1,278.56 RPC-001M REMS Program Management Suppor 3764 01/13/15 45 02/27/15 -18 7750489038 2,173.73 2,173.73 RPC-001M REMS Program Management Suppor 3811 01/13/15 45 02/27/15 -18 7750489038 15,588.33 15,588.33 Total: Sandoz Inc. Sandoz Inc. 14.305.92 14.305.92 The PharmaNetwork, LLC **PHA400** RPC-001P REMS Program Management Suppor 3583 11/25/14 45 01/09/15 31 1,164.50 1,164.50 RPC-001P REMS Program Management Suppor 3637 12/10/14 45 01/24/15 16 (3,504.47)(3,504.47)RPC-001P REMS Program Management Suppor 3673 12/10/14 45 01/24/15 16 (894.72)(894.72)RPC-001P REMS Program Management Suppor 3721 12/22/14 02/05/15 1,430.05 1,430.05 Total: The PharmaNetwork, LLC The PharmaNetwork, LLC (1,804.64) (1,804.64) **UPS001 Upsher-Smith Laboratories** REMS Program Management Suppor RPC-001X 12/10/14 45 01/24/15 16 4500121468 (4.490.59)(4.490.59)3656 REMS Program Management Suppor 12/10/14 45 RPC-001X 3681 01/24/15 16 4500121468 (3,075.86)(3,075.86)



Case: 1:17-md-02804-DAP Doc #: 2313-100 Filed: 08/14/19 45 of 49. PageID #: 369874

F? INVENTIV HE	ALTH								L					
			Invoic	e <u>Date</u>	Terms	Date	DPD	PO#	Amount	Current	1-30 Days	31-60 Days 61	-90 Days 91-	⊦ Days
RPC-001X	REMS Program Management Suppor		3773	01/13/15	45	02/27/15	-18	4500121468	655.32	655.32	-	-	-	-
RPC-001X	REMS Program Management Suppor		3816	01/13/15	45	02/27/15	-18	4500121468	4,699.42	4,699.42	-	-	-	-
	Total: Upsher-Smith Laboratories	Upsher-Smith L	aboratories						(2,211.71)	(2,211.71)		-	-	-
VIS100		VistaPharm, Inc.												
RPC-001Q	REMS Program Management Suppor		3653	12/10/14	45	01/24/15	16	062812JF	(4,490.59)	(4,490.59)	-	-	-	-
RPC-001Q	REMS Program Management Suppor		3674	12/10/14	45	01/24/15	16	062812JF	(3,075.86)	(3,075.86)	-	-	-	-
	Total: VistaPharm, Inc.	VistaPharm, Inc.							(7,566.45)	(7,566.45)	-	-	-	-
WAT100		Watson												
RPC-001R	REMS Program Management Suppor		3482	11/06/14	45	12/21/14	50	062812JF	10,288.16	-	-	10,288.16	-	-
ZOG100	Total: Watson	Watson Zogenix, Inc.							10,288.16	-	-	10,288.16	-	
RPC-001Y	REMS Program Management Suppor		3682	12/10/14	45	01/24/15	16		(3,075.86)	(3,075.86)	-	-	-	-
	Total: Zogenix, Inc.	Zogenix, Inc.							(3,075.86)	(3,075.86)	-	-	-	-
Grand Total:									1,159,639.44	1,103,754.81	45,596.47	10,288.16	-	<u> </u>
									100%	95%	4%	1%	0%	0%

Campbell Alliance INVENTIV HEALTH

	<u>!</u>	PM Invoice	<u>Date</u>	<u>Terms</u>	<u>Due</u>	<u>DPD</u>	<u>Amount</u>	Current	<u>1-30 Days</u>	31-60 Days	61-90 Days	91+ Days
ASH250	Ashfield											
RPC-0001	REMS Program Management Support	20246031	12/11/14	75	02/24/15	-15	2,808.09	2,808.09	-	-		-
	Total: Ashfield						2,808.09	2,808.09	-	-		-
CEN001	Cenveo											
RPC-0001	REMS Program Management Suppor	23443920	11/26/14	75	02/09/15	0	619.13	619.13	-	-	-	-
RPC-0001	REMS Program Management Suppor	23509241	12/30/14	75	03/15/15	-34	581.22	581.22	-	-	-	· -
	Total: Cenveo						1,200.35	1,200.35	-	-	· -	
CLI100	ClinAudits											
RPC-0001	REMS Program Management Suppor	6858	01/12/15	30	02/11/15	-2	12,580.86	12,580.86	-	-	-	-
	Total: ClinAudits						12,580.86	12,580.86	-	-		-
CON001	Constantine Cannon											
RPC-0001	REMS Program Management Suppor	44615	01/08/15	75	03/24/15	-43	15,000.00	15,000.00	-	-	-	-
RPC-0001	REMS Program Management Suppor	44655	01/08/15	75	03/24/15	-43	15,000.00	15,000.00	-	-	-	-
RPC-0001	REMS Program Management Suppor	44688	01/13/15	75	03/29/15	-48	15,000.00	15,000.00	-	-	-	-
	Total: Constantine Cannon						45,000.00	45,000.00	-	-		-
HEA100	HealthCore											
RPC-0001	REMS Program Management Suppor	3214	12/19/14	75	03/04/15	-23	117,246.00	117,246.00	-	-	-	



		PM Invoice	<u>Date</u>	Terms	<u>Due</u>	DPD	<u>Amount</u>	Current	1-30 Days	31-60 Days	61-90 Days	91+ Days
	Total: HealthCore						117,246.00	117,246.00	-	-	-	-
IMS100	IMS											
RPC-0001	REMS Program Management Suppor	407211828	12/26/14	75	03/11/15	-30	33,150.00	33,150.00	-	-	-	-
	Total: IMS						33,150.00	33,150.00	-	-	-	
INF100	Inflexxion											
RPC-0001	REMS Program Management Suppor	4716	09/24/14	75	12/08/14	63	-	-	-	-	-	-
	Total: Inflexxion						-	-	-	-	-	
KIT100	Linda Kitlinski											
RPC-0001	REMS Program Management Suppor	LK001	12/16/14	75	03/01/15	-20	230.29	230.29	-	-	-	-
RPC-0001	REMS Program Management Suppor	LK002	12/16/14	75	03/01/15	-20	6,500.54	6,500.54	-	-	-	-
RPC-0001	REMS Program Management Suppor	LK003	01/06/15	75	03/22/15	-41	1,680.75	1,680.75	-	-	-	-
	Total: Linda Kitlinski						8,411.58	8,411.58	-	-	-	
MCK100	McKesson Specialt	y Arizona, Inc.										
RPC-0001	REMS Program Management Suppor	308407113	12/18/14	75	03/03/15	-22	10,350.00	10,350.00	-	-	-	-
RPC-0001	REMS Program Management Suppor	308530262	01/27/15	75	04/12/15	-62	12,800.00	12,800.00	-	-	-	-
	Total: McKesson Specialty Arizona, Inc.						23,150.00	23,150.00	-	-	-	
MED100	MedBiquitous Cons	sortium, LLC										

Campbell Alliance INVENTIV HEALTH

RPC-0001	PM REMS Program Management Suppor	Invoice 682	<u>Date</u> 07/11/14	<u>Terms</u> 75	Due 09/24/14	<u>DPD</u> 138	Amount -	Current	<u>1-30 Days</u>	31-60 Days	61-90 Days	91+ Days -
	Total: MedBiquitous Consortium, LLC											
OGI100	Ogilvy & Mather											
RPC-0001	REMS Program Management Suppor	30012284	11/18/14	75	02/01/15	8	-					
RPC-0001	REMS Program Management Suppor	30012273	11/24/14	75	02/07/15	2	-					
RPC-0001	REMS Program Management Suppor	30012334	12/01/14	75	02/14/15	-5	-					
	Total: Ogilvy & Mather						-					
PDR001	PDR Network, LLC											
RPC-0001	REMS Program Management Suppor	M100427	10/31/14	75	01/14/15	26	-					
	Total: PDR Network, LLC						-			. <u>-</u>		
PL001	Polaris Solutions, LLC											
RPC-0001	REMS Program Management Suppor	14382	12/02/14	75	02/15/15	-6	2,461.29	2,461.29				
RPC-0001	REMS Program Management Suppor	14383	12/02/14	75	02/15/15	-6	19,577.80	19,577.80				
RPC-0001	REMS Program Management Suppor	14446	01/02/15	75	03/18/15	-37	535.86	535.86				
RPC-0001	REMS Program Management Suppor	14447	01/02/15	75	03/18/15	-37	2,461.29	2,461.29) .			· -
RPC-0001	REMS Program Management Suppor	14448	01/02/15	75	03/18/15	-37	19,577.80	19,577.80) .			· -
	Total: Polaris Solutions, LLC						44,614.04	44,614.04		· -		
RMP001	RMPDC											



		<u>PM</u>	Invoice	<u>Date</u>	<u>Terms</u>	<u>Due</u>	DPD	<u>Amount</u>	Current	1-30 Days	31-60 Days	61-90 Days	91+ Days	
RPC-0001	REMS Program Management Suppor		RD00000303	11/19/14	75	02/02/15	7	-		-			-	
	Total: RMPDC							-		-	<u> </u>		-	
UBC001	UBC Late Stage, In	ıc.												
RPC-0001	REMS Program Management Suppor		71003662	07/31/14	75	10/14/14	-41,926	-		-			. <u>-</u>	
	Total: UBC Late Stage, Inc.							-		-				
Grand Total:								279,749.34	279,749.3	4			_	
Percent of Total:								100%	100.0%	6 0.0%	0.0%	0.0%	0.0%	